ME T H O D S
IN
MO L E C U L A R BI O L O G Y
Series Editor John M. Walker School of Life Sciences University of Hertfordshire Hatfield, Hertfordshire, AL10 9AB, UK
For other titles published in this series, go to www.springer.com/series/7651
TM
Natural Killer Cell Protocols Cellular and Molecular Methods Second Edition
Edited by
Kerry S. Campbell Fox Chase Cancer Center, Philadelphia, PA, USA
Editor Kerry S. Campbell Fox Chase Cancer Center Institute for Cancer Research 333 Cottman Avenue Philadelphia PA 19111-2497 USA
[email protected]
ISSN 1064-3745 e-ISSN 1940-6029 ISBN 978-1-60761-361-9 e-ISBN 978-1-60761-362-6 DOI 10.1007/978-1-60761-362-6 Library of Congress Control Number: 2009939929 © Humana Press, a part of Springer Science+Business Media, LLC 2010 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Printed on acid-free paper springer.com
Preface It is becoming increasingly clear that natural killer (NK) cells are critical sentinels of the innate immune response. NK cells play important roles in protecting the body from numerous pathogens and cancer in addition to contributing to normal pregnancy and impacting the outcomes of transplantation. They have the unique capacity to detect and immediately respond to abnormal cells in the body without prior exposure. NK cell responses include the classical tumor cytolytic activity for which they were named and for the production of a number of cytokines that directly contribute to or potentiate the immune response. Although efficient tolerance mechanisms appear to prevent NK cells from causing autoimmune diseases, a great deal of genetic evidence suggests that match or mismatch of certain NK cell regulatory receptors [namely killer cell Ig-like receptors (KIR)] and their MHC class I ligands can influence a wide variety of human pathological conditions, including altering outcomes of viral infections, transplantations, pregnancies, and tumor therapies. The second edition of Natural Killer Cell Protocols provides a broad collection of some of the most important methods currently being used to study NK cells both in vitro and in vivo. The authors are international leaders in the field, who are directly using these methods to advance our understanding of this fascinating subset of lymphocytes. While the first edition provided a valuable collection of classical cellular and in vivo techniques to study NK cell functions, the chapters in the second edition focus on more recently developed methods, more refined techniques, and protocols designed to study NK cells within specialized tissue sites. These include protocols to analyze the various stages of NK cell development/maturation, to assess NK cell interactions with target cells and dendritic cells, to evaluate signal transduction by NK cell receptors, and to define KIR expression profiles by genotyping or flow cytometry. Additional chapters describe methods for the study of unique subsets of NK cells within the uterus during pregnancy and at intestinal mucosal surfaces, as well as techniques to evaluate NK cell responses to viral infections and malaria. The collection also includes specialized techniques to identify ligands for NK cell receptors, to define promoters regulating human KIR expression, to map receptors encoded within the murine NK cell gene locus that are responsible for resistance to pathogens, and to introduce cDNAs and shRNAs into NK cells using recombinant retrovirus or lentivirus. Finally, the book’s appendix provides a rich resource summarizing available reagents to study NK cells, cross-referencing KIR nomenclature, and detailing the many HLA ligands for various KIR family members. NK cells in rodents and humans are regulated by very different repertoires of receptors. Therefore, protocols from both perspectives are provided in this volume, with the species noted in the title or abstract. Furthermore, we have emphasized the “Notes” sections, which provide important details within each protocol, thereby extending the longstanding tradition of the Methods in Molecular Biology series. NK cells play unique roles in the immune response, but despite several decades of study, there is still much to learn about their functions, maturation, and regulation. The goal of Natural Killer Cell Protocols is to provide open access to important techniques
v
vi
Preface
written by key researchers in the field. I am indebted to the authors who have contributed their time and energies to provide high quality protocols. Their commitment to providing detailed descriptions of the methods was essential in making this project a success. I hope that this collection of methods will make significant contributions to your research and thereby further advance our collective understanding of these fascinating cells for many years to come. Kerry S. Campbell
Contents Preface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
v
Contributors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
xi
1.
2.
Purification of Human NK Cell Developmental Intermediates from Lymph Nodes and Tonsils . . . . . . . . . . . . . . . . . . . . . . . . . . Aharon G. Freud and Michael A. Caligiuri
1
In Vitro Development of Human Killer–Immunoglobulin Receptor-Positive NK Cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . Frank Cichocki and Jeffrey S. Miller
15
3.
Subset Analysis of Human and Mouse Mature NK Cells . . . . . . . . . . . . . Yoshihiro Hayakawa, Daniel M. Andrews, and Mark J. Smyth
27
4.
Assessing Licensing of NK Cells . . . . . . . . . . . . . . . . . . . . . . . . . . A. Helena Jonsson and Wayne M. Yokoyama
39
5.
Use of Stem Cell Radiation Chimeras to Analyze How Domains of Specific Proteins Impact on Murine NK Cell Development In Vivo . . . . . . Rebecca H. Lian and Vinay Kumar
51
6.
Use of Transfected Drosophila S2 Cells to Study NK Cell Activation . . . . . . . Michael E. March, Catharina C. Gross, and Eric O. Long
67
7.
Natural Killer Cell Conjugate Assay Using Two-Color Flow Cytometry . . . . . Deborah N. Burshtyn and Chelsea Davidson
89
8.
Studying NK Cell/Dendritic Cell Interactions . . . . . . . . . . . . . . . . . . Mathias Lucas, Cedric Vonarbourg, Peter Aichele, and Andreas Diefenbach
97
9.
Analysis of the NK Cell Immunological Synapse . . . . . . . . . . . . . . . . . 127 Keri B. Sanborn, Gregory D. Rak, Ashley N. Mentlik, Pinaki P. Banerjee, and Jordan S. Orange
10.
Measuring Intracellular Calcium Signaling in Murine NK Cells by Flow Cytometry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149 Alexander W. MacFarlane IV, James F. Oesterling, and Kerry S. Campbell
11.
Intracellular Staining for Analysis of the Expression and Phosphorylation of Signal Transducers and Activators of Transcription (STATs) in NK Cells . . . . 159 Takuya Miyagi, Seung-Hwan Lee, and Christine A. Biron
12.
A Model System for Studying NK Cell Receptor Signaling . . . . . . . . . . . . 177 Lukasz K. Chlewicki and Vinay Kumar
13.
Expression of cDNAs in Human Natural Killer Cell Lines by Retroviral Transduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 199 S. M. Shahjahan Miah and Kerry S. Campbell
vii
viii
Contents
14.
Lentiviral Gene Transduction in Human and Mouse NK Cell Lines . . . . . . . 209 Ram Savan, Tim Chan, and Howard A. Young
15.
Introduction of shRNAs into Human NK-Like Cell Lines with Retrovirus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 223 Amanda K. Purdy and Kerry S. Campbell
16.
Introduction of shRNAs into Primary NK Cells with Lentivirus . . . . . . . . . 233 Sam K.P. Kung
17.
Methods to Identify and Characterize Different NK Cell Receptors and Their Ligands . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 249 Dikla Lankry, Roi Gazit, and Ofer Mandelboim
18.
Generating NK Cell Receptor-Fc Chimera Proteins from 293T Cells and Considerations of Appropriate Glycosylation . . . . . . . . . . . . . . . . . 275 Alon Zilka, Michal Mendelson, Benyamin Rosental, Oren Hershkovitz, and Angel Porgador
19.
Identification of NK Cell Receptor Ligands Using a Signaling Reporter System . 285 Yoshie-Matsubayashi Iizuka, Nikunj V. Somia, and Koho Iizuka
20.
Determining Ligand Specificity of Ly49 Receptors . . . . . . . . . . . . . . . . 299 Kerry J. Lavender and Kevin P. Kane
21.
Probing the Interactions of NK Cell Receptors with Ligand Expressed in trans and cis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 313 Jonathan Back, L´eonardo Scarpellino, and Werner Held
22.
A Simple Method to Measure NK Cell Cytotoxicity In Vivo . . . . . . . . . . . 325 Aurore Saudemont, Shannon Burke, and Francesco Colucci
23.
Functional Analysis of Human NK Cells by Flow Cytometry . . . . . . . . . . . 335 Yenan T. Bryceson, Cyril Fauriat, Jo˜ ao M. Nunes, Stephanie M. Wood, Niklas K. Bj¨orkstr¨om, Eric O. Long, and Hans-Gustaf Ljunggren
24.
Analysis of the KIR Repertoire in Human NK Cells by Flow Cytometry . . . . . 353 Niklas K. Bj¨orkstr¨om, Cyril Fauriat, Yenan T. Bryceson, Johan K. Sandberg, Hans-Gustaf Ljunggren, and Karl-Johan Malmberg
25.
KIR Genotyping by Multiplex PCR-SSP . . . . . . . . . . . . . . . . . . . . . 365 Smita Kulkarni, Maureen P. Martin, and Mary Carrington
26.
Identification and Analysis of Novel Transcripts and Promoters in the Human Killer Cell Immunoglobulin-like Receptor (KIR) Genes Hongchuan Li, Paul W. Wright, and Stephen K. Anderson
. . . . . 377
27.
Use of Inbred Mouse Strains to Map Recognition Receptors of MCMV Infected Cells in the NK Cell Gene Locus . . . . . . . . . . . . . . . . . . . . 393 Nassima Fodil-Cornu, Michal Pyzik, and Silvia M. Vidal
28.
Studying NK Cell Responses to Ectromelia Virus Infections in Mice . . . . . . . 411 Min Fang and Luis Sigal
Contents
ix
29.
Activation of Human NK Cells by Malaria-Infected Red Blood Cells . . . . . . . 429 Amir Horowitz and Eleanor M. Riley
30.
Natural Killer Cells in Human Pregnancy . . . . . . . . . . . . . . . . . . . . . 447 Victoria Male, Anita Trundley, Lucy Gardner, Jacquie Northfield, Chiwen Chang, Richard Apps, and Ashley Moffett
31.
Analysis of Uterine Natural Killer Cells in Mice . . . . . . . . . . . . . . . . . . 465 B. Anne Croy, Jianhong Zhang, Chandrakant Tayade, Francesco Colucci, Hakim Yadi, and Aureo T. Yamada
32.
Isolation of NK Cells and NK-Like Cells from the Intestinal Lamina Propria . . . 505 Stephanie L. Sanos and Andreas Diefenbach
Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 519 Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 545
Contributors PETER AICHELE • Institute of Medical Microbiology & Hygiene, University of Freiburg Medical Center, Freiburg, Germany STEPHEN K. ANDERSON • Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick Inc., National Cancer Institute-Frederick, Frederick, MD, USA DANIEL M. ANDREWS • Peter MacCallum Cancer Centre, Parkville, Victoria, Australia RICHARD APPS • Department of Pathology, University of Cambridge, Cambridge, UK JONATHAN BACK • Ludwig Institute for Cancer Research Ltd., Lausanne Branch, and University of Lausanne, Epalinges, Switzerland PINAKI P. BANERJEE • Division of Immunology, Children’s Hospital of Philadelphia, Philadelphia, PA, USA CHRISTINE A. BIRON • Department of Molecular Microbiology and Immunology, Division of Biology and Medicine, Brown University, Providence, RI, USA NIKLAS K. BJo¨ RKSTRo¨ M • Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden YENAN T. BRYCESON • Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden SHANNON BURKE • Lymphocyte Signalling and Development, The Babraham Institute, Cambridge, UK DEBORAH N. BURSHTYN • Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada MICHAEL A. CALIGIURI • The Comprehensive Cancer Center and The James Cancer Hospital & Solove Research Institute, The Ohio State University, Columbus, OH, USA KERRY S. CAMPBELL • Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA, USA MARY CARRINGTON • Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick Inc., National Cancer Institute-Frederick, Frederick, MD, USA TIM CHAN • Cancer and Inflammation Program, Laboratory of Experimental Immunology, National Cancer Institute-Frederick, Frederick, MD, USA CHIWEN CHANG • Department of Pathology, University of Cambridge, Cambridge, UK LUKASZ K. CHLEWICKI • Department of Pathology, The University of Chicago, Chicago, IL, USA FRANK CICHOCKI • University of Minnesota Cancer Center, Minneapolis, MN, USA FRANCESCO COLUCCI • Lymphocyte Signalling and Development, The Babraham Institute, Cambridge, UK B. ANNE CROY • Department of Anatomy and Cell Biology, Queen’s University, Kingston, ON, Canada CHELSEA DAVIDSON • Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada
xi
xii
Contributors
ANDREAS DIEFENBACH • Institute of Medical Microbiology & Hygiene, University of Freiburg Medical Center, Freiburg, Germany MIN FANG • Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA, USA CYRIL FAURIAT • Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden NASSIMA FODIL-CORNU • Department of Human Genetics, McGill University, Montreal, QC, Canada AHARON G. FREUD • Department of Pathology, Stanford University, Stanford, CA, USA LUCY GARDNER • Department of Pathology, University of Cambridge, Cambridge, UK ROI GAZIT • The Hebrew University – Hadassah Medical School, Jerusalem, Israel CATHARINA C. GROSS • Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA YOSHIHIRO HAYAKAWA • The University of Tokyo, Bunkyo-Ku, Tokyo, Japan WERNER HELD • Ludwig Institute for Cancer Research Ltd., Lausanne Branch, and University of Lausanne, Epalinges, Switzerland OREN HERSHKOVITZ • Department of Microbiology and Immunology, Ben Gurion University, Beer Sheva, Israel AMIR HOROWITZ • Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK KOHO IIZUKA • Department of Medicine and Center for Immunology, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA YOSHIE-MATSUBAYASHI IIZUKA • Department of Medicine and Center for Immunology, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA A. HELENA JONSSON • Medical Scientist Training Program, Rheumatology Division, Departments of Medicine, Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA KEVIN P. KANE • Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada SMITA KULKARNI • Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick Inc., National Cancer Institute-Frederick, Frederick, MD, USA VINAY KUMAR • Department of Pathology, University of Chicago, Chicago, IL, USA SAM K.P. KUNG • Laboratory of Innate Immunobiology, Department of Immunology, University of Manitoba, Winnipeg, MB, Canada DIKLA LANKRY • The Hebrew University – Hadassah Medical School, Jerusalem, Israel KERRY J. LAVENDER • The Edward Jenner Institute for Vaccine Research, University of Oxford, Oxford, UK SEUNG-HWAN LEE • Department of Molecular Microbiology and Immunology, Division of Biology and Medicine, Brown University, Providence, RI, USA HONGCHUAN LI • Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick Inc., National Cancer Institute-Frederick, Frederick, MD, USA REBECCA H. LIAN • Department of Pathology, University of Chicago, Chicago, IL, USA HANS-GUSTAF LJUNGGREN • Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden ERIC O. LONG • Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA
Contributors
xiii
MATHIAS LUCAS • Institute of Medical Microbiology & Hygiene, University of Freiburg Medical Center, Freiburg, Germany ALEXANDER W. MACFARLANE IV • Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA, USA VICTORIA MALE • Department of Pathology, University of Cambridge, Cambridge, UK KARL-JOHAN MALMBERG • Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden OFER MANDELBOIM • The Hebrew University – Hadassah Medical School, Jerusalem, Israel MICHAEL E. MARCH • Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA MAUREEN P. MARTIN • Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick Inc., National Cancer Institute-Frederick, Frederick, MD, USA MICHAL MENDELSON • Department of Microbiology and Immunology, Ben Gurion University, Beer Sheva, Israel ASHLEY N. MENTLIK • Cell Biology and Physiology Graduate Group, Division of Immunology, Children’s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA, USA S. M. SHAHJAHAN MIAH • Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA, USA JEFFREY S. MILLER • University of Minnesota Cancer Center, Minneapolis, MN, USA TAKUYA MIYAGI • Department of Molecular Microbiology and Immunology, Division of Biology and Medicine, Brown University, Providence, RI, USA ASHLEY MOFFETT • Department of Pathology, University of Cambridge, Cambridge, UK JACQUIE NORTHFIELD • Department of Pathology, University of Cambridge, Cambridge, UK JO˜aO M. NUNES • Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden JAMES F. OESTERLING • Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA, USA JORDAN S. ORANGE • The Joseph Stokes Jr. Research Institute, Division of Immunology, Children’s Hospital of Philadelphia, University of Pennsylvania School of Medicine and School of Veterinary Medicine, Philadelphia, PA, USA ANGEL PORGADOR • Department of Microbiology and Immunology, Ben Gurion University, Beer Sheva, Israel AMANDA K. PURDY • Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA, USA MICHAL PYZIK • Department of Human Genetics, McGill University, Montreal, QC, Canada GREGORY D. RAK • Cell Biology and Physiology Graduate Group, Division of Immunology, Children’s Hospital of Philadelphia, University of Pennsylvania School of Medicine and School of Veterinary Medicine, Philadelphia, PA, USA ELEANOR M. RILEY • Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK BENYAMIN ROSENTAL • Department of Microbiology and Immunology, Ben Gurion University, Beer Sheva, Israel
xiv
Contributors
KERI B. SANBORN • Immunology Graduate Group, Division of Immunology, Children’s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA, USA JOHAN K. SANDBERG • Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden STEPHANIE L. SANOS • Institute of Medical Microbiology & Hygiene, University of Freiburg Medical Center, Freiburg, Germany AURORE SAUDEMONT • Lymphocyte Signalling and Development, The Babraham Institute, Cambridge, UK RAM SAVAN • Cancer and Inflammation Program, Laboratory of Experimental Immunology, National Cancer Institute-Frederick, Frederick, MD, USA L´eONARDO SCARPELLINO • Ludwig Institute for Cancer Research Ltd., Lausanne Branch, and University of Lausanne, Epalinges, Switzerland LUIS SIGAL • Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA, USA MARK J. SMYTH • Peter MacCallum Cancer Centre, Parkville, Victoria, Australia NIKUNJ V. SOMIA • Department of Genetics, Cell Biology and Development, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA CHANDRAKANT TAYADE • Department of Anatomy and Cell Biology, University of Guelph, Guelph, ON, Canada ANITA TRUNDLEY • Department of Pathology, University of Cambridge, Cambridge, UK SILVIA M. VIDAL • Department of Human Genetics, McGill University, Montreal, QC, Canada CEDRIC VONARBOURG • Institute of Medical Microbiology & Hygiene, University of Freiburg Medical Center, Freiburg, Germany STEPHANIE M. WOOD • Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden PAUL W. WRIGHT • Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick Inc., National Cancer Institute-Frederick, Frederick, MD, USA HAKIM YADI • Lymphocyte Signalling and Development, The Babraham Institute, Cambridge, UK AUREO T. YAMADA • Laboratory of Histochemistry and Cytochemistry, Institute of Biology, UNICAMP, Campinas, Brazil WAYNE M. YOKOYAMA • Howard Hughes Medical Institute, Rheumatology Division, Departments of Medicine, Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA HOWARD A. YOUNG • Cancer and Inflammation Program, Laboratory of Experimental Immunology, National Cancer Institute-Frederick, Frederick, MD, USA JIANHONG ZHANG • Department of Anatomy and Cell Biology, Queen’s University, Kingston, ON, Canada ALON ZILKA • Department of Microbiology and Immunology, Ben Gurion University, Beer Sheva, Israel
Chapter 1 Purification of Human NK Cell Developmental Intermediates from Lymph Nodes and Tonsils Aharon G. Freud and Michael A. Caligiuri Abstract Accumulating data indicate that human natural killer (NK) cells undergo terminal maturation in secondary lymphoid tissues (SLTs) including lymph nodes (LNs) and tonsils. In addition, recent studies have revealed that maturing NK cells progress through at least five functionally discrete stages of development within SLTs. These discoveries provide unique possibilities for researchers to investigate the natural processes governing human NK cell development, as they exist in vivo, through analysis of NK cell maturational intermediates found in situ. Herein we describe a detailed, yet simple, four-step protocol for the viable enrichment and purification of human NK cell developmental intermediates from LNs and tonsils. Key words: CD34, lymph node, tonsil, secondary lymphoid tissue, lymphopoiesis, NK development, stages of NK development, NK maturation, purification, isolation, sorting.
1. Introduction Like all other leukocyte populations, natural killer (NK) cells derive from pluripotent hematopoietic progenitor cells (HPCs) through a complicated process of development that involves both differentiation toward the NK cell lineage and maturation into functional competence (1). Traditionally, the process of human NK cell development has been studied almost exclusively in vitro, with researchers culturing purified CD34(+) HPCs in medium plus cytokines in order to derive functionally competent NK cells as well as their immediate precursors. Although such culture systems have provided invaluable insight into numerous aspects of K.S. Campbell (ed.), Natural Killer Cell Protocols, Methods in Molecular Biology 612, DOI 10.1007/978-1-60761-362-6 1, © Humana Press, a part of Springer Science+Business Media, LLC 2010
1
2
Freud and Caligiuri
human NK cell development, they are nonetheless limited by the very fact that it is essentially impossible to wholly recapitulate in vitro what naturally occurs in vivo. Recent discoveries from our laboratory and from others indicate that human NK cells undergo terminal maturation in secondary lymphoid tissues (SLTs) including lymph nodes (LNs) and tonsils (2, 3). Moreover, it is now clear that maturing NK cells progress through at least five functionally discrete stages of development within SLTs: stage 1 CD34(+)CD117(−)CD94(−)CD16(−), stage 2 CD34(+) CD117(+)CD94(−)CD16(−), stage 3 CD34(−)CD117(+) CD94(−)CD16(−), stage 4 CD34(−)CD117(+/−)CD94(+)CD 16(−), and stage 5 CD34(−)CD117(−)CD94(+/−)CD16(+) (4, 5). These findings provide unique possibilities for researchers to investigate the natural processes governing human NK cell development as they exist in vivo, through analysis of NK cell maturational intermediates found in situ. The process of isolating human NK cell developmental intermediates is relatively straightforward, and we have developed a simple, four−step protocol for the viable enrichment and purification of these cells directly from LNs and tonsils using commercially available reagents. The first step in this protocol involves the generation of SLT mononuclear cell (SLTMC) single-cell suspensions from gross tissue. Subsequently, the NK-lineage cells, which are all, by definition, CD3(−)CD19(−), are greatly enriched from SLTMCs via the depletion of total CD3(+) T cells and CD19(+) B-lineage cells that generally constitute >90% of the SLTMCs. Following the depletion step, stage 1 and stage 2 CD34(+) populations are separated from stage 3–5 cells via positive selection of CD34 HPCs. Lastly, each of the stage 1–5 cells may be sorted to purity, and we provide a useful staining procedure and sorting scheme for this purification.
2. Materials 2.1. Generation of SLTMC Single-Cell Suspensions
1. Dulbecco’s phosphate buffered saline (PBS) 1× (without calcium chloride or magnesium chloride) at room temperature (Invitrogen). 2. Ficoll-PaqueTM Plus density gradient at room temperature (GE Healthcare BioSciences). 3. 100− × 20 mm-style polystyrene cell culture dish (Corning Inc.). 4. 70−m cell strainers (BD Biosciences).
Purification of Human NK Precursors
3
5. Small surgical scissors and forceps. 6. 3-ml syringe (Becton Dickinson). 7. 50-ml centrifuge tubes (Greiner Bio-One). 2.2. Depletion of T and B Cells from SLTMCs
1. Midi selection magnet(s) with stand (Miltenyi Biotech). 2. LD depletion columns (Miltenyi Biotech). 3. Anti-human CD3 microbeads (Miltenyi Biotech). 4. Anti-human CD19 microbeads (Miltenyi Biotech). 5. De-gassed PBS+: PBS plus 0.5% fetal bovine serum (FBS) plus 2 mM EDTA (Invitrogen). Keep at 4◦ C or on ice (see Note 1). 6. 50-ml centrifuge tubes. 7. 15-ml centrifuge tubes (Greiner Bio-One). 8. 70-m cell strainers.
2.3. Positive Enrichment of CD34(+) HPCs
1. Mini selection magnet with stand (Miltenyi Biotech). 2. MS selection columns packaged with plungers (Miltenyi Biotech). 3. PBS+. 4. CD34 progenitor isolation kit including Fc-blocking antibody (Ab), anti-CD34 hapten Ab, and anti-hapten microbeads (Miltenyi Biotech). 5. 5-mL round-bottom tubes with caps (Becton Dickinson) (see Note 2).
2.4. Immunofluorescent Staining for Viable Cell Sorting
1. PBS+. 2. Culture medium consisting of RPMI-1640 + Glutamax plus 10% FBS and antibiotics (Invitrogen). 3. Direct fluorochrome-conjugated antibodies: CD45RA fluorescein isothiocyanate (FITC) (clone HI100), CD94 FITC (clone HP-3D9), CD117 phycoerythrin (PE) (clone 104D2), CD34 allophycocyanin (APC) (clone 581), CD3 APC (clone UCHT1), CD16 APC-Cy7 (clone 3G8) (BD Biosciences). 4. 5-mL round-bottom tubes with caps.
3. Methods It is important to appreciate the fact that human NK cell developmental intermediates, while relatively enriched among total HPCs and NK-lineage cells in SLTs compared to the blood or bone
4
Freud and Caligiuri
marrow compartments, nonetheless collectively constitute only a very minor fraction of the total cellularity of tonsils and LNs (4). Indeed these tissues contain not only a predominance of T and B cells but also numerous other cell types, including mast cells, dendritic cells, myeloid cells, endothelial cells, and nonhematopoietic stroma, which normally reside in SLTs. Therefore, although tonsil specimens may provide an average of one billion total mononuclear cells (with LNs providing far less depending upon size), it is common to obtain only a few thousand stage 1 and stage 2 cells and less than 105 stage 3–5 cells each after each isolation. Such low cell yields may preclude some molecular studies. 3.1. Generation of SLTMC Single-Cell Suspensions
1. The bottom and the lid of the Petri dish are separated from each other and each is filled with 20 mL room temperature PBS. The tonsil or the LN is placed into the bottom of the dish and cut into roughly 1 cm3 pieces using the forceps and scissors. Note that as soon as cuts are made into the tissue, cells can be seen diffusing into the surrounding PBS. If the tissue is encroached by fat (as is often the case with LN specimens), the latter should be removed prior to cutting and discarded as much as possible to avoid losing cells sticking to the fat. 2. A 70-m cell strainer is placed into the PBS within the lid of the Petri dish, and the first piece of lymphoid tissue (LT) is then cut as finely as possible over the strainer (being careful not to cut the strainer with the scissors). Using the flat top of the 3-ml syringe plunger, the tissue is gently, yet firmly, mashed against the bottom of the strainer in circular motions so that individual cells pass through into the PBS, whereas fibroadipose pieces of tissue remain within the strainer. The strainer is then discarded (see Note 3). 3. Step 2 is repeated with three more pieces of LT using a new cell strainer for each. 4. The 20mL of PBS-containing strained cells (from a total of four LT pieces) is carefully mixed within the lid with a pipette and then evenly distributed across three 50-ml tubes. 5. The lid of the Petri dish is refilled with 20 mL fresh PBS and Steps 2–4 are repeated until all LT pieces have been mashed and strained. The PBS contained within the bottom of the dish (where the numerous pieces of LT were kept in queue) is then strained and evenly distributed across the three 50ml tubes. All LT cells are now in suspension and divided evenly across three 50-ml tubes.
Purification of Human NK Precursors
5
6. The cells in each 50-ml tube are split across two tubes (thus, there will be six tubes altogether). The volume within each tube is then brought up to 40 mL total with room temperature PBS. 7. Fifteen milliliters of room temperature Ficoll is added to 12 separate 50-ml tubes (see Note 4). Twenty milliliters of cells is then gently and slowly overlaid onto the Ficoll in each of the 12 tubes (see Note 5). 8. The 12 tubes containing cells and Ficoll are centrifuged for 30 min at room temperature, 740 × g with the brake OFF (see Note 6). 9. The mononuclear layers are removed and each is added to a new 50-ml tube (12 tubes altogether). 10. The cells in each tube are washed of the Ficoll by dilution to a total volume of 50 mL with PBS followed by centrifugation for 8 min at 15◦ C, 385 × g with the brake on. 11. The supernatants are aspirated and the cell pellets are combined into one of the 50-ml tubes with a total of 10 mL (see Note 7). The 11 other tubes are then serially washed with 30 mL PBS that is finally added to the 10 mL of combined cells so that all of the SLTMCs are in suspension within a total volume of 40 mL. 12. The cells are thoroughly mixed and a small aliquot is removed for enumeration on a hemocytometer (see Note 8). The SLTMCs can be placed on ice while counting. 3.2. Depletion of T and B Cells from SLTMCs
1. CD3/CD19 depletion involves a one-step staining process followed by depletion across LD columns. 2. The SLTMCs are centrifuged for 8 min at 15◦ C, 385 × g. 3. Following centrifugation, the supernatant is discarded and the cells are resuspended and stained as follows within the 50-ml tube: For every one million cells in the pellet, add 8 L PBS+ plus 1 L CD3 microbeads plus 1 L CD19 microbeads. Thus, the cells will be in a total volume of 10 L/106 cells (see Note 9). 4. The cells are incubated in a 4◦ C refrigerator or cold room (rather than on ice, as per manufacturer’s instructions) for at least 15 min. For total volumes greater than 10 mL, the 50-ml tube should be placed on a nutator mixer or some similar device within a cold room to keep the cells thoroughly mixed in suspension with the microbeads during the incubation period. For samples less than 10 mL, it is sufficient to gently mix the cells via brief vortex or swirling
6
Freud and Caligiuri
the tube in a circular motion by hand for 15 s halfway through the incubation period. 5. During the incubation period, LD columns are placed into Midi magnets as per the manufacturer’s instructions, and the columns are equilibrated with 3 mL PBS+ each(to calculate the total number of LD columns needed for the entire sample, see Note 10). It usually takes 10–12 min for 3 mL to completely flow through each LD column. The LD columns are ready for use once all PBS+ is gone from the reservoir above the magnetic particles within the column and droplets have ceased to form below the column. The magnets and columns should be set up so that a 15-ml centrifuge tube can be placed underneath each column in order to catch the flow-through negative fraction. Every part of this step should be done at room temperature inside a tissue-culture hood to maintain sterility. 6. After the incubation of the cells with the microbeads, it is necessary to wash the cells to remove any unbound microbeads. The cells are diluted with additional PBS+ to a total volume of 50 mL within the 50-ml tube, and then they are centrifuged for 8 min at 15◦ C, 385 × g. The supernatant is discarded and the cells are resuspended in 50 mL PBS+ for a repeat wash step with centrifugation as described above. 7. Following the second wash, the cells are resuspended in ice cold PBS+ for depletion over the equilibrated LD columns. The total volume for depletion is 3 mL multiplied by the total number of LD columns. For example, for 10 LD columns (one billion cells in total), the cells should be resuspended in 30 mL PBS+. Prior to adding the cells to the columns, it is beneficial to filter out any clumps that may have formed during the incubation period. This is done by passing the cells over a 70-m cell strainer into a new 50-ml tube. In this case, to avoid losing cells leftover in the old tube, the cells can first be resuspended in a volume less than the final volume needed (for example, 20 mL rather than 30 mL as in the case above), then passed over the cell strainer, and finally the old tube can be washed with 10 mL PBS+ and passed over the same cell strainer to give a total volume of 30 mL (3 mL per LD column). 8. Once the cells are resuspended in the appropriate volume of PBS+, the cells are mixed thoroughly and distributed across the depletion columns. If there are more cells than columns available, the cells may be placed on ice until the next round of depletion using new LD columns.
Purification of Human NK Precursors
7
9. After the cells have completely passed through the columns (i.e., no cells are left in the LD column reservoirs), the 50-ml tube (if empty) is washed with cold PBS+ (3 mL per LD column) and then 3 mL is added per column. This is the first wash, and the 50-ml tube can now be discarded. It is important to not let the columns go dry, so care should be taken to ensure that the wash steps occur very soon after the cells pass through the columns. 10. A second wash of 3 mL PBS+ per LD column is added to each column after the first wash is complete. 11. After the second wash goes through and no more droplets fall from the bottom of the columns, the 15-ml tubes (now containing approximately 11 mL of cells in PBS+) are removed from the magnet apparatus, capped, and centrifuged for 8 min at 15◦ C, 385 × g. 12. During centrifugation, the LD columns can be discarded unless the T and/or B cells within the columns are to be used. In this case, the columns are removed from the magnets and repeatedly plunged with 5 mL PBS+ (four plunges altogether) into a collection tube. 13. After centrifugation of the 15-ml tubes containing Tand B-cell-depleted SLTMCs (Section 3.2, Step 11), the supernatants are removed and the cells are combined into one 15-ml tube. A small aliquot is then taken for enumeration on a hemocytometer and the rest of the cells are placed on ice (see Note 11). 3.3. Positive Enrichment of CD34(+) HPCs
1. The CD34 enrichment involves a two-step staining process followed by positive selection over MS columns. 2. The T-/B-cell-depleted SLTMCs in the 15-ml tube (Section 3.2, Step 13) are centrifuged for 8 min at 15◦ C, 385 × g. The supernatant is discarded, and the cell pellet is resuspended within the 15-ml tube in 2 L PBS+, 1.5 L Fc-blocking Ab, and 1.5 L anti-CD34 hapten Ab, each per million cells in that order. If the total cell number is less than 10 million cells, they should be stained as if there were 10 million (i.e., not less than 20 L PBS+ plus 15 L each antibody in total). 3. The cells are incubated at 4◦ C in a refrigerator for 15 min, with gentle mixing by swirling the tube for 15 s halfway through the incubation. 4. The cells are then washed by adding 5 mL PBS+ followed by centrifugation for 8 min at 15◦ C, 385 × g. 5. After the spin, the supernatant is discarded and the cells are resuspended in 3.5 L PBS+ plus 1.5 L anti-hapten microbeads per million cells in that order.
8
Freud and Caligiuri
6. The cells are again incubated for 15 min at 4◦ C in a refrigerator, as per Section 3.3, Step 3. 7. During this second incubation, one MS column per sample is equilibrated by placing the column on the Mini magnet and adding 1 mL PBS+ to the reservoir. A sterile 5-mL tube is placed directly underneath the column in order to catch the flow-through. This is all done inside a sterile tissueculture hood. 8. Following incubation, the cells are again washed as in Section 3.3, Step 4. 9. After discarding the supernatant, the cells are resuspended in 1 mL PBS+ and placed into the reservoir of the equilibrated MS column that is on the Mini magnet (the 15ml tube is saved for the next step). Because the CD34(+) HPCs are labeled with microbeads, stage 1 and 2 NK cell developmental intermediates are retained within the column (while it is on the magnet), whereas stage 3–5 cells flow through the column and are collected in the 5-mL tube. 10. Once all the fluid has passed through the column, the bottom of the 15-ml tube is rinsed with 0.5 mL PBS+ that is then added to the reservoir above the column. 11. After the PBS+ rinse has passed through the column (ensuring first that drops have ceased to form under the column tip), the 5-mL tube with the CD34(−) fraction is set aside and replaced with a new sterile 5-mL tube, labeled “NK presort.” 12. The CD34(−) cell fraction in the first 5-mL tube is mixed by gentle pipetting and then passed over the column for a second round in order to retrieve any residual CD34(+) cells that may have initially passed through the column. We have observed this to significantly increase overall yields of CD34(+) HPCs. 13. After the cells have passed through the column, the first 5-mL tube is rinsed with 1 mL PBS+ that is then passed over the column as a wash step. 14. After the last of the drops have fallen from beneath the column, the “NK presort” tube is capped and set aside on ice. The MS column is removed from the magnet and plunged with 1 mL PBS+ into a new 5-mL tube, labeled “34 presort.” For best results, the PBS+ should be forced through the column immediately after it has been added to the column. The plunger is removed from the reservoir of the column and another 1 mL PBS+ is plunged through the column into the “34 presort” tube. This is again repeated
Purification of Human NK Precursors
9
twice for a total of four plunges. These plunges should rapidly follow one after the other, and it is recommended that if working with more than one sample, the first column should be plunged all four times before moving to subsequent columns. 15. At this step there are two tubes per sample (“CD34 presort” and “NK presort”), each with ∼4 mL total. The “34 presort” and “NK presort” tubes are then centrifuged for 8 min at 15◦ C, 385 × g. 16. Following the spin, the supernatants are carefully aspirated, leaving ∼100 L liquid. The cell pellets are resuspended in this residual volume, and the tubes can be placed on ice until proceeding with the immunofluorescent staining protocol. 3.4. Immunofluorescent Staining for Viable Cell Sorting
1. Eight new 5-mL tubes are labeled as follows: “34 unstained,” “34 FITC,” “34 PE,” “NK unstained,” “NK FITC,” “NK PE,” “NK APC,” and “NK APC-Cy7.” These
Table 1.1 Antibodies and volumes for immunofluorescent staining prior to sorting Fluorochrome (volume added) Tube label
FITC
PE
APC
APC-Cy7
34 Unstained
–
–
–
–
34 FITC
CD45RA FITC (2.5 L)
–
–
–
34 PE
–
CD117 PE (5 L)
–
–
34 Presort
CD45RA FITC (2.5 L)
CD117 PE (5 L)
CD34 APC (2.5 L)
–
NK unstained
–
–
–
–
NK FITC
CD94 FITC (10 L)
–
–
–
NK PE
–
–
–
NK APC
–
CD117 PE (5 L) –
CD3, CD34 APC (2.5 L each)
–
NK APC-Cy7
–
–
–
CD16 APC-Cy7 (2.5 L)
NK presort∗
CD94 FITC
CD117 PE
CD3, CD34 APC
CD16 APC-Cy7
∗ The volume of each antibody added to the “NK presort” tube depends upon the total cell number (for simplicity, the total cell number from Section 3.2, Step 13 can be used). For every 2 million cells, add 10 L CD94 FITC, 5 L CD117 PE, 2.5 L CD16 APC-Cy7, 2.5 L CD3 APC, and 2.5 L CD34 APC.
10
Freud and Caligiuri
Fig. 1.1. Representative gating scheme for sorting NK cell developmental intermediates from human SLTs. (A) Enriched tonsil CD34(+) cells were stained as indicated in Table 1.1 and analyzed on a FACSVantage flow cytometer. The dot plots are gated as indicated with the following regions: R1, live cells with size and granularity characteristics typical of progenitor cells; R2, CD45RA(+) events; R3, CD34(+)CD117(−) events; R4, CD34(+)CD117(+) events. (B) Tonsil CD3(−)CD19(−)CD34(−) cells were stained as indicated in Table 1.1 and analyzed on a FACSVantage. The dot plots and histogram are gated as indicated with the following regions: R1, live cells within the typical “lymphocyte” gate (small size, low granularity); R2, CD3(−)CD34(−) events; R3, CD117(+)CD94(−) events; R4, CD117(dim/−)CD94(+) events; R5, CD16(−) events; R6, CD16(+) events.
are the control tubes for setting the voltage, amplitude, and compensation parameters on the cell sorter (see Note 12). 2. One hundred microliters of ice cold PBS+ are added to each of the control tubes. 3. Three microliters of cells from the “34 presort” and “NK presort” tubes are then added to each of the corresponding control tubes listed in Section 3.4, Step 1. 4. The cells in each of the tubes are stained with fluorochromelabeled Abs as shown in Table 1.1. We provide the volumes of antibodies typically used in our laboratory, but it is rec-
Purification of Human NK Precursors
11
ommended that these Abs be titrated for optimal staining prior to use as there may be variations from lot to lot. After adding the appropriate volume of each of the Abs, the samples are incubated on ice and covered from light for at least 15 min. 5. Following incubation, the cells are washed with 2 mL PBS+ and then centrifuged for 8 min at 15◦ C, 385 × g.
3.5. Gating Scheme for Sorting Stages 1–5
6. The supernatants are discarded, and the cell pellets are resuspended in the following volumes of culture medium: 300 L for each of the control tubes; 1 mL for the “34 presort” tube; and 3 mL for the “NK presort” tube (see Note 13). The cells are kept on ice and covered from light until they are sorted. 1. Figure 1.1 shows dot plots from a sort for human NK cell developmental intermediates using the staining protocol outlined in Section 3.4. 2. Using the staining protocol outlined herein, stage 1–5 cells are sorted as follows: a. Stage 1 cells: R1 + R2 + R3 (Fig. 1.1A) b. Stage 2 cells: R1 + R2 + R4 (Fig. 1.1A) c. Stage 3 cells: R1 + R2 + R3 (Fig. 1.1B) d. Stage 4 cells: R1 + R2 + R4 + R5 (Fig. 1.1B) e. Stage 5 cells: R1 + R2 + R4 + R6 (Fig. 1.1B) (see Note 14)
4. Notes 1. The SLTMCs are kept in PBS+ solution for most of the protocol following the Ficoll centrifugation step during which the PBS and Ficoll are used at room temperature (see Note 6). For better viability and less chance that the cells will become activated through the procedure, the PBS+ should be kept cold even though many steps of the protocol, aside from incubations and centrifugations, are performed in a sterile hood at room temperature. In addition, to prevent microbubbles from clogging the magnetic columns, the manufacturers recommend that the PBS+ be “de-gassed” prior to use. This can be done by filtering the freshly made PBS+ through a 0.22−m vacuum filter (e.g., Steriflip products by Millipore) and leaving the vacuum attached for 30 min after the liquid has been filtered. 2. Both polystyrene and polypropylene 5-mL round-bottom tubes are commercially available. Either can be used for this
12
Freud and Caligiuri
protocol, but compatibility with the cell sorter may depend on the make and model of the latter. Researchers should determine which kind of tube is to be used at their institution. 3. Most of the LTs consist of hematopoietic cells that will go into suspension. Therefore, a good rule of thumb is to continue gently grinding the tonsil or the LN piece against the strainer until all that is left is white, fibroadipose tissue. 4. In our experience, the majority of tonsils provide between 0.5 and 2 × 109 SLTMCs in total. For this number of cells, 12 Ficoll tubes is an appropriate number so as not to overwhelm the Ficoll and have potentially inefficient separation of the mononuclear cells from the fat, debris, endothelial cells, and other non-mononuclear cells. However, for small LN specimens or very large tonsil specimens, individuals may choose to use fewer or more Ficoll tubes, respectively. 5. One must take care to pipette very slowly when initially overlaying the cells upon the Ficoll so as not to mix the cells with the former prior to centrifugation. For those with experience in overlaying blood upon Ficoll, note that blood is much thicker and, thus, less likely to mix with the Ficoll during the overlay compared to LT cells in suspension in PBS. A helpful technique is to angle the 50-ml Ficoll tube at 45◦ and to disperse the cells near the top of the tube very slowly so that the cells run down the side and gently lay over the Ficoll. 6. It is very important to leave the centrifuge break off so that the mononuclear cell layers are not disrupted by an abrupt stop. In addition, the centrifuge should be set at room temperature in order to increase the probability of obtaining very distinct mononuclear layers above the Ficoll. In our experience, centrifugation at cold temperatures results in suboptimal results with hazy mononuclear layers. This is why room temperature PBS and Ficoll are used prior to the centrifugation step. 7. For this step, 10 mL PBS is used to resuspend the cell pellet in the first tube. This cell suspension is then used to resuspend the next cell pellet and so on until all cell pellets have been resuspended and combined in a total of 10 mL within one 50-ml tube. 8. For counting the cells, we generally start with a 40-fold dilution of the cells by first removing 10 L from the mixed cell sample, diluting this 1:10 with PBS, and then diluting the cells again 1:4 with trypan blue. This prevents an excess waste of trypan blue, which is also toxic to cells at high exposure.
Purification of Human NK Precursors
13
9. With so many cells in one 50-ml tube, the cell pellet is very large. To ensure proper resuspension, it is recommended to first use a 5-mL pipette (smaller volume pipettes have smaller diameter tips through which the cells are forced) with 3–5 mL PBS+ and to repeatedly spray the cells against the side of the tube multiple times until there are no visible clumps. Subsequently, additional PBS+ can be added up to the desired volume. This procedure is recommended in general for resuspending large cell pellets. 10. As per the manufacturer’s instructions, each LD column can efficiently deplete up to a maximum of 1 × 108 cells in total. In our laboratory, to determine the number of LD columns to use, we round the total number of cells to the nearest 108 and divide by 108 . For example, for a sample with 9.3 × 108 cells, nine LD columns are used. Note: Because one Midi magnet can hold only one LD column, it is beneficial to purchase multiple Midi magnets and stands so that cells can be passed over the LD columns in parallel rather than in series. This is very important in terms of saving time, because one round of depletion over an LD column, including the initial cell suspension followed by two sequential washes, takes roughly 45 min. With 10 Midi magnets, one can deplete a total of one billion SLTMCs in 45 min, whereas it would take 7.5 h with the use of only one magnet for the same total number of SLTMCs. 11. It is common for the cell yield following T- and B-cell depletion to be approximately 1% of the initial SLTMC count. As such, the cell pellets are much smaller (1–2 mm in diameter) after the depletion step. Nonetheless, the NKlineage cells are greatly enriched within this cell mixture. 12. This staining protocol is applicable for sorting human NK cell developmental intermediates using a FACSVantage or a FACSAria cell sorter from BD Biosciences. Alternative staining protocols may be required if using different sorting machines. 13. In our practice, we prefer to put the cells in culture medium (on ice) prior to the sort in the event that there may be unforeseen delays in sorting the cells. If it is anticipated that the cells will be on ice only for a short amount of time prior to sorting, it is fine to put the cells in PBS+ rather than medium. In addition, we have found that it is preferable to dilute the cells as much as reasonably possible so that there is less chance of cell clumping that could clog the sorter. 14. The minimal CD3(−)CD16(+) phenotype is not sufficient to identify stage 5 NK cells, because non-NK-lineage cells,
14
Freud and Caligiuri
including monocytes and granulocytes, can express CD16 within SLTs. In contrast, the CD3(−)CD94(+)CD16(+) phenotype does unequivocally identify CD56(+) NK cells in these tissues (data not shown). Given that the vast majority of stage 5 cells express CD94, for practical purposes we sort stage 5 cells as CD3(−)CD34(−)CD94(+)CD16(+) and forgo the rare stage 5 cells with background level fluorescent intensity staining of CD94.
Acknowledgments The authors would like to thank Tamra Brooks for her assistance with the chapter. Funding for the Caligiuri laboratory is provided by the National Cancer Institute (P30 CA16059, CA68458 and CA95426) (M.A.C.). References 1. Colucci F., Caligiuri M. A., Di Santo J. P. (2003) What does it take to make a natural killer? Nat Rev Immunol 3, 413–25. 2. Ferlazzo G., Thomas D., Lin S. L., Goodman K., Morandi B., Muller W. A., Moretta A., M¨unz C. (2004) The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic J Immunol 172, 1455–62. 3. Freud A. G., Becknell B., Roychowdhury S., Mao H. C., Ferketich A. K., Nuovo G. J., Hughes T. L., Marburger T. B., Sung
J., Baiocchi R. A., Guimond M., Caligiuri M. A. (2005) A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells Immunity 22, 295–304. 4. Freud A. G., Caligiuri M. A. (2006) Human natural killer cell development Immunol Rev 214, 56–72. 5. Freud A. G., Yokohama A., Becknell B., Lee M. T., Mao H. C., Ferketich A. K., Caligiuri M. A. (2006) Evidence for discrete stages of human natural killer cell differentiation in vivo J Exp Med 203, 1033–43.
Chapter 2 In Vitro Development of Human Killer–Immunoglobulin Receptor-Positive NK Cells Frank Cichocki and Jeffrey S. Miller Abstract The in vitro culture system outlined in this chapter allows for the delineation of events that occur during the development of CD34+ hematopoietic precursor cells into mature KIR+ human NK cells. This system can also be utilized to study the effects of gene overexpression or knockdown on the process of NK cell differentiation through retroviral transduction and long-term culture. The necessary soluble factors and contact-dependent conditions for in vitro human NK cell development have been worked out in our laboratory over the past 16 years. Key words: Human NK cell development, lymphocyte differentiation from hematopoietic precursors
1. Introduction Both mouse and human natural killer cells recognize transformed and virally infected cells and influence the direction of the adaptive immune response in infectious settings (1). However, there are several notable differences between mouse and human NK cells with respect to differentiation markers, making developmental comparisons between the species difficult (2–4). To evaluate and manipulate human natural killer cell differentiation, a robust ex vivo cell culture system is necessary. To this end, our laboratory has developed a long-term culture system for studying human NK cell development from primitive progenitor cells (5–9). In 1992, we were the first to show that primitive progenitors from adult bone marrow can give rise to functional NK cells K.S. Campbell (ed.), Natural Killer Cell Protocols, Methods in Molecular Biology 612, DOI 10.1007/978-1-60761-362-6 2, © Humana Press, a part of Springer Science+Business Media, LLC 2010
15
16
Cichocki and Miller
when cultured in contact with human bone marrow stroma (5). In 1994, we found that in the absence of factors known to support NK cell differentiation, direct contact with human allogeneic stroma is critical for NK cell differentiation (6). In 1998, after an explosion of new data describing novel NK cell receptors recognizing class I MHC, we found that our in vitro model of NK cell differentiation supported the acquisition of KIR (specifically KIR3DL1 in this initial description) (7). Limitations of these initial studies included the heterogeneity and variability of primary human stroma, low cloning frequency when plating primitive stem cell populations, and the inability to support differentiation at the single cell level. These issues raise the possibility of starting progenitor contamination. Therefore, definitive study of NK cell precursors was technically difficult. In 1999, we pioneered the use of a novel murine stromal cell line, called AFT024, which was derived from day 14 gestational fetal liver cells immortalized by a retrovirus containing a temperature-sensitive SV40 T antigen. The most important finding for the success of NK cell development cultures is that AFT024 could officially support NK cell differentiation of human cells at the single cell level. Using this system, we have shown that KIR and NKG2/CD94 receptors are acquired late in NK cell development (8). In 2008, we further improved this system by comparing NK cell development on a novel murine cell line called EL08-1D2 cloned from a culture of embryonic liver at day 11 of gestation. EL08-1D2 was chosen for these studies because of its ability to support generation of human hematopoietic progenitors from CD34+ umbilical cord blood cells without the addition of any cytokines. Use of EL08-1D2 identified several novel properties of this stromal feeder. First, when IL-15 was eliminated from the culture medium, there was an accumulation of CD56− NK cell precursors defined as CD34+ /CD7− , CD34+ /CD7+ , and CD34− /CD7+ . The role of IL-3 and IL-3 plus Flt3 ligand was established, and c-kit ligand and IL-7 appear to add efficiency to the system but are not absolutely required for NK cell differentiation. EL08-1D2 was superior to AFT024 for supporting differentiation of NK cell precursors, NK cell commitment, the acquisition of KIR, and overall proliferation (9). EL08-1D2 has been the stromal feeder of choice in our laboratory based on its ability to recapitulate the acquisition of class I recognizing receptors and developmental intermediates which may be important in NK cell maturation (10). There has been support in the literature for NK cell differentiation cultures in the absence of stroma. In review of this literature, our stromal-based cultures seemed to better allow the acquisition of NK cell receptors where NK cell differentiation in the absence of stroma but in the presence of high concentrations of human cytokines allows NK cell commitment with poor expression of
In Vitro Development of Human Killer–Immunoglobulin Receptor-Positive
17
KIR (11). Our data support the notion that unique signals from stroma are important in the acquisition of NK cell receptors. Further proof is the finding that CD56bright KIR− cells can transition into CD56dim KIR+ cells on EL08-1D2 and human IL-15 (12). In summary, methods for NK cell differentiation cultures using EL08-1D2 will be described here. Other stromal cell lines, such as OP9 and MS5, have been used in the literature for similar purposes and could possibly be substituted here but direct comparisons with EL08-1D2 have not been performed in our laboratory (13, 14). CD34+ hematopoietic progenitors from umbilical cord blood are highly efficient in NK cell development in terms of both cloning efficiency and proliferation. Other hematopoietic stem cell sources such as bone marrow, peripheral blood progenitors, and fetal liver have been tested in our laboratory and can be substituted here if desired, but their efficiency may differ from the bulk of our work using human umbilical cord blood progenitors.
2. Materials This protocol includes the experimental procedures that our laboratory has developed to retrovirally transduce CD34+ cells prior to long-term culture in order to study the effects of gene overexpression or knockdown. If the user does not desire to carry out retroviral transduction, Section 2.3 and steps 24–42 in Section 3.3 can be excluded from the protocol. 2.1. EL08-1D2 Cell Culture and Irradiation
1. EL08-1D2 cells: mouse embryonic liver cells. These cells were obtained from E. Dzierzak at Erasmus University MC, Rotterdam, the Netherlands. 2. EL08-1D2 medium: 202.5 ml ␣-MEM medium (Gibco, R M5300 medium (StemCarlsbad, CA), 250 ml Myelocult Cell Technologies Inc., Vancouver, BC, Canada), 37.5 ml fetal calf serum (see Note 1), 5 ml Penicillin + Streptomycin, 5 ml 100× Glutamax (Gibco), 35.0 l -mercaptoethanol (0.143 M stock: 1:100 in H2 O), and hydrocortisone at a final concentration of 10−6 M. Hydrocortisone must be added fresh at the time of use. This medium (without hydrocortisone) can be stored at 4◦ C for up to 1 month. Note that these additives should be included on top of what is already R M5300 medium. present in the Myelocult 3. Ultrapure water with 0.1% gelatin (Chemicon Intl., Billerica, MA). 4. Trypsin/EDTA (Gibco).
18
Cichocki and Miller
5. Flat-bottom 96-well cell culture plates (Becton Dickinson, Franklin Lakes, NJ). 6. Multi-channel pipetter. 7. Cesium irradiator. 2.2. CD34+ Cell Isolation from Umbilical Cord Blood
R 1. Histopaque -1077 (Sigma-Aldrich, St. Louis, MO).
2. Ammonium chloride solution (StemCell Technologies Inc.). R (Beckman Coulter, Fullerton, 3. Coulter Particle Counter CA).
4. PBS/0.3% BSA. 5. Direct CD34 Progenitor Cell Isolation Kit, human (Miltenyi Biotech, Oberlin, CA). R LS separation columns (Miltenyi Biotech). 6. MACS R pre-separation filters (Miltenyi Biotech). 7. MACS R magnetic stand and magnets (Miltenyi Biotech). 8. MACS
9. Cycling Medium: Iscove’s Modified Dulbecco’s Medium (with L-glutamine), 20% fetal bovine serum, 1% Penicillin + Streptomycin with 20 ng/ml IL-7, 20 ng/ml c-kit ligand, 20 ng/ml Flt3 ligand, and 20 ng/ml thrombopoietin. This medium can be stored at 4◦ C for up to 1 month. 10. 24-well cell culture plates (Becton Dickinson). 2.3. Retroviral Transduction and Cell Sorting of CD34+ Cells
1. Four separate 3 ml aliquots of retroviral supernatant (see Note 2). 2. Transwells with sterile 6-well culture plates − 0.4 M PTFE membrane, 24 mm insert (Corning Incorporated, Corning, NY). 3. Tweezers. 4. RetroNectin (r-Fibronectin) (Otsu, Shiga, Japan). 5. PBS/2% BSA. 6. Iscove’s Modified Dulbecco’s Medium (with L-glutamine) without fetal bovine serum (Gibco). 7. Cycling medium (see Section 2.2). 8. APC-conjugated anti-CD34 monoclonal antibody (clone 8G12, mouse IgG1 ; BD Biosciences) 9. APC-conjugated IgG1 isotype control monoclonal antibody (BD Bioscience). 10. 5 ml polystyrene round-bottom tubes with cell-strainer cap (BD Biosciences). 11. A fluorescence-activated cell sorter.
In Vitro Development of Human Killer–Immunoglobulin Receptor-Positive
2.4. Long-Term Culture of Sorted CD34+ Cells on the EL08-D12 Stromal Line
19
1. Basal Culture Medium: A 2:1 (vol:vol) mix of Dulbecco’s Modification of Eagle’s Medium (DMEM) with 4.5 g/l glucose, L-glutamine, and sodium pyruvate/Ham’s F12 Medium. This medium mixture is then supplemented with 24 M 2-mercaptoethanol, 50 M ethanolamine, 20 mg/l ascorbic acid, 50 g/l sodium selenite, 1% penicillin + streptomycin and 20% heat-inactivated human AB serum (Valley Biomedical, Inc., Winchester, VA). The following cytokines must also be added: 10 ng/ml IL-15, 5 ng/ml IL3, 20 ng/ml IL-7, 20 ng/ml c-kit ligand, and 10 ng/ml Flt3 ligand. This medium can be stored at 4◦ C for up to 1 month. 2. Multi-channel pipetter.
3. Methods 3.1. General Culture Conditions for EL08-1D2 Cells
1. Coat sterile cell culture flasks (75 cm2 or 150 cm2 ) with enough sterile ultrapure water with 0.1% gelatin to cover the bottom of the flask. Let the flask sit in the culture hood at room temperature for 10 min. The gelatin water is necessary to promote adherence of the EL08-1D2 cells. 2. After 10 min, remove the ultrapure water with 0.1% gelatin and gently rinse the bottom of the culture flask with PBS. Remove the PBS. 3. Plate cells at approximately 4000 cells/cm2 on gelatincoated flasks in an appropriate volume of EL08-1D2 medium (12 ml for a 75 cm2 flask or 24 ml for a 150 cm2 flask) containing 20% conditioned EL08-1D2 medium (see Note 3). 4. Culture cells in an incubator set to 32◦ C 5% CO2 . This is important, as the cells grow in a temperature-sensitive manner. 5. Once the cells are 95–99% confluent, they can be split into new flasks. 6. To split cells, remove the spent medium, filter, and store at −20◦ C. Add enough 1× trypsin/EDTA to cover the bottom of the flask and incubate at room temperature until the cells start to lift off the bottom of the flask. Add 5 ml of 0.2 m-filtered EL08-1D2 conditioned supernatant to neutralize the trypsin and collect cells in a 15 ml centrifuge tube. 7. Count cells using a hemocytometer. Remove the desired number of cells (approximately 4000 cells/cm2 ) to seed a new flask(s).
20
Cichocki and Miller
8. Centrifuge at 550 × g for 4 min and decant supernatant. 9. Resuspend cells in freshly prepared EL medium and gently transfer to a flask(s) freshly coated with gelatin water. 10. Return flask(s) to a 32◦ C 5% CO2 incubator. 3.2. Irradiation of EL08-1D2 Cells
1. Use a multi-channel pipette to add 50 l of ultrapure water with 0.1% gelatin per well into the desired number of flatbottom 96-well cell culture plates. Let plates incubate for 10 min at room temperature. 2. After 10 min, remove the ultrapure water with 0.1% gelatin and gently rinse the bottom of the culture plates with PBS. Remove the PBS. 3. Resuspend EL08-1D2 cells in fresh EL08-1D2 medium (with 20% conditioned medium and hydrocortisone) at a concentration of 104 cells/ml. 4. Add 103 cells per well (100 l) to the gelatin-coated and rinsed plates. Incubate plates at 32◦ C 5% CO2 for 3–5 days until the plates are 95–99% confluent. 5. Irradiate confluent plates with 30 Gy of radiation and let the plates incubate at 32◦ C 5% CO2 for at least 2 h before use. Irradiated plates can be kept for up to 1 week before use in an NK cell developmental assay.
3.3. CD34+ Cell Isolation and Retroviral Transduction
Day 1 R -1077 and PBS to room temperature. 1. Warm Histopaque 2. Transfer umbilical cord blood into a sterile container and add 50 ml PBS to dilute the blood. R -1077 to the necessary number of 3. Add 20 ml Histopaque 50 ml centrifuge tubes. R 4. Slowly layer 30 ml diluted blood over the Histopaque 1077.
5. Centrifuge at 550 × g for 30 min at room temperature with the brake off. 6. Slowly aspirate the plasma layer leaving approximately 1/2 R inch of liquid above the lymphocyte/Histopaque -1077 interface. 7. Harvest the lymphocytes from the lymphocyte interface and transfer to a new 50 ml centrifuge tube. Fill up to 50 ml with PBS and centrifuge at 850 × g for 5 min. 8. Gently decant the supernatant and resuspend cells in 10 ml ice-cold ammonium chloride solution. Incubate the cells on ice for 10 min. 9. Centrifuge for 5 min at 850 × g. Gently decant supernatant and resuspend cells in 20 ml PBS.
In Vitro Development of Human Killer–Immunoglobulin Receptor-Positive
21
10. Determine total cell number using a Coulter Particle R (see Note 4). Counter 11. Wash the cells by adding another 30 ml of PBS to the cell suspension. Centrifuge for 5 min at 850 × g. 12. Gently decant the supernatant and resuspend cells in 300 l PBS/0.3% BSA per 108 cells. Keep the PBS/0.3% BSA cold throughout the isolation procedure. 13. Label cells for isolation by adding 100 l FcR blocking reagent for every 108 cells. Next, add 100 l CD34 Microbeads for every 108 cells. Incubate for 30 min on ice in the dark. 14. Add 30 ml of PBS/0.3% BSA and centrifuge for 5 min at 850 × g. 15. Gently decant the supernatant and resuspend the cells in 0.5 ml of PBS/0.3% BSA. R LS column per cord blood donor on 16. Set up one MACS R R pre-separation a MACS Magnetic Stand. Place a MACS filter on top of each column and equilibrate the column with 3 ml of PBS/0.3% BSA. R pre-separation 17. Pipette the labeled cells into the MACS filter and let the cells pass through the column. There is no need to save the effluent, as the CD34+ cells will be retained within the column.
18. Wash the column three times with PBS/0.3% BSA. R 19. Remove the MACS pre-separation filter, pull the column off the magnet, and transfer the column to a 15 ml centrifuge tube. Apply 5 ml of PBS/0.3% BSA and forcefully plunge the liquid through the column to purge the labeled cells. R LS column. It is 20. Repeat steps 16–19 with a new MACS necessary to double-column the labeled cells in order to obtain a CD34+ population with a high level of purity.
21. Count the total number of cells in the CD34+ fraction using a hemocytometer. 22. Centrifuge cells for 4 min at 550 × g at 4◦ C (see Note 5). 23. Gently decant the supernatant and resuspend the cell pellet in Cycling Medium at a concentration of 5 × 105 cells/ml. Transfer the cells in Cycling Medium to a 6-well or 24-well cell culture plate and place in an incubator set to 37◦ C 5% CO2 . If cells are resuspended in less than 2 ml of medium (1 × 106 cells or less), they should be added to a well of a 24-well plate. Larger volumes should be added to a 6-well plate. The number of cells isolated will vary widely between
22
Cichocki and Miller
umbilical cord blood donors. Let the cells proliferate in the Cycling Medium for 3 days (see Note 6). Day 4 24. Three days after the CD34+ cell isolation, reconstitute one vial of RetroNectin at a concentration of 0.05 mg/ml according to the manufacturer’s instructions. 25. Transfer two transwells per umbilical cord donor to a 6-well culture plate using a pair of sterilized tweezers. 26. Coat transwells in the 6-well plate with 0.1 mg of RetroNectin (2 ml of 0.05 mg/ml RetroNectin per well). Incubate plate for 2 h at room temperature. 27. Remove RetroNectin from both the top and the bottom of the transwells. 28. Wash by adding 2 ml of PBS/2% BSA to the transwell. Let the transwells sit for 1/2 h at room temperature (see Note 7). 29. Remove PBS/2% BSA from both the top and the bottom of the transwells. 30. Add 2 ml of Iscove’s Medium (without FBS) to each transwell and let the transwell sit for 1/2 h at room temperature. 31. Remove all Iscove’s Medium from the top and the bottom of the transwells. 32. Add 2 × 105 CD34+ cells (at a concentration of 4 × 105 cells per ml) to each transwell along with 3 ml of the desired viral supernatant. Do not let the virus sit at room temperature longer than necessary before adding it to the transwell. 33. Place plates in an incubator set to 37◦ C 5% CO2 for 6 h. 34. Remove the viral supernatant from the bottom of the transwells, taking care to disturb the cells on the top of the transwell as little as possible. 35. Place the transwell plate back into the incubator for 5 min to allow the rest of the viral supernatant to pass through the transwell. 36. Remove the remaining viral supernatant from the bottom of the transwells. 37. Slowly add 3 ml Cycling Medium to the top of each transwell and place the transwell plate back in the incubator overnight. Day 5 38. Remove the Cycling Medium from the bottom of the transwells and allow all of the medium to pass through. Remove the remaining medium from the bottom of the transwells. 39. Add 3 ml of the same type of viral supernatant used during the previous day for transduction to each transwell.
In Vitro Development of Human Killer–Immunoglobulin Receptor-Positive
23
40. Place plates in an incubator set to 37◦ C 5% CO2 for 6 h. 41. Repeat steps 34–37 in this section. Day 7 42. Harvest the cells from each transwell by pipetting up and down a few times and washing the top of the transwells with 1 ml of medium taken from the bottom of the transwells. Place the cells into a 15 ml centrifuge tube. 43. Remove 100 l from each GFP control sample and put aside on ice for an isotype control. 44. Count cells using a hemocytometer. Generally, you should expect to observe a two- to threefold increase in cell number over the course of the retroviral transduction due to expansion in the Cycling Medium. 45. Centrifuge cells at 550 × g for 4 min. 46. Gently decant the supernatant and add 10 l of anti-CD34 APC-conjugated monoclonal antibody per 1 × 106 cells. 47. Add 1.5 l of APC-conjugated mouse IgG1 antibody to the 100 l of cell set aside for the isotype control. 48. Incubate samples in the dark on ice for 30 min. 49. Wash off excess antibody by adding 5 ml of PBS/0.3% BSA and centrifuging at 550 × g for 4 min. 50. Gently decant supernatant and resuspend stained cells in approximately 0.3 ml of PBS/0.3% BSA. 51. Pass the labeled cells through the strainer cap and into a 5 ml FACS tube. 52. Collect the double-positive GFP+ /CD34+ population using a fluorescence-activated cell sorter (see Note 8 and Fig . 2.1A). 53. Resuspend sorted GFP+ CD34+ cells at a concentration of 500 cells per ml in Basal Culture Medium. 54. Remove the 96-well plates containing irradiated EL08D12 cells from the incubator and gently remove the EL08D12 medium using a multi-channel pipette. 55. Add 100 l of sorted cells in Basal Culture Medium to each well containing irradiated EL08-D12 cells. This will result in a plating of 50 transduced CD34+ cells per well. 56. Place plates in an incubator set to 37◦ C and 5% CO2 . 3.4. Long-Term Culture of Sorted CD34+ Cells on the EL08-1D2 Stromal Line
1. After 7 days have passed, add 100 l of Basal Culture Medium to each well and place the plates back into the incubator. 2. After 14 days have passed, carefully remove 150 l of medium from each well without disturbing the cells on the bottom of the wells. Add 150 l of Basal Culture Medium to
24
Cichocki and Miller
Fig. 2.1. (A) Representative phenotypes of retrovirally transduced CD34+ cells harvested at the time of sorting. A fairly conservative CD34+ /GFP+ gate should be selected to collect this population for long-term culture. The CD34− cells in this plot represent cells that have already begun to differentiate during the cycling phase of the protocol. These cells should not be collected. (B) Representative phenotypes of long-term cultures of CD34+ cells differentiated on EL08-1D2 stroma in the presence of 10 ng/ml IL-15, 5 ng/ml IL-3, 20 ng/ml IL-7, 20 ng/ml c-kit ligand, and 10 ng/ml Flt3 ligand. CD56 and KIR (mixture of DX9, EB6, GL183, and FES172 monoclonal anti-KIR antibodies conjugated with a common fluorochrome) expressions on cells harvested from day 14 and day 21 cultures are shown. As this figure illustrates, the major transition of hematopoietic cells into mature NK cells occurs between 2 and 3 weeks after plating.
each well. At this time point, a proportion of the cells in culture begin to express CD56, but do not express significant levels of KIR as determined by FACS analysis. 3. After 21 days, change the medium again by removing 150 l of medium from each well and adding back 150 l of Basal Culture Medium. At this time point, a significant number of cells in culture express both CD56 and KIR as determined by FACS analysis (see Note 9 and Fig. 2.1B). 4. Full NK cell maturation will be observed after 21 or 28 days in culture, and this is usually used as an endpoint for in vitro NK cell development experiments (see Note 10).
4. Notes 1. The fetal calf serum used for EL08-D12 cell culture is specially designed for the maintenance of stromal cell lines from mouse embryonic tissues and is distributed by StemCell Technologies, Inc. Other types of serum should not be substituted without comparative testing. 2. For this protocol, it is necessary to prepare ahead of time two 3 ml aliquots of retroviral supernatant prepared using a control GFP construct for each umbilical cord blood donor. You will also need two 3 ml aliquots of retroviral supernatant prepared using a construct containing GFP and your gene-of-interest for each umbilical cord donor.
In Vitro Development of Human Killer–Immunoglobulin Receptor-Positive
25
We have consistently used Murine Stem Cell Virus (MSCV) promoter constructs for gene overexpression in CD34+ cells. We package MSCV retroviral particles in the 293kj cell line using the PCL packaging plasmid as previously described (15). 3. The “conditioned” EL08-1D2 medium refers to the supernatant from EL08-1D2 culture flasks that are at or near confluency. This medium should be harvested, 0.2 mfiltered, and frozen at −20◦ C for storage up to 6 months. Conditioned medium should be added to the EL Medium immediately before use at a 20% concentration. 4. Because of the high cell counts per unit of umbilical cord blood, counting with a hemacytometer will be less accurate. We also recommend that the user add 5–6 drops of Zap-oglobinTM II Lytic Reagent (Beckman Coulter) to the Isotone reagent before counting to obtain a more accurate lymphocyte count. 5. There is considerable variability in CD34+ cell yields between umbilical cord donors. This may be because of age from procurement to use or due to individual unit variability. Final cell counts generally fall between 3 × 105 cells and 1.5 × 106 cells. It is our experience that fresh umbilical cord blood units are more efficient in NK cell differentiation cultures than cryopreserved cells which work but with slightly less efficiency. 6. If gene modification with an EGFP marker is considered, it is important to setup the experiment so that you can sort the cells using a fluorescence-activated cell sorter 6 days after the CD34+ cell isolation. 7. Because of variability in the manufacturing of the transwells, the RetroNectin solution may or may not pass through individual transwells. This will not affect the experiment. However, if the RetroNectin does not pass through, we recommend adding 1 ml of PBS/0.3% BSA to the bottom of the transwell and 1 ml of PBS/0.3% BSA to the top of the transwell during the washing step to soak the transwell so that viral supernatant can pass through. 8. The percentage of GFP+ /CD34+ cells in culture depends on the size of the retroviral construct and the potency of the virus. We routinely observe that, when using conservative gating, 1–5% of cells are GFP+ /CD34+ at the time of the sort. 9. A reduction in the number of EL08-D12 cells will usually be observed after 21 days in culture due to their lysis by NK cells. The EL08-D12 stromal layer will disappear completely at later time points.
26
Cichocki and Miller
10. There is considerable variability between umbilical cord donors with respect to the rates of differentiation and proliferation in culture, which may be due to the intrinsic sensitivity of individual donors to the cytokines used in culture. Therefore, we recommend that at least four to six donors are analyzed and compared for each experiment. References 1. Colucci, F., Caligiuri, M.A., and Di Santo, J.P. (2003) What does it take to make a natural killer? Nat. Rev. Immunol. 3, 413–425. 2. Huntington, N.D., Vosshenrich, C.A., and Di Santo, J.P. (2007) Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat. Rev. Immunol. 7, 703–714. 3. Kim, S., Iizuka, K., Kang, H.P., Dokun, A., French, A.R., Greco, A., and Yokoyama, W.M. (2002) In vivo developmental stages in murine natural killer cell development. Nat. Immunol. 3, 523–528. 4. Freud, A.J., Yokohama, A., Becknell, A., Lee, M.T., Mao, H.C., Ferketich, A.K., and Caligiuri, M.A. (2006) Evidence for discrete stages of human natural killer cell differentiation in vivo. J. Exp. Med. 203, 1033–1043. 5. Miller, J.S., Verfaille, C., and McGlave, P. (1992) The generation of human natural killer cells from CD34+ /DR– primitive progenitors in long-term bone marrow culture. Blood. 80, 2182–2187. 6. Miller, J.S., Alley, K.A., and McGlave, P. (1994) Differentiation of natural killer (NK) cells from human primitive marrow progenitors in a stroma-based long-term culture system: identification of a CD34+ 7+ NK progenitor. Blood. 9, 2594–2601. 7. Miller, J.S., McCullar, V., and Verfaillie, C.M. (1998) Ex vivo culture of CD34+ /Lin− /DR− cells in stromaderived soluble factors, interleukin-3, and macrophage inflammatory protein-1␣ maintains not only myeloid but also lymphoid progenitors in a novel switch culture assay. Blood. 12, 4516–4522. 8. Miller, J.S., and McCullar, V. (2001) Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2. Blood. 98, 705–713.
9. McCullare, V., Oostendorp, R., PanoskaltsisMortari, A., Yun, G., Lutz, C.T., Wagner, J.E., and Miller, J.S. (2008) Mouse fetal and embryonic liver cells differentiate human umbilical cord blood progenitors into CD56negative natural killer cell precursors in the absence of interleukin-15. Exp. Hematol. 36, 598–608. 10. Grzywacz, B., Kataria, N., Sikora, M., Oostendorp, R.A., Dzierzak, E.A., et al. (2006) Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood. 108, 3824–3833. 11. Yu, H., Fehniger, T.A., Fuchshuber, P., Thiel, K.S., Vivier, E., et al. (1998) Flt3 ligand promotes the generation of a distinct CD34+ human natural killer cell progenitor that responds to interleukin-15. Blood. 92, 3647– 3657. 12. Cooley, S., Xiao, F., Pitt, M., Gleason, M., McCullar, V. et al. (2007) A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. Blood. 110, 578–586. 13. Nakayama, N., Fang, I., and Elliott, G. (1998) Natural killer and B-lymphoid potential in CD34+ cells derived from embryonic stem cells differentiated in the presence of vascular endothelial growth factor. Blood. 1, 2283–2295. 14. Giarratana, M.C., Verge, V., Schmitt, C., Tertho, J.M., et al. (2000) Presence of primitive lymphoid progenitors with NK or B potential in ex vivo expanded bone marrow cell cultures. Exp. Hematol. 28, 46–54. 15. Chiorean, E.G., Dylla, S., Olsen, K., Lenvik, T., Soignier, Y., et al. (2003) BCR/ABL alters the function of NK cells and the acquisition of killer immunoglobulin-like receptors (KIR). Blood. 101, 3327–3533.
Chapter 3 Subset Analysis of Human and Mouse Mature NK Cells Yoshihiro Hayakawa, Daniel M. Andrews, and Mark J. Smyth Abstract Identification of natural killer (NK) cell subsets has gained attention with the recent discovery that mature mouse NK cells comprise two distinct stages. Delineation of the stages is performed using the markers CD27 and CD11b on gated NK cells. The significance of this finding is underpinned by recent discoveries that mature human NK cells can also be discriminated by differential expression of CD27. This chapter will describe the methods required for the purification of lymphocytes from blood and other organs and the delineation of NK cell subsets by flow cytometry. Key words: Flow cytometry, natural killer, murine, human, CD27, CD11b, CD56.
1. Introduction Peripheral NK cells mediate numerous functions including the cytotoxic control of tumors and virus-infected cells as well as the production of cytokines such as IFN-␥ and TNF-␣ (1). Principally, NK cells have been regarded as mediators of natural host immune resistance. More recently it has been demonstrated that NK cells can act to regulate the generation of the adaptive immune response. Clearly, a high level of complexity underlies mature NK cells in secondary lymphoid and peripheral organs. The first dissection of NK cells into subsets arose through the work of Lewis Lanier in 1983 (2). However, it was not until 1989 that a universal method of human NK cell subset identification was identified (3). It is now widely accepted that human mature NK cells are comprised of CD56dim and CD56high cells; however, this antigen is not expressed on mouse K.S. Campbell (ed.), Natural Killer Cell Protocols, Methods in Molecular Biology 612, DOI 10.1007/978-1-60761-362-6 3, © Humana Press, a part of Springer Science+Business Media, LLC 2010
27
28
Hayakawa, Andrews, and Smyth
NK cells, and thus the translation of biological information concerning NK cells in the mouse has been problematic. While the development of mouse NK cells from precursors has been quite widely studied (4), the identification of mature stages has been largely ignored. Developmentally, mouse NK cells were defined as mature once expression of the integrin CD11b (Mac1) was detected (5). Subsequently, work from our laboratory showed that NK cells could be further identified on the basis of TRAIL expression in adult livers (6). This underlying suggestion of heterogeneity within mature murine NK cells was ultimately demonstrated by delineating two stages of mature NK cells on the basis of CD27 and CD11b (7). Significantly, human NK cells have also been shown to differentially express CD27 (8, 9), making comparative interpretations of the subsets functionality more clear. In the mouse, CD161+ (NK1.1) CD3− (or TCR␣− ) NK cells can be divided into CD27lo CD11blo , CD27hi CD11blo , CD27hi CD11bhi , and CD27lo CD11bhi stages. The CD27lo CD11blo stage remains poorly characterized and may be the most immature, but differentiation has been shown to proceed from CD27hi CD11blo through CD27hi CD11bhi to CD27lo CD11bhi (7). The most mature CD27lo NK cell subset possesses a higher threshold to stimulation and appears to be tightly regulated by the expression of NK cell inhibitory receptors (Ly-49/NKG2A). Comparatively, the CD27hi NK cell subset displays a greater effector function, exhibits a distinct tissue distribution and responsiveness to chemokines, and interacts productively with dendritic cells. Importantly, we and others have verified that CD27hi and CD27lo subsets with distinct cell surface phenotypes also exist in human peripheral blood (8, 9). These findings clearly reclassify mature NK cells into distinct stages and begin to discern their specific role in immune responses. The protocol for enriching lymphocytes from specific organs and delineating mature NK cell subsets by flow cytometry is described below.
2. Materials 2.1. Human PBMC Enrichment
1. Ficoll-Paque PLUS (Amersham Biosciences, Piscataway, NJ, USA). Store at 4◦ C. 2. Phosphate-buffered saline (PBS): Prepare stocks at 3.2 mM Na2 HPO4 , 0.5 mM KH2 PO4 , 1.3 mM KCl, and 135 mM NaCl. Adjust to pH 7.4 with HCl if necessary. Store at room temperature. R . 13 × 75 mm, 4 ml. 3. BD Vacutainer
4. 15 ml centrifuge tubes (BD Falcon, Bedford, MA, USA).
Subset Analysis of Human and Mouse Mature NK Cells
2.2. Mouse Lymphocyte Enrichment
29
1. Roswell Park Memorial Institute (RPMI) 1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 2% fetal bovine serum (FBS, Mt Wellington, Auckland, NZ). Store at 4◦ C. 2. Type IV collagenase (Worthington Biochemicals, Lakewood, NJ, USA) dissolved in PBS at 1 mg/ml. Store at 4◦ C. 3. Extraction buffer: RPMI-2% FBS supplemented with Type IV collagenase (10 g/ml). 4. ACK lysis buffer: 8.29 g/L NH4 Cl, 1 g/L KHCO3 , 0.0367 g/L Na2 -EDTA. Adjust to pH 7.2–7.4 with HCl. Store at room temperature. 5. Percoll (Amersham Biosciences, Piscataway, NJ, USA). Store at 4◦ C. 6. 10× PBS: Prepare stocks at 32 mM Na2 HPO4 , 5 mM KH2 PO4 , 13 mM KCl, and 1.35 M NaCl. Store at room temperature. 7. 15 and 50 ml centrifuge tubes (BD Falcon, Bedford, MA, USA). 8. 40 m cell strainers (BD Falcon, Bedford, MA, USA). 9. Spoon sieves (see Note 1).
2.3. Flow Cytometry Reagents
1. PBS 2% FBS: PBS supplemented with 2% fetal bovine serum (FBS, Mt Wellington, Auckland, NZ). Store at 4◦ C. Keep sterile. 2. Blocking buffer: Add at 2 g/ml anti-Fc␥RII/Fc␥RIII monoclonal antibody (clone 2.4G2) to PBS 2% FBS. Prepare fresh each time. Store at 4◦ C. 3. 7AAD or Fluorogold (Sigma, St Louis, MO). Store at 4◦ C. Keep in darkness to prevent photobleaching. 4. 24-well tissue culture plates and 96-well U-bottom plates (BD Falcon). 5. 1.2 ml microtiter tubes (Molecular BioProducts, USA). 6. Monoclonal antibodies: Anti-human: CD161 (DX12, BD Pharmingen), CD3 (SK7, BD Pharmingen), CD27 (LG.3A10 or LG.7F9, eBioscience), CD56 (MEM188 or B159, BD Pharmingen). Anti-mouse: NK1.1 (PK136, eBioscience), CD3 (145-2C11, BD Pharmingen), CD27 (LG.7F9, eBioscience), CD11b (M1/70, eBioscience). Store at 4◦ C. Keep in darkness to prevent photobleaching.
30
Hayakawa, Andrews, and Smyth
3. Methods NK cells are lymphocytes and thus have some characteristics of T and B cells. In studying NK cells by flow cytometry it is critically important to exclude any populations that may share a common marker. For instance, NKT cells in the mouse also express NK1.1 (albeit at a lower level than T cells) making it possible to accidentally include this cell population during analysis. The following protocol will outline how to ensure analysis is restricted to NK cells only and will provide details for their enrichment from peripheral organs. For obvious reasons our understanding of mouse NK cells in lymphoid and peripheral organs is much better, thus the detection of human NK cells in this chapter will be restricted to blood. Although the process for isolation of lymphocytes from mouse organs is, for the most part, generic, several aspects require some attention and will be addressed in the notes section. 3.1. Enrichment of Human PBMC from Whole Blood
R 1. 2 ml of whole blood is drawn into a BD vacutainer and supplemented with 2 ml of PBS (see Note 2).
2. The blood and PBS should be mixed. 3. Invert the Ficoll-Paque to ensure that it is mixed. Remove 3 ml and add to a 15 ml centrifuge tube. 4. Overlay the diluted blood sample onto the Ficoll-Paque ensuring that the blood and Ficoll-Paque do not mix. 5. Centrifuge the cells at 400× g for 30 min at room temperature. 6. Aspirate the supernatant to leave the lymphocytes intact (see Note 3). 7. Transfer the lymphocytes to a clean centrifuge tube (see Note 4). Add at least three volumes of PBS to the lymphocytes. 8. Centrifuge at 300× g for 7 min at room temperature. 9. Aspirate supernatant and wash as per steps 7 and 8. 10. Aspirate supernatant and resuspend cells in PBS 2% FBS.
3.2. Isolation of Lymphocytes from Mouse Organs
1. Pre-warm extraction buffer (see Section 2.2). Add extraction buffer to 24-well plate appropriate to organ. For spleen and lung add 1 ml, for lymph nodes add 200 l. Livers should not be extracted in the presence of collagenase (see Note 5). 2. Enrichment of lymphocytes from the liver requires perfusion of this organ. Expose the femurs (upper leg bones), viscera,
Subset Analysis of Human and Mouse Mature NK Cells
31
and chest of euthanized mice and cut the left ventricle of the heart. Expose the portal vein by moving the ventral liver lobe up toward the chest. Insert a 25G needle into the portal vein and perfuse the liver with 5–10 ml of PBS. Successful perfusion will result in the liver becoming beige in color. 3. Remove all organs and chop into small pieces (excluding the femurs) in extraction buffer (remembering not to use collagenase for the liver). Spleen, lung, and lymph nodes should be incubated at 37◦ C for 25 min with agitation. 4. For livers, chop into small pieces and wash through a metal spoon sieve by using the barrel of a 10 ml syringe to disrupt the liver across the sieve. Transfer cells into a 50 ml centrifuge tube. 5. The ends of the femurs should be cut with a scalpel. Using a 25 g syringe, aspirate the marrow with 5 ml of PBS. Aspirate through a 40 m cell strainer inserted into a 50 ml tube to remove large chunks and wash through with 4 ml of PBS. 6. For spleen, lymph node, and lung transfer digested tissue and media into a 40 m cell strainer inserted into a 50 ml tube. Wash wells of 24-well plate with 1 ml of PBS and add to tube containing organ. Disrupt organ through sieve using barrel of 10 ml syringe. Wash cells through strainer using 8 ml of PBS (2 × 4 ml at a time). 7. Centrifuge cells from all organs at 300× g for 7 min. 8. For the liver aspirate supernatant, add 10 ml of PBS and wash again as per step 7. 3.2.1. Preparation of Lymphocytes from Spleen, Lymph Node, and Bone Marrow
1. Once centrifuged, cells from the lymph node can be resuspended in blocking buffer (see Note 6). Maintain at 4◦ C. 2. Lyse red blood cells in bone marrow and spleen using ACK lysis buffer. Resuspend spleen or marrow cells in 1 ml of buffer for 2 min at room temperature. Stop lysis by addition of 4 ml of PBS and immediately centrifuge at 300× g for 7 min. 3. Resuspend cells in blocking buffer (see Note 6). Maintain at 4◦ C.
3.2.2. Preparation of Lymphocytes from Liver
1. Prepare a 37.5% Percoll solution. Adjust Percoll to 90% (mouse osmolarity) using 10× PBS. (i.e., add 5 ml of 10× PBS to 45 ml of Percoll). Dilute 90% Percoll to 37.5% using PBS (i.e., add 37.5 ml of 90% Percoll to 62.5 ml of PBS. Adjust volumes accordingly for scaling up) (see Note 7). 2. Resuspend aspirated liver preparations (Section 3.2, step 8) in 1 ml of 37.5% Percoll using a P1000 (see Note 8). Transfer cells from 50 ml centrifuge tube into a 15 ml centrifuge tube.
32
Hayakawa, Andrews, and Smyth
Top up to 15 ml with remaining Percoll and centrifuge at 690× g for 12 min at room temperature. 3. Following centrifugation lymphocytes will pellet, while hepatocytes will float to the top. Aspirate the hepatocytes and supernatant, leaving the lymphocytes intact. 4. Lyse red blood cells in ACK lysis buffer as per Section 3.2.1, step 2 (see Note 9). 5. Resuspend cells in blocking buffer (see Note 6). Maintain at 4◦ C.
3.2.3. Preparation of Lymphocytes from Lung
1. Prepare a 90% Percoll solution as described in Section 3.2.2, step 1. Use this solution to prepare 45% and 67.5% solutions (i.e., for the 45% solution add 4 ml of 90% Percoll to 4 ml of PBS and for the 67.5% solution add 6 ml of 90% Percoll to 2 ml of PBS. Adjust volumes accordingly for scaling up) (see Note 7). 2. Resuspend aspirated lung preparations in 1 ml of 67.5% Percoll using a P1000 (see Note 8). Transfer cells from 50 ml centrifuge tube into a 15 ml centrifuge tube. Add further 2 ml of 67.5% Percoll to make a final volume of 3 ml. Carefully overlay 2 ml of 45% Percoll onto the cell suspension. Avoid mixing of the 45% and 67.5% layer. 3. Centrifuge at 800× g for 15 min at room temperature. Ensure that brake and acceleration are turned to minimum. 4. After centrifugation, lymphocytes will form a band at the interface of the 45% and 67.5% gradients. Aspirate the 45% gradient, leaving the lymphocyte band intact. 5. Transfer the lymphocytes to a 15 ml centrifuge tube and add PBS to fill the tube. 6. Centrifuge at 300× g for 7 min. 7. Lyse red blood cells in ACK lysis buffer as per Section 3.2.1 part 2. 8. Resuspend cells in blocking buffer (see Note 6). Maintain at 4◦ C.
3.3. Preparation/ Blocking of Cells for Staining with Fluorescent Antibodies
1. Cells should be counted and aliquoted in blocking buffer at 106 cells per stain (see Note 10). 2. For multiple samples use a 96-well U-bottom plate. Add 106 cells per well and maintain at 4◦ C for at least 30 min to ensure appropriate blocking of the Fc receptors. 3. Centrifuge plate at 200× g for 4 min. and aspirate supernatant.
Subset Analysis of Human and Mouse Mature NK Cells
3.4. Staining of Cells with Fluorescent Antibodies to Detect NK Cells
33
1. Prepare a cocktail of antibodies comprising CD161, CD3, CD27, and CD56. Add an appropriate volume (see Note 11) per well and resuspend cells using a pipette. 2. Maintain cells at 4◦ C for at least 1 h.
3.4.1. Detecting Human NK Cell Subsets
3.4.2. Detecting Mouse NK Cell Subsets
1. Prepare a cocktail of antibodies comprising NK1.1, CD3, CD27, and CD11b. Add an appropriate volume (see Note 11) per well and resuspend cells using a pipette. 2. Maintain cells at 4◦ C for at least 1 h.
3.4.3. Labeling Dead Cells for Exclusion on the Flow Cytometer
1. Centrifuge labeled cells at 200× g for 4 min. 2. Aspirate supernatant and resuspend cells in 50–100 l of either PBS 2% FBS with 2 g/ml 7AAD or PBS 2% FBS with 2 g/ml Fluorogold. Leave for 1 min at room temperature. FACS instruments with a 355 nm laser (such as the LSR-II) can use Fluorogold. Most bench top instruments (such as the CANTO) do not have this laser and must use the 488 nm laser to excite 7AAD. 3. Centrifuge cells at 200× g for 4 min. 4. Resuspend cells in 200–400 l of PBS 2% FBS. Transfer to 1.2 ml microtiter tubes (see Note 12). Maintain in the dark and keep cool before acquiring samples on the flow cytometer.
3.5. Acquisition and Gating of Human and Mouse NK Cells by Flow Cytometry
1. Ensure that correct PMT voltages and compensation are applied to the cytometer. 2. In the first instance set an acquisition plot of forward scatter height (FSC-H) vs. forward scatter area (FSC-A) and place a gate around singlet cells (Fig. 3.1A). 3. Within the singlet population set an acquisition plot of FSCA vs. 7AAD or Fluorogold (consult with your FACS operator for correct channels on appropriate instruments). Set a gate around cells that have excluded the viability die. 4. On the live cells, set an acquisition plot of NK1.1 vs. CD3 (for mouse) or CD161 vs. CD3 (for human). In each instance set a gate around the NK1.1+ /CD3− or CD161+ /CD3− cells (Figs. 3.1 and 3.2). 5. On the NK cells set an acquisition plot of CD27 vs. CD11b (for mouse) or CD27 vs. CD56 (for human). Mouse NK cell subsets are identified as immature (CD27− /CD11b− , CD27+ /CD11b− ) and mature and can be subdivided into CD27+ /CD11b+ and CD27− /CD11b+ (Fig. 3.1).
34
Hayakawa, Andrews, and Smyth
Fig. 3.1. The gating procedure and use of fluorescent minus one staining (FMO) to detect mouse NK cell subsets. (A) Singlet cells (to exclude cell doublets, which can appear as cells expressing both fluorochromes) are gated on the 45◦ angle of a plot between FSCA and FSC-H prior to gating on live cells (represented here are fluorogold (FG)-negative cells). The live population is then shown with NK1.1 and CD3, NK cells are gated as NK1.1+ and CD3− . (B) In order to set the gates properly for the subsets FMO are used. The first panel shows gated NK cells (NK1.1+ /CD3− ) on which only CD11b is stained, while in the second panel only CD27 is stained. This allows the quadrant gates to be set appropriately on CD11b+ and CD27+ . The final panel in part B shows the four major subsets (CD27− CD11b− a, CD27+ /CD11b− b; CD27+ /CD11b+ c; CD27− /CD11b+ d). The quadrant gates have been set correctly by the use of the FMO setup tubes.
Human NK cell subsets are identified as CD56dim /CD27− , CD56hi /CD27− , and CD56hi /CD27+ (Fig. 3.2). See Note 13 for choice of fluorochromes and setting gates appropriately.
Fig. 3.2. The gating procedure and use of fluorescent minus one staining (FMO) to detect human NK cell subsets. Singlet cells (to exclude cell doublets, which can appear as cells on the line of identity between FSC-A and FSC-H) are gated on the 45◦ angle prior to gating on live cells (represented here are fluorogold-negative cells) as shown in Fig. 3.1. The live population is then shown in a plot of CD161 vs. CD3, and NK cells are gated as CD161+ and CD3− . In order to set the gates properly for the subsets, FMO are used. The second panel shows gated NK cells (CD161+ /CD3− ) on which only CD56 is stained, while in the third panel only CD27 is stained. This allows the gates to be set appropriately on CD56+ and CD27+ subsets. The final panel shows the three major subsets (CD56dim /CD27− ; CD56hi /CD27− ; CD56hi /CD27+ ). Box gates have been set correctly by the use of the FMO setup tubes. CD27hi /CD56hi cells are gated by aligning the vertical edges of the CD27 box with the CD56hi box.
Subset Analysis of Human and Mouse Mature NK Cells
35
6. Set the cytometer to acquire samples. For analysis of NK cell subsets it is appropriate to collect at least 2000 NK cell events from each organ (Fig. 3.3).
Fig. 3.3. Representative density plots showing mouse NK cells and their subsets in the spleen, liver, lung, bone marrow, and lymph node. (A) Identification of NK cells by using NK1.1 and CD3 on preparations from the spleen, liver, lung, and bone marrow and lymph node. (B) Identification of the NK cell subsets in the different organs. The subsets of CD3− NK1.1+ NK cells are differentially represented across a range of lymphoid and non-lymphoid organs.
4. Notes 1. Spoon sieves with a pore size of around 1–2 mm are most appropriate. Any larger than this and the liver in particular will not be sufficiently homogenized prior to centrifugation. 2. Although mouse blood can be treated in the same manner as human blood, in order to enrich murine lymphocytes this protocol is not necessary. The simpler method for mouse blood is to harvest blood directly into a 1 ml centrifuge tube into which 20 l of 50 mM EDTA has been added. The blood/EDTA is then mixed to prevent coagulation and the cells pelleted by centrifugation. At this point it is possible to then process as per Section 3.2.1, step 2. 3. Always aspirate gently and leave around 500 l of serum remaining above the lymphocyte band. 4. When harvesting lymphocytes from a band within a gradient it is best to aspirate from slightly above the cells. Try to remove as little of the gradient mixture (in this case Ficoll) as this will add to the density of the subsequent wash. If too much gradient and not enough PBS is in the wash step then the lymphocytes will not pellet.
36
Hayakawa, Andrews, and Smyth
5. Although it is possible to remove lymphocytes from spleen and lymph node by mechanical disruption between glass slides we have found this process to be less efficient and more damaging to the cells than collagenase digestion. Digesting organs in collagenase removes cells from the stroma, thereby increasing yields. Although collagenase may increase yields from liver and lung, collagenase should never be used when analyzing liver NK cells for CD27. CD27 expression in the liver is extremely sensitive to collagenase digestion resulting in NK cell preparations in which CD27 cannot be detected. 6. Lymph nodes are free from red blood cells and thus do not need ACK lysis. Naive lymph nodes and lungs have very few cells (˜106 ), thus volumes for resuspending should be carefully controlled in order to have accurate cell counts. The most appropriate volume for resuspending of bone marrow, spleen, and livers for accurate counting is 1 ml. Our laboratory normally resuspends lymph nodes in 200 l of blocking buffer. For trypan blue exclusion counting a 1:10 to 1:20 dilution is acceptable while a 1:500 dilution is fine for use in a Coulter Counter. Using the volumes described here will result in high cell densities. This is important when transferring the cells to a 96-well U-bottom plate. The maximum volume in these wells is around 200 l. Thus, resuspending the organs in a higher density in blocking buffer allows their transfer directly from the centrifuge tube to the 96-well plate without having to spin the cells and increase their density before transferring to the 96-well plate. 7. Percoll needs to be at room temperature when spinning. Always prepare fresh the morning of the experiment, prior to organ collection. As stock Percoll is kept at 4◦ C it is advisable to place the prepared gradients in a 37◦ C water bath while collecting organs. 8. The use of a P1000 pipette is more appropriate as this will better homogenize the pellet than larger pipettes (i.e., a 5–10 ml pipette). A more homogenized pellet will allow better separation of the lymphocytes from the hepatocytes or lung parenchyma. 9. When the lymphocytes are in ACK lysis buffer transfer them to a fresh tube. If the cells are pelleted in the same tube that the Percoll gradient was used for, some hepatocytes that can stick to the top of the tube may pellet with the lymphocytes following centrifugation of the ACK lysed cells. These hepatocytes can block the flow cytometer.
Subset Analysis of Human and Mouse Mature NK Cells
37
10. Cell numbers used in the FACS protocol must always be equivalent in order to ensure reproducibility of the FACS staining. If doing multiple stains it may only be possible to stain 105 cells (especially in the lung where only 106 total cells are recovered). 11. While most commercial outlets claim that 100 l per well of 106 cells/cocktail is necessary we routinely use 20 l per well on 106 cells. This is beneficial as it reduces reagent use by fivefold. It is always best to titrate amounts of antibodies used to optimize staining intensity and thereby assure that adequate gating can be achieved. 12. The use of microtiter tubes can greatly facilitate large experiments. These tubes can be inserted into a 96-well plate or 200 l tip box. In contrast to the larger centrifuge tubes, the 1.2 ml tubes are small enough for all 12 ends of a multichannel pipette to fit. Thus, transfer of 12 wells at a time is possible. 13. When analyzing NK cell subsets the choice of fluorochromes is important. Our laboratory routinely uses NK1.1-PE (2 g/ml), CD3-PECy5.5 (2 g/ml), CD27APC (1 g/ml), and CD11b-FITC (1 g/ml). It is important to note that many mouse strains do not have NK1.1, including BALB/c. In order to identify NK cells in BALB/c mice it is necessary to use DX5 in replacement of NK1.1. DX5 should be used quite concentrated as the antigen is expressed weakly and DX5lo cells (which are also CD3− ) are not mature NK cells and may make analysis difficult. More recently an antibody to NKp46 has become available. This antigen is restricted to NK cells and is found in all mouse strains; however, it is yet to replace NK1.1 for FACS identification. The use of NK1.1-PE results in a bright signal for NK cells and is then easily discriminated from T cells and NKT cells (can be confirmed with CD1d tetramer). We do not encourage the use of similar fluorochromes for analysis of CD27 and CD11b. For example the use of CD27-APC and CD11b-APC-Cy7 is problematic. As these fluorochromes have very similar excitation and emission characteristics it is difficult to compensate them accurately. This makes it difficult to accurately discriminate the three NK cell stages. While APC-Alexa750 does not bleed into the APC channel as much, a similar problem regarding the subsets is still observed. In order to gate the subsets accurately it is necessary to include Fluorescent Minus One tubes (FMO). These tubes will contain either NK1.1/CD3/CD27 or NK1.1/CD3/CD11b. The use of these FMO tubes will allow quadrant gates to be set accurately.
38
Hayakawa, Andrews, and Smyth
Acknowledgments The authors would like to thank Ms. Anabel Silva for her assistance with developing the protocols for identifying human NK cell subsets with CD27. This work was supported by a National Health and Medical Research Council of Australia Program Grant and Doherty Fellowship (DMA, MJS). References 1. Smyth, M. J., Hayakawa, Y., Takeda, K., and Yagita, H. (2002) New aspects of naturalkiller-cell surveillance and therapy of cancer. Nat Rev Cancer 2, 850–61. 2. Lanier, L. L., Le, A. M., Phillips, J. H., Warner, N. L., and Babcock, G. F. (1983) Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK1) and Leu-11 (NK-15) antigens. J Immunol 131, 1789–96. 3. Ellis, T. M., and Fisher, R. I. (1989) Functional heterogeneity of Leu 19”bright”+ and Leu 19”dim”+ lymphokineactivated killer cells. J Immunol 142, 2949–54. 4. Huntington, N. D., Vosshenrich, C. A., and Di Santo, J. P. (2007) Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol 7, 703–14. 5. Kim, S., Iizuka, K., Kang, H. S., Dokun, A., French, A. R., Greco, S., and Yokoyama, W. M. (2002) In vivo developmental stages
6.
7.
8.
9.
in murine natural killer cell maturation. Nat Immunol 3, 523–8. Takeda, K., Cretney, E., Hayakawa, Y., Ota, T., Akiba, H., Ogasawara, K., Yagita, H., Kinoshita, K., Okumura, K., and Smyth, M. J. (2005) TRAIL identifies immature natural killer cells in newborn mice and adult mouse liver. Blood 105, 2082–9. Hayakawa, Y., Huntington, N. D., Nutt, S. L., and Smyth, M. J. (2006) Functional subsets of mouse natural killer cells. Immunol Rev 214, 47–55. Silva, A., Andrews, D. M., Brooks, A. G., Smyth, M. J., and Hayakawa, Y. (2008) Application of CD27 as a marker for distinguishing human NK cell subsets. Int Immunol 20, 625–30. Vossen, M. T., Matmati, M., Hertoghs, K. M., Baars, P. A., Gent, M. R., Leclercq, G., Hamann, J., Kuijpers, T. W., and van Lier, R. A. (2008) CD27 defines phenotypically and functionally different human NK cell subsets. J Immunol 180, 3739–45.
Chapter 4 Assessing Licensing of NK Cells A. Helena Jonsson and Wayne M. Yokoyama Abstract Natural killer (NK) cells express receptors to detect and kill target cells based on expression of target cell surface molecules. Through a process termed NK cell licensing, only NK cells that express inhibitory receptors (e.g., Ly49 receptors in the mouse) for self-major histocompatibility complex (MHC) class I molecules become functionally competent to be triggered through their activation receptors. To determine the licensing status of particular Ly49+ murine NK cell subsets, splenocytes are stimulated with plate-bound anti-NK1.1 monoclonal antibody in the presence of brefeldin A and then assessed for NK cell activation on a single-cell basis using intracellular cytokine interferon-␥ staining and flow cytometry. Key words: Natural killer cells, NK cells, NK cell licensing, NK cell education, Ly49, inhibitory receptors, self-tolerance, NK cell activation.
1. Introduction Natural killer (NK) cells express receptors to detect and kill target cells that display cell surface ligands for these receptors (1). To accomplish this task, NK cells use activation and inhibitory receptors to balance the ability to recognize “missing” or “induced” self with the need to maintain self-tolerance (2, 3). Through an NK cell education process termed licensing, only NK cells that express inhibitory receptors for self-major histocompatibility complex (MHC) class I molecules become functionally competent to be triggered through their activation receptors (Fig. 4.1) (4–6). Conversely, NK cells that lack inhibitory receptors for selfMHC or develop in an environment devoid of MHC class I are unresponsive to most conventional NK cell activation receptor stimuli and hence are termed “unlicensed” (4). While the initial K.S. Campbell (ed.), Natural Killer Cell Protocols, Methods in Molecular Biology 612, DOI 10.1007/978-1-60761-362-6 4, © Humana Press, a part of Springer Science+Business Media, LLC 2010
39
40
Helena Jonsson and Yokoyama
Fig. 4.1. Licensing of NK cells. A developing NK cell stochastically expresses some but not all inhibitory NK cell receptors. In a host with an MHC environment where the NK cell is able to bind MHC class I via one or more of its inhibitory receptors (shown as matching black Ly49 and MHC class I molecules), the NK cell receives a licensing signal. This licensing signal requires an intact cytoplasmic Ly49 tail, including the ITIM. An NK cell that cannot engage MHC class I with any of its inhibitory receptors remains unlicensed, i.e., hyporesponsive. Upon stimulation via their activation receptors ex vivo, a higher percentage of licensed NK cells produce cytokines as compared to unlicensed NK cells.
studies of licensing were performed in mice, recent studies suggest a similar process occurs in humans (7, 8). In mice, the major NK cell inhibitory receptors that bind selectively to specific classical MHC class I alleles include members of the C-type lectin-like Ly49 family, such as Ly49A, C, I, and G2. For example, Ly49A binds H-2Dd but not H-2Kb , whereas the more promiscuous Ly49C binds H-2Kb well and H2Dd relatively weakly (9). Furthermore, inhibitory Ly49 receptors are expressed in a stochastic or probabilistic fashion such that each individual NK cell expresses a random assortment of the genome-encoded Ly49 molecules (10, 11). Because of these expression and binding patterns of Ly49 receptors, a significant portion of the NK cell population in any given mouse may be unable to engage self-MHC class I expressed on normal cells (4, 12). The unlicensed state of these cells ensures
Assessing Licensing of NK Cells
41
their self-tolerance since they are unable to respond to “missing self” stimuli. Notably, unlicensed cells are not hyporesponsive due to exhaustion because phorbol ester and ionomycin stimulation induces abundant cytokine production by these cells comparable to licensed NK cell populations (4). Finally, unlicensed NK cells can be induced to become functionally responsive in an MHCindependent manner by other stimuli, such as cytokine exposure in vivo or in vitro (4). In the laboratory, a licensed NK cell population is currently revealed by response to activation receptor cross-linking. AntiNK1.1 (Nkrp1c) has been most widely used though licensed NK cells can also respond to cross-linking of Ly49D, NKG2D, CD16, and YAC-1 targets (4). The use of brefeldin A and intracellular cytokine staining enables single-cell detection of activation and surface receptor expression using flow cytometry. The frequency of cytokine production by a given subset reflects its licensing status (Fig. 4.1).
2. Materials 1. Mice, including suitable positive and negative control strains (see Note 1). 2. R10 culture medium: RPMI-1640 supplemented with 10% heat-inactivated (45 min, 56◦ C) fetal bovine serum (FBS), 2 mM supplemental L-glutamine, 10 U/mL penicillin (optional), 10 g/mL streptomycin (optional), 0.1 mM 2mercaptoethanol. Store at 4◦ C. 3. Phosphate-buffered saline (PBS): 137 mM NaCl, 8 mM Na2 HPO4 , 2.7 mM KCl, 1.5 mM KH2 PO4 , 0.5 mM MgCl2 , pH 7.2. Store at room temperature. 4. FACS staining buffer: 1× PBS (see above) supplemented with 1% FBS and 0.2% sodium azide (see Note 2). Store at 4◦ C. 5. Tissue culture-treated 6-well plates (see Note 3). 6. Purified PK136 (anti-NK1.1) antibody (#HB-191 at American Type Culture Collection (ATCC), Manassas, VA). 7. Brefeldin A – GolgiPlug (BD Biosciences, San Jose, CA) contains 0.1% BFA in DMSO (see Note 4). Store in 50 L aliquots at 4◦ C (optional). 8. Phorbol ester and ionomycin – as optional positive control for cytokine production. Store aliquoted stock solutions of phorbol ester and ionomycin in DMSO at 0.5 and 1 mg/mL, respectively, at –20◦ C. Aliquot volumes of 10 and 20 L, respectively, are convenient.
42
Helena Jonsson and Yokoyama
9. BD Cytofix/Cytoperm Fixation/Permeabilization Kit (BD Biosciences). Includes a formaldehyde- and saponin-based fixation and permeabilization reagent as well as a 10x concentrate of Perm/Wash buffer containing saponin to maintain permeabilization. 10. Staining tubes or plates (see Note 5). 11. Cell lineage antibodies (Table 4.1). These should include antibodies to gate out CD3+ cells and ideally also CD19+ cells. There should also be an antibody to positively gate on NK cells, such as a monoclonal antibody directed at NKp46, NK1.1 (in C57BL/6 mice), or integrin ␣2 (i.e., mAb clone DX5).
Table 4.1 Recommended fluorochrome selections for four-color flow cytometry Channel (FACSCalibur)
Staining setup #1
Staining setup #2
FL1
FITC-conjugated anti-Ly49 mAb
FITC-conjugated anti-IFN␥ mAb
FL2
PE-conjugated anti-IFN␥ mAb
Biotinylated anti-Ly49 mAb; PE-conjugated streptavidin
FL3
PerCP Cy5.5-conjugated anti-CD3 and anti-CD19 mAbs
PerCP Cy5.5-conjugated antiCD3 and anti-CD19 mAbs
FL4
APC-conjugated anti-NK1.1 mAb
APC-conjugated anti-NK1.1 mAb
12. Antibody monospecific for the inhibitory NK cell receptor of interest (see Note 6). 13. Antibody against murine interferon-␥ (clone XMG1.2). 14. Fc␥RII/III block, e.g., 2.4G2 supernatant (#HB-197 at ATCC). 14. 40 m nylon mesh through which to filter cells after staining.
3. Methods 3.1. Preparation of Reagents 3.1.1. Prepare Splenocyte Suspension 3.1.2. Prepare Antibody-Coated Plates
1. For murine NK cells, harvest spleens and prepare RBC-lysed single-cell suspensions at a concentration of 107 cells/mL in cold, fresh R10 medium. 1. Dilute purified PK136 (anti-NK1.1) antibody to concentrations of 5, 2, and 0.5 g/mL, respectively, in PBS (see Notes 7 and 8).
Assessing Licensing of NK Cells
43
2. Add 1 mL of antibody dilution to each well of polystyrene 6-well plates, making one well per stimulation dose per mouse. For example, for 10 mice, make 10 wells of 5 g/mL PK136, 10 wells of 2 g/mL PK136, and 10 wells of 0.5 g/mL PK136. 3. Also make uncoated wells (one per mouse) by adding PBS alone or purified isotype control antibody diluted in PBS, for unstimulated control samples. 4. Incubate the plates in 37◦ C 5% CO2 incubator for 90 min. 5. Rinse the plate 3× with PBS. Do not let the wells dry at any time. Immediately add cells to the wells as described below. 3.2. Stimulation of NK Cells 3.2.1. Plate-Bound Monoclonal Antibody Stimulation of Murine Splenocytes
1. Add 107 splenocytes (i.e., 1 mL cell suspension) to each well. Gently swirl the plates to assure uniform distribution of cells over the bottom of the well. 2. If including a phorbol ester and ionomycin positive control, dilute them together in R10 medium to concentrations of 0.5 and 4 g/mL, respectively. For example, dilute 5 L of 0.5 mg/mL phorbol ester and 20 L of 1 mg/mL ionomycin into 5 mL of R10 medium. Add 1 mL of this dilution to 1 mL of cell suspension. 3. Incubate the cells in a 37◦ C 5% CO2 incubator for 1 h (see Note 9). 4. After 1 h of stimulation, add Brefeldin A (BD GolgiPlug) as follows: dilute 50 L of 0.1% BFA stock into 450 L of R10 medium for 100× working stock, and add 12 L working stock to each sample to each sample for a final concentration of 1.2×. Mix well by gently swirling the plate. 5. Incubate the cells for an additional 7 h in a 37◦ C 5% CO2 incubator (see Note 10). 6. Stop the stimulation by adding 5 mL cold FACS staining buffer and storing the plates at 4◦ C until ready to proceed to cell harvest (usually overnight) (see Note 11).
3.2.2. Cell Harvest
1. Harvest cells by pipeting up and down repeatedly with a 5 or 10 mL pipet. Collect the cells into a 15 mL tube. Wash the well with an additional 5 mL FACS staining buffer. Collect the wash into the same 15 mL tube. 2. Spin tubes at 500g for 5 min at 4◦ C. Discard supernatant. 3. Resuspend pellet in the remaining buffer and transfer the cell suspension to a FACS tube or deep-well plate (see Note 5). 4. Also set up unstained and single-stain control tubes or wells using pooled residual stimulated cells or fresh splenocytes (see Note 12).
44
Helena Jonsson and Yokoyama
3.3. Immunofluorescent Staining of Stimulated Cells 3.3.1. Surface Staining
1. If using a biotinylated anti-Ly49 receptor monoclonal antibody, dilute this antibody in Fc ␥R block (e.g., 2.4G2 supernatant) and add to the cells (see Note 6). If the anti-Ly49 receptor antibody is directly conjugated, proceed to Step 4. Incubate the cells on ice for 30 min. 2. Wash twice in 1 mL FACS staining buffer. Spin tubes or plates at 500g after each wash. After second wash, resuspend cells in 100 L FACS buffer. 3. Make antibody master mix by combining anti-CD3, CD19, and -NKp46 antibodies and either the directly conjugated anti-Ly49 receptor or a secondary reagent (e.g., streptavidin-PE) in Fc␥R block (2.4G2 supernatant) in a total volume of 70 L per tube or well. Aliquot the master mix to each tube and pipet or vortex to mix. Also make single-stain controls. Incubate the cells on ice for 30 min. 4. Wash twice in 1 mL FACS staining buffer. Spin tubes or plates at 500g after each wash.
3.3.2. Intracellular Cytokine Staining
1. After aspirating or decanting the supernatant from the last wash of the surface staining, vortex the plate or tubes to loosen the pellets. 2. Add 250 L Cytofix/Cytoperm to each sample and pipet repeatedly to mix. Incubate on ice for 25 min, shaking the tubes or plate after 12 min. 3. Add 1 mL of Perm/Wash buffer to each sample and incubate 5 min on ice. 4. Spin at 500g for 5 min and discard supernatant. 5. Add 1 mL of Perm/Wash buffer and resuspend the pellet by pipeting. Spin for 5 min at 500g and discard supernatant. 6. Make a master mix of anti-IFN␥ antibody diluted in Perm/Wash buffer to a final volume of 50 L per sample. Aliquot the master mix to each of the wells and pipet or vortex to mix. Incubate the cells 30 min on ice. 7. Wash twice in 1 mL Perm/Wash buffer. 8. Add 300 L of FACS staining buffer, resuspend the pellet by pipeting, and filter each sample through 40 m nylon mesh into new FACS tubes. 9. Store FACS tubes at 4◦ C, protected from light, until ready to analyze by flow cytometry (see Note 13).
3.4. Flow Cytometric Data Collection and Analysis 3.4.1. Data Collection
1. Arrange the flow cytometer settings for post-collection compensation (see Notes 14 and 15). 2. For best results, collect flow cytometry data for at least 106 live cells (approximately 15,000 NK cells, gated as NKp46+
Assessing Licensing of NK Cells
45
Fig. 4.2. Analysis of licensing assay data. To quantify licensing, graph NK cells (NK1.1+ CD3− CD19− ) on a dot plot with Ly49 on the vertical axis and IFN␥ on the horizontal axis and make a quadrant gate to frame the four populations. In this example, the middle plot displays NK cells from a B10.D2 (H-2d ) mouse, whereas the bottom plot displays NK cells from a C57BL/10 (H-2b ) mouse. The frequency of IFN␥ production by Ly49+ NK cells is calculated using the formula UR/(UR+UL)∗ 100. A high frequency of IFN␥ production (usually 12–25%) indicates licensing of that Ly49+ population. The “licensing ratio” describes the increased propensity of Ly49A+ NK cells to produce IFN-␥ relative to Ly49A− NK cells and is the result of dividing the percentage of Ly49A+ NK cells that produce IFN␥ by the percentage of Ly49A− NK cells that produce IFN␥. If the Ly49 receptor does not mediate licensing, the licensing ratio is approximately 1 (usually 0.8– 1.2). If the Ly49 receptor mediates licensing, the licensing ratio will be over 1.5.
CD3− CD19− ). This often means collecting all events until the sample runs out. 3.4.2. Analyze Flow Cytometry Data
1. Gate on live cells using a forward scatter and side scatter dot plot. Subsequently, gate on NK cells (NKp46+ CD3− CD19− ) (see Note 16).
46
Helena Jonsson and Yokoyama
2. Display NK cells on a dot plot with Ly49 on the vertical axis and IFN␥ on the horizontal axis and make a quadrant gate to frame your four populations (Fig. 4.2). The quadrants will henceforth be referred to as UR (upper right), UL (upper left), LL (lower left), and LR (lower right). 3. Calculate the frequency of IFN␥ production by Ly49+ NK cells using the formula UR/(UR+UL)∗ 100. A high frequency of IFN␥ production (usually 12–25%) indicates licensing of that Ly49+ population. 4. Calculate the “licensing ratio” of the Ly49+ NK cell population using the formula (UR/(UR+UL))/(LR/(LR+LL)). If the Ly49 receptor does not mediate licensing, the licensing ratio is approximately 1 (usually 0.8–1.2). If the Ly49 receptor mediates licensing, the licensing ratio will be over 1.5 (see Note 17). Positive and negative control samples are very important in these calculations (see Note 1).
4. Notes 1. Including appropriate positive and negative control strains is very important. For Ly49C+ NK cells, a C57BL/6 control mouse is a good positive control for licensing. For experiments addressing licensing through Ly49A, a B10.D2 mouse (H-2d , Stock #000463, Jackson Labs, Bar Harbor, ME) or a H-2Dd -transgenic mouse is an appropriate positive control. In most cases, a MHC class I-deficient mice (e.g., 2 m−/− ) is a good negative control for cytokine production: NK cells from these mice should produce little if any cytokine in this assay, although they can respond to high concentrations of cross-linking antibody. Nonetheless, licensed NK cells respond better than unlicensed NK cells regardless of strength of activation (4). It is also often useful to include a MHC-sufficient strain that is known not to license the Ly49+ population of interest. For example, a B10.D2 mouse (H-2d ) can serve as an unlicensed control for studies of Ly49C+ NK cells, as can a C57BL/6 mouse (H-2b ) for studies of Ly49A+ NK cells. In addition, the use of age-matched mice is important as NK cell activity changes with age in early adult mice. Dates of birth should ideally be matched to within 2–3 weeks. Mice younger than 7 weeks and older than 16 weeks may have poor NK cell responses and should be avoided. 2. In addition to preventing contamination, azide in the FACS staining buffer blocks internalization or shedding of antibody–receptor complexes.
Assessing Licensing of NK Cells
47
3. This assay is normally performed in 6-well plates using 107 splenocytes in a 1 mL reaction volume. However, the assay can be scaled down if necessary for other applications where cell number is limited. 4. Monensin can be used as an alternative to brefeldin A, if desired. 5. For staining of stimulated cells, conventional 12 × 75 mm round bottom culture tubes work well. For processing of larger numbers of samples, deep-well conical-bottom plates (e.g., 2.2 mL Mark II plates (#AB-0932), ABgene, Surrey, UK) may be more convenient. Washes can then be performed quickly and easily with a P1000 multichannel pipetman. Traditional 96-well conical bottom plates are less ideal for staining several million cells per well as they can only hold small volumes and therefore will require extra wash steps. 6. The anti-Ly49 monoclonal antibody (mAb) must be selected with care. For best results, the mAb should be monospecific, such as clones 4LO33 (anti-Ly49C) and JR9 (anti-Ly49A). Certain mAbs, such as clone A1 (antiLy49A), are very sensitive to cis engagement of Ly49 with MHC class I expressed on the same cell, which results in decreased mAb reactivity (4, 13). These mAb clones should be avoided because it may be difficult or impossible to distinguish the relevant Ly49+ and Ly49– populations. If alternative mAb clones are not available, carefully optimize the choice of fluorochromes and staining conditions. For example, biotinylated 4LO33 (anti-Ly49C) followed by PE-conjugated streptavidin produces a Ly49C+ population that is clearly distinguishable from the Ly49C− cells, while staining with FITC-conjugated 4LO33 does not. 7. The cell suspensions should be ready to go by the time the plates are washed. The timing usually works out right if the purified PK136 antibody is added to the plates immediately after RBC lysis of the splenocytes. The 90-min incubation of the plates provides enough time to count the cells and resuspend them to 107 cells/mL. 8. If enough cells are available, do one well of each antibody concentration for each mouse. If cell number is a limitation, omit the 0.5 and 5 g/mL PK136 stimulations. 9. Incubation of less than 1 h before adding BFA results in significantly lower yield of intracellular cytokines. 10. After the addition of BFA, each hour of incubation increases the amount of intracellular cytokines. However, incubations longer than 8 h may increase cell death due to
48
Helena Jonsson and Yokoyama
BFA toxicity. Seven hours of incubation with BFA allows for ample accumulation of intracellular cytokines without any noticeable cytotoxic effects. 11. The overnight incubation at 4◦ C is not a necessary step but is merely for convenience. 12. Single-stain controls should be made for each fluorochrome. Since NK cells are rare among splenocytes, avoid anti-NK1.1 or anti-Ly49 antibodies for these controls. Instead, use fluorochrome-conjugated antibodies directed at more common markers such as CD19 or CD8 that are expressed at similar levels to markers of interest in NK cells. The unstained control should consist of cells pooled from the remainder of the stimulation. The single-stained controls can be made of these cells as well or from fresh splenocytes. Alternatively, compensation control beads (BD Biosciences) can be used in place of cells. 13. Since the cells are fixed, flow cytometric data collection can be postponed for up to 1 week. However, best results are obtained by analyzing the cells within 24 h of staining. 14. Licensing assays require the use of a flow cytometer that can distinguish at least four colors. Table 4.1 lists two fluorochrome combinations that work well on BD FACSCalibur machines. If simultaneous analysis of multiple Ly49 populations is desired, the fluorochromes must be selected with care to avoid compensation issues since the NK cell subset populations are so rare. 15. If possible, perform compensation after data collection (14). Many contemporary flow cytometry analysis software programs (e.g., FlowJo, Treestar, Ashland, OR) feature easy-to-use post-collection compensation functions. 16. If using NK1.1 to define the NK cell population, be aware that plate-bound PK136 stimulation partially inhibits subsequent staining with fluorochrome-conjugated antiNK1.1 antibodies. In this situation, use a free-form polygon gate to gate on all NK1.1+ cells, even those exhibiting intermediate staining. (NK cells with lower NK1.1 expression are often the most robust cytokine-producing cells.) Also, stimulating with a lower concentration (e.g., 2 g/mL or lower) of plate-bound PK136 may make the NK1.1+ population more distinct. Alternatively, use antibodies against a different marker, such as NKp46 or integrin ␣2 (DX5), to identify NK cells. 17. The licensing ratio is dependent on the “background” IFN-␥ production by NK cells, i.e., the percentage of IFN␥+ cells among NK cells that lack the receptor of inter-
Assessing Licensing of NK Cells
49
est. This ratio may therefore falsely indicate no licensing of a given Ly49 subset if the Ly49-negative subset expresses another receptor capable of self-MHC recognition. Care must be taken when using licensing ratios, especially between murine strains and Ly49/MHC combinations that differ from the Ly49A-H-2Dd and Ly49C-H2 Kb interactions already documented. Absolute frequencies of IFN␥ production may be preferable in these situations. It is also possible that if the NK cells had been previously stimulated in vivo or in vitro with cytokines or other stimuli, then it may be difficult to show an MHCdependent licensing effect because the stimuli may induce unlicensed NK cells to become functionally competent (4).
References 1. Yokoyama, W. M. (2008) Chapter 17. Natural killer cells, in Fundamental Immunology. (Paul, W. E., ed.), Lippincott-Raven, New York. pp. 483–517. 2. Diefenbach, A., and Raulet, D. H. (2003) Innate immune recognition by stimulatory immunoreceptors. Curr Opin Immunol 15, 37–44. 3. Ljunggren, H. G., and Karre, K. (1990) In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today 11, 237–244. 4. Kim, S., Poursine-Laurent, J., Truscott, S. M., Lybarger, L., Song, Y. J., Yang, L., French, A. R., Sunwoo, J. B., Lemieux, S., Hansen, T. H., and Yokoyama, W. M. (2005) Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436, 709–713. 5. Yokoyama, W. M., and Kim, S. (2006) How do natural killer cells find self to achieve tolerance? Immunity 24, 249–257. 6. Yokoyama, W. M., and Kim, S. (2006) Licensing of natural killer cells by self-major histocompatibility complex class I. Immunol Rev 214, 143–154. 7. Anfossi, N., Robbins, S. H., Ugolini, S., Georgel, P., Hoebe, K., Bouneaud, C., Ronet, C., Kaser, A., DiCioccio, C. B., Tomasello, E., Blumberg, R. S., Beutler, B., Reiner, S. L., Alexopoulou, L., Lantz, O., Raulet, D. H., Brossay, L., and Vivier, E. (2004) Expansion and function of CD8+ T cells expressing Ly49 inhibitory receptors specific for MHC class I molecules. J Immunol 173, 3773–3782. 8. Kim, S., Sunwoo, J. B., Yang, L., Choi, T., Song, Y. J., French, A. R., Vlahiotis,
9.
10.
11.
12.
13.
14.
A., Piccirillo, J. F., Cella, M., Colonna, M., Mohanakumar, T., Hsu, K. C., Dupont, B., and Yokoyama, W. M. (2008) HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc Natl Acad Sci U S A 105, 3053–3058. Hanke, T., Takizawa, H., McMahon, C. W., Busch, D. H., Pamer, E. G., Miller, J. D., Altman, J. D., Liu, Y., Cado, D., Lemonnier, F. A., Bjorkman, P. J., and Raulet, D. H. (1999) Direct assessment of MHC class I binding by seven Ly49 inhibitory NK cell receptors. Immunity 11, 67–77. Raulet, D. H., Vance, R. E., and McMahon, C. W. (2001) Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol 19, 291–330. Pascal, V., Stulberg, M. J., and Anderson, S. K. (2006) Regulation of class I major histocompatibility complex receptor expression in natural killer cells: one promoter is not enough! Immunol Rev 214, 9–21. Fernandez, N. C., Treiner, E., Vance, R. E., Jamieson, A. M., Lemieux, S., and Raulet, D. H. (2005) A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for selfMHC molecules. Blood 105, 4416–4423. Doucey, M. A., Scarpellino, L., Zimmer, J., Guillaume, P., Luescher, I. F., Bron, C., and Held, W. (2004) Cis association of Ly49A with MHC class I restricts natural killer cell inhibition. Nat Immunol 5, 328–336. Herzenberg, L. A., Tung, J., Moore, W. A., Herzenberg, L. A., and Parks, D. R. (2006) Interpreting flow cytometry data: a guide for the perplexed. Nat Immunol 7, 681–685.
Chapter 5 Use of Stem Cell Radiation Chimeras to Analyze How Domains of Specific Proteins Impact on Murine NK Cell Development In Vivo Rebecca H. Lian and Vinay Kumar Abstract Although the use of mutant mice has been extremely useful in identifying those proteins and molecules specifically required for the development of NK cells, the establishment of a well-defined protocol to replicate in vitro the major steps corresponding to the process of NK cell differentiation and maturation has enabled us to dissect the molecular events governing certain aspects of NK cell development. This chapter describes a protocol that combines both the use of mutant mice and the in vitro bone marrow (BM) culture system for examining the role of proteins and their putative signaling domains in NK cell development. BM-derived Lin–c-kit+ stem cells expressing the protein of interest are first cultured for 6 days in a cocktail of cytokines that promote lymphoid development. The semi-differentiated cells are then transplanted into mice to complete their development in vivo. While all hematopoietic lineages can develop from these transplanted cells, we focus primarily on assessing the effect of the protein on the production of NK cells, as well as the acquisition of Ly49 receptors. The most prevalent advantage of this method is the ability to potentially link signaling regulators to known aspects of NK cell development. Key Words: Stem cell chimeras, natural killer cells, Ly49, IL-15R␣.
1. Introduction The biological importance of certain protein receptors or signaling molecules is most often revealed through studies using mutant mice (1). Likewise, in the process of identifying the necessary components needed for natural killer (NK) cell development, molecules such as lymphotoxin, IL-15, IL-15R, IL-2R, Id2, IRF1, Ets-1, and many others were, through the use of genetically deficient mice, categorically described as indispensable for the normal production and maturation of NK cells (2). However, K.S. Campbell (ed.), Natural Killer Cell Protocols, Methods in Molecular Biology 612, DOI 10.1007/978-1-60761-362-6 5, © Humana Press, a part of Springer Science+Business Media, LLC 2010
51
52
Lian and Kumar
linking the biochemical nature of a particular region within a surface receptor or intracellular protein to its specific developmental function in vivo would require generating multiple mutant mice, each transgenically expressing a point mutation or truncation in the protein of interest. Although a viable option, we have instead employed the use of generating radiation chimeras in which donor whole bone marrow cells are substituted with genetically modified stem cells. Traditional radiation chimeras are generated by transplanting whole bone marrow (BM) cells from one donor mouse into a lethally irradiated recipient mouse and then monitoring the developmental path of the donor cells in the milieu of the recipient. In this chapter, we describe a method to study how mutated forms of a protein that is known to be essential in NK development affect the process of differentiation and development of NK progenitors that express those proteins. For obvious reasons, the BM cells for transplantation must originate from a donor that is null for the protein of interest. Then, because whole BM cells contain a mixed population of cells undergoing various stages and lineages of development, purified undifferentiated stem cells are a preferred choice as donors for transplantation. Also, if the protein being analyzed is required for NK cell production, the BM population of these mice would, therefore, most likely lack NK progenitors, leaving the stem cells as the best candidates for study. Finally, the use of stem cells lets us manipulate the system to enrich for only those cells that are successfully expressing cDNA encoding the protein of interest. In this protocol Lin–c-kit+ stem cells are purified from the whole bone marrow of a knock-out (KO) mouse, cultured in vitro under conditions that initiate NK cell differentiation (3, 4), retrovirally transduced with cDNA encoding various mutated forms of the knock-out protein, and consequently re-established in a recipient wild-type mouse. The NK cell progenitors whose development was promoted by the in vitro differentiation system will continue their maturation in vivo in a normal bone marrow milieu, but under the influence of a mutated receptor that is expressed on the progenitors. Because fully matured NK cells acquire various NK lineage markers, including Ly49 receptors (5, 6), the effect of the mutated receptor on proper NK cell development and production can be easily assessed by analyzing the splenocytes of the chimeric mice by flow cytometry for these markers.
2. Materials 1. RNA extraction reagent such as Trizol (www.invitrogen. com) or the RNeasy Plus kit (www1.qiagen.com).
Use of Stem Cell Radiation Chimeras
53
2. A first-strand cDNA synthesis kit (www.fermentas.com). 3. pCR2.1-TOPO cloning kit (Invitrogen). 4. pMIGR1-GFP retroviral vector is available from most labs that routinely perform retrovirus-based transfection methods. Use the standard protocol for requesting and obtaining reagents from other research labs – e-mailing a request usually suffices. 5. Retrovirus packaging cell line: we use PlatE cells, but any 293-based packaging cell line (such as GP293, 293FT, or Phoenix) can be used as long as the vectors encoding the gag, pol, or env genes are available for co-transfection with the retroviral vector. 6. Reagents for PlatE cell maintenance and transfection: 0.25% Trypsin-1 mM EDTA solution, blastocidin, and puromycin (both from InvivoGen, www.invivogen.com); ExGen500 In Vitro Transfection Reagent (Fermentas), sterile 150 mM NaCl. 7. Mice: Mice that are deficient in the protein of interest (knock-out, KO) that is on the C57BL/6J background (CD45.2, wild type), 4–6 weeks old (JAX, stock no. 000664) to provide donor stem cells; B6.SJLPtprca Pepcb /BoyJ congenic mice (CD45.1), approximately 6 weeks old (JAX, stock no. 002014) to serve as recipient animals. After transplantation, donor cells of KO mice can be differentiated from host congenic mouse cells by their respective CD45.2 or CD45.1 protein marker. 8. Flavored pediatric Bactrim (Trimethoprim-Sulfoxaxole) can be obtained from the animal housing facility veterinarian or staff and administered to mice before and after irradiation. 9. QuadroMACSTM and MiniMACSTM cell separation units and the MACS MultiStand (Miltenyi Biotec; www.miltenyibiotec.com). 10. LS and MS columns (Miltenyi Biotec). 11. Streptavidin (SA) magnetic microbeads or particles for binding to biotinylated antibodies (Miltenyi Biotec, cat# 130-048-102 or BD Biosciences, cat# 557811) and antiFITC magnetic microbeads (Milteny Biotec). 12. MACS buffer: 1× Dulbecco’s phosphate-buffered saline (DPBS) containing 2 mM EDTA and 0.5% bovine serum albumin. 13. DMEM-10 medium: Dulbecco’s Modified Eagle’s Medium (DMEM) containing 4,500 mg/L D-glucose with 10% fetal bovine serum, 100 units/ml penicillin,
54
Lian and Kumar
100 g/ml streptomycin, 10 mM HEPES, 1 mM sodium pyruvate, 0.1 mM MEM nonessential amino acids, and 50 M 2-mercaptoethanol. 14. Differentiation medium: DMEM-10 medium containing 1 g/ml indomethacin, 0.5 ng/ml murine IL-7, 30 ng/ml murine stem cell factor (SCF), and 20 ng/ml human Flt3ligand. 15. Antibodies: Conjugated monoclonal antibodies (mAbs) recognizing CD45.1, CD45.2, NK1.1 (clone PK136), CD3 (clone 2C11), Ly49A (any clone), Ly49C/I (clone 5E6), Ly49G2 (clone 4D11), and Ly49D (clone 4E5). Other mAbs used for purification of bone marrow (BM)-derived stem cells include biotinylated forms of anti-CD11b (Mac-1), anti-Gr-1, anti-B220, antierythroid cells (TER-119), and anti-CD2. All mAbs can be purchased from BD Biosciences or eBioscience (www.ebioscience.com) at stock concentrations of 0.5 mg/ml. Also needed will be a biotinylated mAb that recognizes the protein of interest if it is expressed on the cell surface. 16. Cytokines and growth factors: Recombinant murine IL7, Flt3-Ligand (Flt3L), and stem cell factor (SCF) can be purchased from Invitrogen or from R&D Systems (www.rndsystems.com). 17. Flow cytometry: Cell acquisition is performed using the FACS Diva software on the FACSCanto (BD Biosciences). Sorting of BM stem cells is accomplished using the MoFlo (Beckman Coulter, Miami, FL) and data are analyzed using FlowJo software (www.flowjo.com). 18. 2.4G2 hybridoma supernatant (cell line from ATCC, cat# HB-197). 19. Other reagents: 0.2% NaCl and 1.6% NaCl for lysis of erythrocytes; hexadimethrine bromide (Sigma-Aldrich) for enhancing retroviral infection.
3. Methods 3.1. Cloning Your Gene into the Retroviral Expression Vector pMIGR1-GFP
The pMIGR1-GFP retroviral vector contains an IRES sequence directly upstream of the GFP gene. Therefore, subcloning your gene upstream of the IRES sequence will permit the expression of the GFP marker in tandem with your gene of interest (see Fig. 5.1). Due to this bi-cistronic system of expression, transfected or transduced cells that are GFP+ are, therefore, more than
Use of Stem Cell Radiation Chimeras
55
Fig. 5.1. The pMIGR1-GPF vector for transfection of purified Lin–c-kit+ stem cells. It is 6056 bp in size, contains an internal ribosomal entry site (IRES), and a multiple cloning site at BglII (1406) to EcoRI (1424).
likely to also express the gene that is subcloned upstream of the IRES-GFP sequence. The GFP marker also facilitates easy and rapid monitoring of transfection and transduction efficiencies, as well as permits enrichment of positive cells by cell sorting using GFP fluorescence without the need for antibody staining. 1. Amplify your gene of interest (wild type or mutated) by PCR and insert the cDNA into any sub-cloning vector such as pCR3.2-TOPO (Invitrogen) using TA cloning methods according to the manufacturer’s instructions. To generate point or deletion mutants, it is easiest to incorporate the mutation sites into the PCR primers used for cloning. 2. Sequence the cDNA to verify that the gene has been correctly cloned with respect to length and PCR proofreading accuracy. 3. Excise the gene and insert into the pMIGR1 expression vector containing an IRES-controlled GFP gene. 4. Digest the vector and gene at the appropriate sites and sequence the final construct to verify that the gene has been correctly inserted with respect to orientation. 3.2. Preparing Viral Supernatant Using PlatE Packaging Cells
PlatE cells have been genetically manipulated and already contain vectors encoding all the genes necessary for virus particle packaging – gag, pol, and env(7). To maintain only a population of useful (positive) cells, they are cultured in the presence of antibiotics until just 24 h prior to transfection.
56
Lian and Kumar
3.2.1. Culture of PlatE Cells
1. To maintain cultures, grow cells in DMEM-10 medium containing 1 g/ml of puromycin and 10 g/ml blastocidin to keep cells under selective pressure. These antibiotics are necessary to prevent the outgrowth of vector-negative PlatE cells. Prolonged maintenance of these cells beyond 6 weeks is not recommended since the cultures may phenotypically and/or functionally drift. 2. When the cells are confluent, divide them at a 1:10 dilution.
3.2.2. Transfection of cDNA into PlatE Cells Using the ExGen500 Reagent
1. 24 h before transfection, plate 2 × 106 PlatE cells in 10 ml of DMEM-10 medium without puromycin or blastocidin into a 100 mm tissue culture dish. Optimum density should be achieved 12–16 h postplating. 2. The next day, remove the medium from the dish containing the cells and add 3 ml of fresh DMEM-10 medium. 3. For each dish of PlatE cells to be transfected, prepare one sterile Eppendorf (microfuge) tube containing a mixture of 5 g of cDNA and 300 l sterile 150 mM NaCl. Add 16.45 l of ExGen500 reagent into the DNA/salt solution and mix gently for 10 s. Let the mixture incubate for 10 min at room temperature. Following this, add the DNA/salt/ExGen500 mixture dropwise and evenly onto the PlatE cells. Gently rock the plate back and forth to evenly distribute the DNA solution. If possible, spin the plate for 5 min at 280 × g at room temperature. Incubate these cells overnight in 37◦ C/5% CO2 . For production of mock virus supernatant, add nuclease-free water instead of cDNA. 4. The day after transfection, remove the medium from the cells and add 3 ml of fresh DMEM-10 medium to the culture dish. Return cells to the incubator. 5. To verify that the transfected PlatE cells are expressing your gene of interest, harvest a small sample of the cells 48–72 h posttransfection and analyze for GFP expression by flow cytometry (see Note 1). 6. Harvest supernatant from cells whose GFP expression levels are equivalent to or more than 90%. This supernatant contains virus particles and will be used for infection of mouse stem cells (see Note 2). 7. Filter the supernatant through a sterile 45 m syringe filter to remove any cellular debris, aliquot into sterile tubes, and store at −80◦ C to −135◦ C. Supernatants can be thawed just prior to each use. Repeat freezing and thawing is not recommended.
Use of Stem Cell Radiation Chimeras
3.3. Preparing NK Progenitors from Mouse Bone Marrow for Retroviral Infection and Transplantation 3.3.1. Harvesting Whole Bone Marrow Cells from Mice
57
1. Euthanize mice whose bone marrow cells are to be harvested for transplanting into a recipient. The donor mice are those that are deficient for the protein of interest and usually KO mice of the CD45.2 genotype. 2. Remove both the large femoral bones from the mice. Scrape away all muscle tissue and place all the cleaned bones into a sterile ceramic mortar containing 5–10 ml of DMEM-10 medium. 3. Using a sterile pestle, carefully grind the bones to release the cells in the marrow space. 4. Place a 70 m cell strainer (BD Falcon) over the mouth of a sterile 50-ml tube, and using a pipet, transfer the cell solution into the tube through the strainer. This step filters out the bone debris. 5. Add 5–10 ml of sterile 1X PBS to the mortar dish and swirl to rinse the bones. Transfer the cell solution into the same 50-ml tube, again filtering through the cell strainer. 6. Continue adding fresh 1× PBS to the 50-ml tube through the strainer until the tube is filled. 7. Centrifuge at 500 × g for 10 min at 4◦ C to pellet the cells. 8. Loosen the pellet by vortexing. Lyse the erythrocytes by adding 10 ml of sterile 0.2% NaCl solution followed immediately by equal volumes of 1.6% NaCl solution. The first salt solution is hypotonic and quickly lyses the erythrocytes, whereas the second salt solution is hypertonic and is required to restore osmotic balance to the cell environment. Delay in adding the hypertonic salt solution may result in lysis of the other cell types, thus lowering your yield. 9. Fill the remaining volume in the tube with DMEM-10 medium. 10. Centrifuge to pellet the cells. Resuspend the pellet in 5–10 ml of sterile azide-free 2.4G2 hybridoma supernatant and remove the cell debris by filtering through a cell strainer. 11. Count cells to determine total cell count. 12. Incubate the cells (resuspended in the 2.4G2 supernatant) at 4–8◦ C for 20 min.
3.3.2. Purifying Lin– c-kit+ Stem Cells
1. Centrifuge to pellet the whole BM cells that were incubating in 2.4G2 hybridoma supernatant. 2. Decant the 2.4G2 supernatant and loosen the cell pellet. To the pellet add 2–3 l of each of the following biotinylated mAbs (taken directly from the stock without
58
Lian and Kumar
dilution): anti-CD2, anti-CD3, anti-Gr-1, TER119, antiMac-1 (CD11b), anti-NK1.1, and anti-B220. At this time, 2–3 l of FITC-labeled anti-c-kit mAb is also added to the cells. 3. Incubate cells with mAbs on ice for 30 min. 4. Wash cells 1× with sterile ice-cold MACS buffer by centrifugation. 5. Resuspend the pellet with 90 l of MACS buffer for every 1 × 107 (or fewer) total cells. Add 10 l of SA microbeads (Miltenyi Biotec) or SA particles (BD Biosciences) for every 1 × 107 (or fewer) total cells. 6. Mix thoroughly and incubate cells with beads on ice for 20–30 min or at 4◦ C for 12–15 min. 7. During this incubation, prepare the LS column (use more than 1 column if cell number is >3 × 108 total) by placing it on the QuadroMACSTM magnet and rinsing it with 5 ml of de-gassed ice-cold MACS buffer. Discard the flowthrough buffer. 8. When the cells have completed their incubation, wash them once with excess MACS buffer and resuspend the pellet in 3 ml of de-gassed MACS buffer. 9. Add the cell solution to the previously rinsed LS column(s) and allow the cell mixture to flow through the column bed. Collect the flow-through – this fraction contains the Lin– cells. 10. Wash the column 3× with MACS buffer and collect the flow through from each wash. 11. To collect the c-kit+ population, centrifuge the flowthrough to pellet the Lin– cells. 12. To the pellet, add 90 l of MACS buffer and 10 l of antiFITC microbeads for every 1 × 107 (or fewer) total cells. 13. Mix thoroughly and incubate at 4◦ C for 20 min. 14. While cells are incubating, prepare the MS column (may need to use two columns depending on the total cell number) by attaching it to the MiniMACSTM separation magnet and rinsing it with 1 ml of de-gassed MACS buffer. Discard the flow-through. 15. After incubation, collect the cells by washing with excess volumes of MACS buffer. 16. Resuspend the pellet in 0.5 ml MACS buffer and transfer the mixture to the previously rinsed MS column(s). Allow the cell mixture to flow through the column bed. Discard the flow-through – it contains the c-kit− cells. 17. Wash the column 3× with MACS buffer and discard the flow-through from each wash.
Use of Stem Cell Radiation Chimeras
59
18. Transfer the MS column to a clean (sterile) 5-ml tube, add 1 ml of DMEM-10 medium and immediately elute the c-kit+ cells using the column plunger. 19. Centrifuge and resuspend in DMEM-10 medium. Count and resuspend cells at 8 × 105 –1.5 × 106 cells/ml of Differentiation medium. Distribute 2 ml of the cell solution into each well of a 24-well sterile tissue culture plate with lid and incubate overnight at 37◦ C with 5% CO2 . 3.3.3. Retroviral Infection of Lin–c-kit+ Stem Cells
1. Carefully remove 1 ml of medium from each well of stem cells. 2. Add 1 ml of viral supernatant stock to each well of cells. As a control, add 1 ml of mock virus (no particles) supernatant to a few wells. 3. To each well also add 10 mM HEPES and 2 g/ml hexadimethrine bromide, also known as polybrene, and mix gently. Polybrene is a cationic compound that enhances the interaction between virus particles and the cell surface membrane by neutralizing repulsion charges between the virus and the cell membrane. 4. Carefully wrap the plate and centrifuge at 1,300 × g for 90 min at 30◦ C (spinfection step). 5. Resuspend cells by gentle mixing and incubate at 37◦ C and 5% CO2 for 2–4 h. 6. Harvest cells, pooling them according to their condition, and centrifuge as usual. 7. Resuspend the cells in Differentiation medium and reculture them in a clean 24-well plate at 2 ml per well. 8. Incubate at 37◦ C and 5% CO2 overnight. 9. Repeat the virus spinfection steps the next day, and if desired, the following day as well for a total of three rounds of infection (see Note 3). 10. On day 5, GFP expression can be assessed by flow cytometry. GFP+ cells can be enriched by FACS sorting (see Note 4). 11. After enrichment, culture the cells for one additional day in Differentiation medium prior to transplantation into lethally irradiated recipients.
3.4. Generating Radiation Chimeras 3.4.1. Transplanting Whole BM Cells
Since the idea is to use stem cells instead of whole bone marrow cells for transfer, it is important to make a side-by-side comparison of mouse chimeras generated from each donor cell type. The goal here is to show that using Lin–c-kit+ stem cells that had been cultured in vitro for 6 days (see Fig. 5.2A) is equivalent
60
Lian and Kumar
Fig. 5.2. Reciprocal radiation chimeras whose donor cells are obtained from cultured stem cells are equivalent to those from total bone marrow preparations. FACS analysis of freshly isolated spleen cells obtained after 2, 4, or 8 weeks after transplantation. Data are shown as percent positive of cells that were gated on the CD3− NK1.1+ lymphocyte population. Insets show the percent splenic NK cells of each chimera examined. (A) A total of 10 × 106 Lin–c-kit+ stem cells purified from whole BM of WT or IL-15R␣KO mice were transduced with “mock” virus supernatant and cultured for 6 days in SCF, IL-7, and Flt3L before transplanting into lethally irradiated recipient mice. In (B), 10 × 106 total BM cells were harvested and immediately transplanted into recipients.
to using freshly isolated whole BM preparations as donor cells (see Fig. 5.2B). These experiments conclusively eliminate the possibility that a failure to reconstitute NK cells is caused by the method of using cultured stem cells as donor cells. Also, to verify that the mutated proteins are effectively and properly expressed in the cell, transduce the cDNA constructs encoding the mutations into purified stem cells (or a cell line deficient for your protein) and assay by flow cytometry (surface protein) or Western Blotting (intracellular protein). For example, in our own experiments, we were able to demonstrate that our transduced cells correctly expressed
Use of Stem Cell Radiation Chimeras
61
Fig. 5.3. FACS analysis of 58−/− cells expressing cloned WT or cytoplasmic mutants of IL-15R␣ (Y227F, 16 and 30). Successful transduction was measured by GFP fluorescence with surface expression of WT and mutant IL-15R␣ also detected by staining with anti-mouse IL-15R␣ mAb.
either wild-type or various cytoplasmic mutant forms of the IL15R␣ gene on the cell surface and at fairly equivalent levels (see Fig. 5.3). 1. 7–10 days before transplantation, begin a regimen of Bactrim suspension (5–250 ml of drinking water) for the intended recipient mice, which in most cases will be the CD45.1 congenic mice. All aspects of drug administration should be approved by your institution’s veterinarian and comply with all guidelines specified by your animal facility. 2. 24 h before transplantation, lethally irradiate (10 Gy) recipient mice. Prepare at least three mice per experimental condition, including three control mice (to receive PBS instead of cells) (see Note 5). 3. On the day of transplantation, harvest donor whole nucleated BM cells (depleted of erythrocytes), which, in most cases will be the gene KO mice expressing the CD45.2 marker. 4. Resuspend the cells in sterile PBS to a concentration of 5 × 107 –1 × 108 cells/ml. 5. Using a tuberculin syringe and 27-gauge needle, inject 100 l of the cell solution into the tail veins of the lethally irradiated recipient mice. The absolute number of cells injected into each mouse will be 5 × 106 –1 × 107 cells. Equivalent numbers should be injected for each
62
Lian and Kumar
experimental condition. Continue with treatment of Bactrim for two more weeks after transplantation. 6. Analyze the chimeric mice 8 weeks post-BM transfer, at which time >96% of the splenic leukocytes are donor derived. 7. For details on analysis, see Section 3.5. 3.4.2. Transplanting BM-Derived Stem Cells
1. Prepare recipient mice as before (see previous section). 2. On the day of transplantation, harvest Lin–c-kit+ stem cells previously isolated from donor mice that have been cultured with SCF, Flt3L, and IL-7 for 5 days, infected with virus particles and enriched for GFP expression (see Note 6). 3. Wash the cells several times with sterile PBS to remove traces of cytokines. 4. Resuspend the cells in sterile PBS to a concentration of 1 × 107 –5 × 107 cells/ml. 5. Inject 100 l of the cell solution into the tail veins of lethally irradiated recipient mice. The absolute number of cells injected into each mouse will be 1 × 106 –5 × 106 cells. Equivalent numbers should be injected for each experimental condition. 6. Analyze the chimeric mice 8 weeks after stem cell transfer, at which time >96% of the splenic leukocytes are donor derived. 7. For details on analysis, see Section 3.5.
3.5. Analyzing the Radiation Chimeras by Flow Cytometry
1. Harvest spleen cells from the chimeric mice and lyse erythrocytes as usual. 2. Pre-incubate nucleated cells with the 2.4G2 (anti-FcR) hybridoma supernatant and aliquot 5 × 105 cells into each analysis tube. 3. Follow the standard protocol of antibody staining for flow cytometry. 4. To each tube of cells, add the following fluorochromeconjugated mAbs: anti-CD3, anti-NK1.1, anti-CD45.2, and one anti-Ly49 mAb. For example, a combination of antiCD3 PE-Cy7, anti-NK1.1 PE, anti-CD45.2 PE-Cy5.5, and anti-Ly49G2 FITC can be used for one of the tubes. One tube of cells should only contain the first three mAbs, and instead of an anti-Ly49 mAb, use an isotype-matched control mAb. 5. For analysis, quantitate Ly49 expression on cells after gating on the population that is CD3− , NK1.1+ , and CD45.2+ (see Note 7). Figure 5.4 shows results that are representative of
Use of Stem Cell Radiation Chimeras
63
Fig. 5.4. FACS analysis of freshly isolated splenocytes harvested from chimeric mice that were transplanted 8 weeks prior with Lin–c-kit+ stem cells transduced with vector alone, wild-type, or mutated forms of IL-15R␣. Data show percent splenic NK cells (inset) and Ly49 expression of cells gated on CD3− NK1.1+ CD45.2+ for each mouse. The results here indicate that IL-15R␣-mediated signals are important for NK cell production as well as the expression of certain Ly49 molecules.
these experiments. Here, the flow cytometric data indicate the importance of the cytoplasmic domains of the IL-15R␣ protein in NK production and Ly49 expression.
4. Notes 1. Harvesting a small sample of the transfected PlatE cells can be easily done by using a 200–1000 l pipetter and sterile tip to draw 500 l of culture medium while scraping across the bottom of the dish. Since these cells are used as a quick and rough measure to survey the extent of transfection, there is no need to count the cells prior to flow cytometric analysis. Just a quick wash in PBS containing 2% FBS and filtration through a 70 m sieve is sufficient preparation for analysis. 2. The efficiency of transduction can sometimes fluctuate and, therefore, result in the production of insufficient numbers of GFP+ progenitor cells for successful transfer into mice. One extremely important factor that should not be overlooked is the “potency” of the virus supernatant for transduction. If supernatant is collected on days when fewer than 70% of transfected PlatE cells are GFP+ , the supernatant may not contain high enough titers of virus particles to be effective.
64
Lian and Kumar
Therefore, transduction efficiency and quality is determined by the concentration of virus particles in the supernatant. Given this, supernatants can be concentrated using special filters. However, three easier and less expensive methods would be (1) to harvest the supernatant when more than 90% of PlatE cells are GFP+ , (2) to enrich the supernatant by incubating the cells for a longer period with medium prior to harvesting, and (3) to enrich the supernatant by reducing the volume of medium added to the PlatE cells following transfection. In terms of quality, freshly harvested supernatants are the most effective, followed by freshly thawed stocks of supernatant. Supernatant stocks kept at 4◦ F will quickly lose their potency. Repeated freezing and thawing of stocks are also not recommended. 3. Three rounds of infection typically yield 50–65% GFP+ cells. However, we have in the past obtained improved results by following a more labor-intensive protocol involving the use of fibronectin (FN) (8, 9). For that method, pre-coat the 24well plates with 20 g of sterile FN (from BD Biosciences) per well and incubate 2–3 h at room temperature. After that, remove the FN solution and add PBS containing 2% BSA to the same wells for 30 min at room temperature to block nonspecific binding sites. Remove the PBS/BSA solution, wash once with DMEM-10 medium, followed by adding 1 ml of virus supernatant stock to each treated well. Incubate 1 h at room temperature. Remember to add 1 ml of “mock” virus supernatant to one or more wells as control. Finally add 1 ml of cells that were pre-washed and resuspended in 2X Differentiation medium containing 20 mM HEPES and 40 g/ml of polybrene. The rest of the protocol is the same as described in Section 3.3.3, step 4. 4. Magnetic-based methods can be used only if the protein of study is a receptor (i.e., expressed on the surface) for which antibodies are available. 5. Lethally irradiated mice that only receive PBS and not BM cells will usually die within 10 days. 6. To obtain the results in Fig. 5.2A, transplant with stem cells previously infected with mock virus supernatant, i.e., contains no virus particles. An even better control is to use cells infected with virus particles expressing the empty pMIGR1GFP vector. 7. Except when performing reciprocal transfers, in most cases the KO mouse-derived donor cells express the CD45.2 marker, and the recipient cells express the CD45.1 marker of the congenic mouse strain. As such, staining the splenocytes with anti-CD45.2 will identify the donor cells co-expressing
Use of Stem Cell Radiation Chimeras
65
your wild-type or mutated protein. Although all the donor cells presumably originated from GFP+ stem cells, the differentiated population has undergone several cycles of division, during which time GFP expression is extensively diluted and often undetectable in the final analysis. References 1. Williams, N. S., Klem, J., Puzanov, I. J., Sivakumar, P. V., Schatzle, J. D., Bennett, M., and Kumar, V. (1998) Natural killer cell differentiation: insights from knockout and transgenic mouse models and in vitro systems Immunol Rev 165, 47–61. 2. Lian, R. H., and Kumar, V. (2002) Murine natural killer cell progenitors and their requirements for development Semin Immunol 14, 453–60. 3. Williams, N. S., Moore, T. A., Schatzle, J. D., Puzanov, I. J., Sivakumar, P. V., Zlotnik, A., Bennett, M., and Kumar, V. (1997) Generation of lytic natural killer 1.1+, Ly49- cells from multipotential murine bone marrow progenitors in a stroma-free culture: definition of cytokine requirements and developmental intermediates J Exp Med 186, 1609–14. 4. Williams, N. S., Klem, J., Puzanov, I. J., Sivakumar, P. V., Bennett, M., and Kumar, V. (1999) Differentation of NK1.1+, Ly49+ NK cells from flt3+ multipotent marrow progenitor cells J Immunol 163, 2648–56.
5. Dorfman, J. R., and Raulet, D. H. (1998) Acquisition of Ly49 receptor expression by developing natural killer cells J Exp Med 187, 609–18. 6. Roth, C., Carlyle, J. R., Takizawa, H., and Raulet, D. H. (2000) Clonal acquisition of inhibitory Ly49 receptors on developing NK cells is successively restricted and regulated by stromal class I MHC Immunity 13, 143–53. 7. Morita, S., Kojima T., and Kitamura, T. (2000) Plat-E: an efficient and stable system for transient packaging of retroviruses Gene Ther 7, 1063–6. 8. Moritz, T., Dutt, P., Xiao, X., Carstanjen, D., Vik, T., Hanenberg, H., and Williams, D. A. (1996) Fibronectin improves transduction of reconstituting hematopoietic stem cells by retroviral vectors: evidence of direct viral binding to chymotryptic carboxy-terminal fragments Blood 88, 855–62. 9. Bajaj, B., Behshad, S., and Andreadis, S. T. (2002) Retroviral gene transfer to human epidermal keratinocytes correlates with integrin expression and is significantly enhanced on fibronectin Hum Gene Ther 13, 1821–31.
Chapter 6 Use of Transfected Drosophila S2 Cells to Study NK Cell Activation Michael E. March, Catharina C. Gross, and Eric O. Long Abstract Determining the contribution of individual receptors to natural killer (NK) cell function is complicated by the multiplicity of activating and inhibitory NK cell receptors. Mammalian target cells typically express a variety of ligands for NK cell receptors. Engagement of NK cell receptors by antibodies may not mimic activation by natural ligands. To define requirements for activation and dissect the contribution of receptors to NK cell function, we have generated Drosophila Schneider line 2 (S2) cell transfectants expressing ligands for NK cell receptors. The evolutionary distance between Drosophila and mammals greatly reduces the potential of recognition of insect cell molecules by mammalian NK cells. Here, we present methods for maintenance and transfection of S2 cells, as well as protocols for their use in NK cell assays. Key words: Drosophila, S2, insect cells, NK cells, activation, inhibition, transfection.
1. Introduction The activation of natural killer (NK) cells is controlled by combinations of activating and inhibitory receptors expressed by NK cells. Integration of the signals downstream from a wide variety of receptors determines whether or not the NK cells respond (1– 4). Higher expression of activating ligands on target cells induces activation of NK cells, whereas higher expression of inhibitory ligands prevents it. Human NK cells express a wide variety of activating receptors, which respond to a wide variety of ligands. The natural cytotoxicity receptors (NCRs) NKp46, NKp44, and NKp30 and receptors NKG2D, 2B4 (CD244), CD2, LFA1 (CD11a/CD18), and DNAM-1 (CD226) are some of the K.S. Campbell (ed.), Natural Killer Cell Protocols, Methods in Molecular Biology 612, DOI 10.1007/978-1-60761-362-6 6, © Humana Press, a part of Springer Science+Business Media, LLC 2010
67
68
March et al.
receptors known to deliver activating signals to NK cells. Engagement of combinations of these receptors can activate NK cell functions such as adhesion, cytotoxicity, and cytokine secretion (5–7). NK cells are also potent mediators of antibody-dependent cellular cytotoxicity (ADCC) through the low-affinity Fc ␥RIII (CD16). Inhibitory receptors are expressed on NK cells in a clonally distributed manner, where individual NK cells may express single or multiple inhibitory receptors in an essentially random manner. Inhibitory receptors in humans include members of the killer cell Ig-like receptor (KIR) family, which recognize alleles of HLA class I, members of the CD94/NKG2 family that recognize HLA-E, and several other inhibitory receptors that bind to non-MHC ligands (4, 8). The response of NK cells to signals from individual receptors, or combinations of receptors, is often studied by masking the receptors with antibodies in order to block a response to a given target cell (9–13) or by cross-linking the receptors on the surface of NK cells with antibodies in order to provoke a response in the absence of target cells (7, 14). Such experiments can be very informative; however, antibodies typically have much higher affinities for receptors than the natural ligands do and may fail to stimulate those receptors in the physiological way. This is particularly true for receptors such as integrins that undergo conformational changes upon ligand binding (15, 16), which may not occur following antibody cross-linking. Cell lines that are susceptible or resistant to NK cell cytotoxicity are also used to probe NK cell responses. Ectopic expression of ligands in cell lines has revealed much about the contributions of both activating and inhibitory receptors to the regulation of NK cells (9, 13, 17, 18). Interpretation of such experiments can be complicated by the expression of many, often uncharacterized, ligands on target cell lines. For example, the EBV-transformed B cell line 721.221 expresses ICAM-1 (CD54), ICAM-2 (CD102), and ICAM-3 (CD50) (ligands for the integrin LFA-1), CD48 (ligand for 2B4), and B7 (CD80, a ligand of CD28) (19). The erythroblastoid cell line K562 expresses ULBP2 and MICA/B (ligands for NKG2D) (20, 21) along with ICAM-1 and ICAM-2 (22). Additionally, the Fc␥R+ mouse cell line P815, which is often used to stimulate NK cells with antibodies via redirected lysis (10, 11), expresses the mouse ICAM-1, which binds to human LFA-1 (23). In addition, P815 cells are more sensitive to lysis by NK cells that express high levels of NKp46, suggesting that they may express ligands for this NCR (24). Ligands for the NCRs have not been fully characterized, and the pattern of expression on many NK target cell lines is unknown. These uncertainties created a need for a target cell line in which expression of ligands is more easily characterized and controlled. A cell line derived from an evolutionarily distant species,
Transfected Insect Cells as Targets of NK Cells
69
which would also be easy to transfect and maintain, would be a useful surrogate target cell. Schneider line 2 (S2) cells fulfill these requirements. The S2 cell line was derived from latestage embryos of Drosophila melanogaster (25). The cells grow in a loose monolayer. S2 cells are easily transfected. They can be adapted to growth in serum-free medium, suitable for the purification of recombinant secreted proteins. S2 cells have been used to produce and purify proteins in sufficient quantities for structural and biochemical studies (26). Expression of exogenous proteins is often accomplished by transfection with the pRmHa3 plasmid, which uses the Drosophila metallothionein gene promoter for inducible expression, allowing high expression even for proteins that prove deleterious to the growth of S2 cells (27). Transfected S2 cells have been used previously to investigate the minimal requirements for T-cell activation and costimulation. S2 cells expressing peptide-loaded MHC class I, either alone or in combination with ICAM-1 and B7, were used as antigen-presenting cells (APCs) for the stimulation of na¨ıve T cells expressing the 2C transgenic TCR (28, 29). The results demonstrated that signaling through the TCR alone is not sufficient to activate na¨ıve CD8+ T cells and that B7 and ICAM-1 could provide the required co-stimulation for activation. Optimal co-stimulation occurred with both B7 and ICAM-1 expressed on the same MHC class I+ S2 cell. Besides confirming the two-signal hypothesis for T-cell activation, these data also demonstrated that co-engagement of the TCR with a co-stimulatory receptor is sufficient for T-cell activation. The use of S2 cells as APCs for T cells indicated that this Drosophila cell line could be used to reconstitute a sensitive target cell for NK cells. We have successfully used S2 cells to investigate the response of primary human NK cells to stimulation and inhibition through individual receptors (5, 30, 31). A notable advantage of this system is that resting NK cells, freshly isolated from human blood, can be used directly in functional assays with S2 cell transfectants, without further manipulation. In most assays examining degranulation or cytokine secretion, untransfected S2 cells induce minimal or no response from either primary NK cells or NK cell lines. Expression of individual ligands by stable transfection is sufficient to induce responses such as adhesion (5) and granule polarization (30, 31), whereas multiple ligands may be required to induce other responses such as degranulation (Y. Bryceson, unpublished). Transmembrane proteins expressed in S2 cells are glycosylated, which may be important for recognition by some NK cell receptors. S2 cells are easily transfected, either transiently or stably, and can be substituted for mammalian target cells in many NK cell assays with little or no modification. We will present here methods for stable transfection of S2 cells, methods for isolation of cells expressing the transfected protein,
70
March et al.
as well as specific protocols for the use of S2 cells in assays for NK cell function.
2. Materials 2.1. Care and Culture of S2 Cells 2.1.1. Standard Culture
1. S2 culture medium: Schneider’s Drosophila medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) (Hyclone, Logan, UT; complement inactivated by heating at 56◦ C for 30 min). 2. 75 cm2 tissue culture flasks (Costar, Corning, Lowell, MA). 3. Freezing medium: Fresh S2 cell culture medium mixed with an equal volume of conditioned medium (the medium in which S2 cells have been grown) supplemented with 10% dimethyl sulfoxide (DMSO) (Sigma Aldrich, St. Louis, MO). Alternatively, freezing medium can be composed of 90% FBS supplemented with 10% DMSO. 4. Reagent for inducible expression: Expression from metallothionein promoter-based plasmids is induced by the addition of cupric sulfate (CuSO4 , Sigma Aldrich) to the cell culture to a final concentration of 1 mM. A 100 mM CuSO4 stock solution is made in deionized water and then sterilized by filtration through a 0.45 m filter.
2.1.2. Adaptation of S2 Cells to Culture in Serum-Free Conditions
1. Bio Whittaker Insect-Xpress medium (Lonza, Basel Switzerland). 2. Iscove’s Modified Dulbecco’s Medium (Invitrogen) supplemented with 0.2% BSA (see Note 1). 3. Fetal Bovine Serum (Hyclone). 4. 75 cm2 tissue culture flasks (Costar, Corning). 5. 125 ml Disposable Erlenmeyer Flask with 0.2 m PTFE Vented Closure (Bellco Glass Inc, Vineland, NJ). 6. Orbital shaker capable of handling 125 ml flasks, at 27◦ C.
2.2. Transfection of S2 Cells 2.2.1. Calcium Phosphate Transfection
1. HEPES buffered saline (HBS) for calcium phosphate transfection: 50 mM HEPES, 1.5 mM Na2 HPO4 , and 280 mM NaCl, in water, adjusted to pH 7.1, sterilized by filtration through a 0.45 m filter. 2. CaCl2 for calcium phosphate transfection: 2 M CaCl2 (Sigma Aldrich) in water, sterilized by filtration through a 0.45 m filter. 3. 6-well tissue culture plates (Costar, Corning).
Transfected Insect Cells as Targets of NK Cells
71
4. pAc5.1-V5-His: Plasmid for constitutive expression in S2 cells using the Drosophila Actin 5 promoter (requires a licensing agreement with Invitrogen). 5. pRmHa3: Plasmid for inducible expression in S2 cells using the metallothionein promoter (available to not-for-profit labs from the Drosophila Genome Research Center, Bloomington, IN). 6. Plasmids for selection of transfectants, which include pNeoFly (27), pCoBlast (Invitrogen), and pCoHygro (Invitrogen). 7. Agents for selection of stable transfectants: Geneticin (G418 sulfate, Invitrogen), Puromycin dihydrochloride (Sigma Aldrich), Hygromycin B (Roche Diagnostics GmbH, Basel Switzerland), Blasticidin S HCl (Invitrogen). 8. 6 ml polypropylene, round bottom tubes, sterile (Falcon, BD Biosciences, San Jose, CA). 9. 15 ml polystyrene conical screw cap tubes (Sarstedt, Newton, NC). 2.2.2. Transfection with Cellfectin
1. Schneider’s Drosophila medium (Invitrogen) ± 10% FBS. 2. Cellfectin Transfection Reagent (Invitrogen). 3. Expression and drug resistance plasmids and agents for selection of stable transfectants (see Section 2.2.1). 4. 6-well tissue culture plates (Costar, Corning). 5. 6 ml polypropylene, round bottom tubes, sterile (Falcon, BD Biosciences).
2.2.3. Enrichment of Expressing Cells
1. Antibodies for the transfected proteins. For fluorescenceactivated cell sorting (FACS), antibodies directly coupled to fluorescent labels may be used when available. Alternatively, unlabeled primary antibodies can be stained with fluorescently labeled secondary antibodies. For enrichment of cells expressing a given protein using magnetic beads coated with goat anti-mouse antibodies, unlabeled primary antibodies are recommended. 2. Buffer for FACS sort: PBS supplemented with 2% heatinactivated FBS, 2 mM EDTA, 100 U/ml Penicillin, and 100 g/ml Streptomycin. 3. FACS tubes: 5 ml polystyrene tubes, 12 × 75 mm (Falcon, BD Biosciences). 4. Dynabeads Goat anti-mouse IgG and selection magnet (Invitrogen). 5. 14 ml Polypropylene Round Bottom Tubes (Falcon, BD Biosciences).
72
March et al.
6. Flat bottomed 96-well plates (Costar, Corning). 2.3. S2 Cells as Targets in NK Cell Assays
1. Anti-CD56 mAb (clone NCAM 16.2) PE (BD Bioscience).
2.3.1. CD107a Degranulation Assay
1. PKH26 Red Fluorescent Cell Linker Kit (Sigma Aldrich).
2.3.2. Conjugate Assay
3. Hank’s Buffered Saline Solution (Invitrogen) supplemented with 5% FBS.
2. Anti-CD107a mAb (clone H4A3) FITC (BD Bioscience).
2. CellTracker Green CMFDA (Invitrogen).
4. IMDM + 10% FBS. 5. FACS tubes: 5 ml polystyrene tubes, 12 × 75 mm (BD Biosciences). 6. 0.5% Paraformaldehye (16% solution from Electron Microscopy Sciences, Hatfield, PA, diluted in phosphatebuffered saline (PBS)). 2.3.3. Perforin Polarization Assay
1. 15 ml polystyrene conical screw cap tubes (Sarstedt). 2. Hank’s Buffered Saline Solution (HBSS) (Invitrogen) supplemented with 3% FBS. 3. Poly-D-Lysine coated 2-well Culture Slides (BD BioCoat, BD Biosciences). 4. 4% Paraformaldehye (16% solution Microscopy Sciences diluted in PBS).
from
Electron
5. Normal donkey serum (Jackson ImmunoResearch Laboratories, West Grove, PA) reconstituted in 10 ml water. 6. Triton X-100 (Sigma Aldrich). 7. Permeablization buffer: 10% normal donkey serum and 0.5% Triton X-100 in PBS. 8. Staining buffer: 3% normal donkey serum and 0.5% Triton X-100 in PBS. 9. CellTracker Green CMFDA (Invitrogen). 10. Anti-perforin antibody, clone ␦G9 (Thermo Scientific, Rockford, IL). 11. Alexa Fluor 568 conjugated goat anti-mouse secondary antibody (Invitrogen). 12. Prolong Gold antifade reagent (Invitrogen). 2.3.4. Flow Cytometry-Based Cytotoxicity Assay
1. PKH67 Green Fluorescent Cell Linker Kit (Sigma Aldrich). 2. 15 ml polystyrene conical screw cap tubes (Sarstedt). 3. Iscove’s Modified Dulbecco’s Medium with and 25 mM HEPES (Invitrogen).
L -Glutamine
4. Propidium iodide solution, 1 mg/ml (Sigma Aldrich).
Transfected Insect Cells as Targets of NK Cells
73
5. FACS tubes: 5 ml polystyrene tubes, 12 × 75 mm (BD Biosciences)
3. Methods 3.1. Care and Culture of S2 Cells 3.1.1. Standard Culture
1. S2 cells grow at or slightly above room temperature. Additional carbon dioxide (CO2 ) is not required. Incubators, without CO2 injection, can be used to maintain an optimal temperature of approximately 27◦ C. Alternatively, S2 cells will grow reasonably well in a drawer or any location at room temperature that is protected from light. 2. S2 cells should be thawed at room temperature. Since S2 cells undergo a heat shock at 37◦ C, thawing the cells in a warm water bath will reduce viability. 3. Cell cultures should be maintained between 1 × 106 and 2.5 × 106 cells/ml in Schneider cell medium supplemented with 10% FBS. Cells grow best when diluted no more than 1:3 at each passage. Maintenance of a healthy culture of growing cells requires a 1:2 passage every other day (see Note 2). 4. Freezing of S2 cells is most successful when large numbers of cells from a healthy culture are frozen, such as 20–30 million cells per vial. S2 cells can be frozen in a variety of freezing media. We have used mainly 45% fresh culture medium combined with 45% conditioned S2 cell medium (the medium in which the cells have been grown) supplemented with 10% DMSO. Alternatively, a simple mixture of 90% FBS supplemented with 10% DMSO has been used. 5. Proteins can be expressed by transfection with either a constitutive or an inducible promoter-containing plasmid. Plasmid pAc5.1 (Invitrogen) drives expression with a Drosophila Actin 5 promoter, which results in constitutive expression. Plasmid pRmHa3 uses a metallothionein promoter, the activity of which is induced with 1 mM CuSO4 . A total of 48 h of induction with 1 mM CuSO4 is sufficient to yield maximal expression of transfected proteins. A fraction of the cell culture is reserved, without induction, for continued culture. Constitutive expression is more convenient, as the transfected proteins are always expressed and variability introduced by induction is avoided. Expression from a constitutive promoter is often more uniform over time than induced expression, which often yields heterogeneous expression levels. Constitutive expression can also be beneficial in transient transfections, where cells already dealing with the stress of the transfection may be adversely affected
74
March et al.
even further by the induction in cupric sulfate. Inducible expression is advantageous when a transfected protein is toxic to the S2 cells. Induced expression is also often used for large-scale protein production in S2 cells, where constitutive expression may slow the expansion of the cultures. The cells can be expanded without expressing the protein, and expression can be induced in 24–48 h. 6. Co-expression of multiple proteins in transfected S2 cells can be achieved either by co-transfection of all the required plasmids at once or by sequential transfections (see Notes 3 and 4). 7. Expression of MHC class I molecules in S2 cells requires co-transfection with 2 -microglobulin. Furthermore, exogenous peptides have to be loaded onto MHC class I because insect cells do not have the endogenous peptide loading machinery (e.g., TAP transporter, chaperones) (32). Peptide loading is very efficient because “empty” class I–2 microglobulin dimers are readily expressed at the surface of S2 cells at 27◦ C. Appropriate peptides are added to the S2 cell culture at a final concentration of 1 m 1 day prior to the assay with NK cells. 8. Using S2 cells in NK cell assays is often a matter of simply replacing the conventional target cells in the assay with S2 cells. However, there are two important considerations. First, insect cells undergo heat shock and will eventually die at 37◦ C. Second, S2 cells exposed to human serum that has not been heat inactivated are killed in less than 1 h. Each of those issues can be addressed as follows. The viability of S2 cells following incubation at 37◦ C is not significantly reduced for at least 3 h. The assays described here using S2 cells at 37◦ C do not exceed 3 h. S2 cells grow happily at 27◦ C in heat-inactivated bovine serum. However, our primary human NK cells are usually cultured in human serum, which is not routinely heat inactivated. To avoid exposure of S2 cells to human serum, the simplest approach is to wash and resuspend NK cells in medium containing FBS prior to the assays with S2 cells. Although, in our hands, primary human NK cells survive and proliferate best in medium containing 10% human serum, they remain functional in medium containing FBS in short-term assays (see Note 1). 3.1.2. Adaptation of S2 Cells to Culture in Serum-Free Conditions
S2 cells used for production of proteins are often cultured in serum-free conditions in order to simplify the purification of the protein of interest. Serum-free culture of S2 cells has an additional advantage, of interest when using S2 cells as target cells in NK cell assays. Drosophila does not synthesize sterols. Its sole source of cholesterol is from the diet. Culture of S2 cells in serum-free
Transfected Insect Cells as Targets of NK Cells
75
medium is therefore a method to deplete the cells of cholesterol without using compounds such as -methylcyclodextrin. Therefore, S2 cells grown in serum-free conditions may be a useful tool to investigate the role of cholesterol-dependent membrane microdomains on the behavior of ligands of NK cell receptors. A previous report indicated that the inclusion of MICA in lipid rafts on target cells is necessary for the NKG2D-dependent response of NK cells (33). 1. S2 cells to be adapted should be thawed from frozen stocks and cultured in 75 cm2 flasks in Insect-Xpress medium supplemented with 5% FBS. Cells should be expanded until a healthy growing culture at 2 × 106 cells/ml is obtained. 2. Pellet 150 × 106 cells at 135g. Resuspend in 30 ml InsectXpress + 5% FBS and transfer the cell suspension to a 125 ml disposable Erlenmeyer Flask. 3. Expand the cells by culturing on a shaker at 140 rpm at 27◦ C for 2–3 days. 4. Pellet 150 × 106 cells at 135g. Resuspend in 30 ml InsectXpress + 2.5% FBS and transfer the cell suspension to a 125 ml disposable Erlenmeyer Flask. 5. Again, expand the cells by culturing on a shaker at 140 rpm at 27◦ C for 2–3 days. 6. Perform three more cycles of pelleting 150 × 106 cells, resuspending in Insect-Xpress medium, and expanding the cells in shaking culture for 2–3 days, using medium that contains 1% FBS, then 0.5% FBS, and finally no serum. 7. Cells should be cultured in serum-free medium for a further 2 weeks before use in an assay (see Note 1). 3.2. Transfection of S2 Cells
For most NK cell assays, it is preferable to use S2 cells that express ligands at a fairly uniform level. To this end, stable transfectants of S2 cells are usually generated, from which the desired expressing cells can be enriched or cloned, when necessary. Two protocols for the generation of stable S2 cell lines are presented here. In some cases, transient transfections of S2 cells can be used. Transient expression is advantageous to test expression from new plasmids, for preliminary functional assays (where appropriate), and for the rapid screening of a very large number of transfectants. However, there is less control over protein expression levels in transient transfections, and there will usually be a sizeable fraction of the S2 cells that do not express the transfected proteins (see Note 5).
3.2.1. Calcium Phosphate Transfection
1. For transfection, S2 cells should be growing logarithmically, at a density around 2 × 106 /ml, with high viability. Cells can be counted on a hemacytometer with trypan blue staining.
76
March et al.
2. The day before transfection, spin down 3 × 106 cells per transfection in a 15 ml conical tube at 215g. Resuspend the cells at 1 × 106 cells/ml and plate 3 ml (3 × 106 cells) in a well of a 6-well plate. Incubate overnight at 27◦ C. 3. Set up the transfection mix. In one 6 ml tube, aliquot 300 l of HBS. In a second 6 ml tube, mix 36 l of 2 M CaCl2 with 19 g of sterile DNA and sterile water to a total volume of 300 l. This mixture should contain 18 g of the plasmid expressing the protein of interest and 1 g of the desired selection plasmid (see Notes 6 and 7). Vortex the tube containing the HBS at a moderate setting. While vortexing, slowly add the CaCl2 /DNA mixture dropwise to the HBS. This process should take approximately 1 min. Incubate the mixture at room temperature for 30 min. 4. Add the DNA mixture to the S2 cells that had been plated the day before. The mixture should be added to the medium on the cells in a dropwise manner. Gently swirl the plate in order to mix the medium and DNA. Incubate the cells overnight with the transfection mixture at 27◦ C. 5. Pipet the cells into a 15 ml conical tube. Wash the well with 5 ml of S2 medium in order to recover adherent cells. Pellet the cells at 215g and wash the cells once with 10 ml of medium. Plate the cells into a fresh well in a 6-well plate in 3 ml medium and incubate for 48 h at 27◦ C. 6. Add the appropriate selection (see Note 8). Incubate the cells for up to 2 weeks, until the resistant cells expand through the selection. The drug-resistant cells should be assayed for protein expression by flow cytometry. 3.2.2. Cellfectin Transfection
1. The day before the transfection, plate 1 × 106 cells into a well of a 6-well plate in 3 ml of Schneider’s Drosophila medium + 10% FBS. Culture the cells overnight. 2. Prepare the transfection mixture. a. In a 6 ml polypropylene tube, prepare a mixture consisting of 0.5 g of the drug resistance plasmid and 5 g of each protein expression plasmid in 100 l of serum-free Schneider’s Drosophila medium (see Notes 6 and 7). The DNA should be sterile. b. In a second tube, add 10 l Cellfectin Reagent to 90 l serum-free Schneider’s Drosophila medium. c. Add the Cellfectin-containing medium to the tube containing the DNA mixture. Mix gently. d. Incubate the combined mixture at room temperature for 15 min.
Transfected Insect Cells as Targets of NK Cells
77
e. Add 800 l serum-free Schneider’s Drosophila medium to the mixture. 3. Gently aspirate the medium from the S2 cells. Carefully wash the cells once with 2 ml serum-free Schneider’s Drosophila medium. Aspirate the wash medium. 4. Add the Cellfectin/DNA mixture to the cells. Incubate the cells for 18 h at 27◦ C. 5. Replace the DNA-containing medium with Schneider’s Drosophila medium + 10% FBS. Incubate for 48 h at 27◦ C. 6. At this point, the cells can be analyzed by flow cytometry for the expression of proteins from constitutively expressing plasmids, and protein expression from inducible plasmids can be induced with 1 mM CuSO4 and examined after another 48 h. 7. To select stable transfectants, the cells from Step 5 should be harvested and collected by centrifugation and resuspended in 3 ml Schneider’s Drosophila medium + 10% FBS containing the required selection reagent (see Note 8). Cells can be replated into the same well of the 6-well plate in which the transfection was performed. The cells should be incubated at 27◦ C, and the medium exchanged for fresh growth medium every 7 days, until stably transfected cells begin to expand. 3.2.3. Enrichment of Expressing Cells
Cells that have been selected through drug resistance often contain only a subpopulation of cells that express the protein(s) of interest. Although this amount of expression is sometimes sufficient for use in certain assays, it is usually preferable to obtain a more uniform profile of expression. 1. Expressing cells can be enriched with magnetic beads. We have had success with Dynabeads from Invitrogen, simply following the manufacturer’s protocol. This type of enrichment works best with relatively high levels of expression. The S2 cells must be stained with a saturating amount of primary antibody and must be kept cold (preferably on ice) for the duration of the procedure. S2 cells are phagocytic. If the S2 cells are allowed to phagocytose magnetic beads at room temperature, the enrichment for expression will be contaminated with non-expressing cells. 2. Expressing cells can be isolated by FACS. Again, it is critical to obtain the brightest antibody staining possible to ensure the removal of non-expressing cells. When expression of a protein is marginal, it is recommended that only the brightest cells are selected. 3. After enrichment of expressing cells by magnetic beads or FACS, it is necessary to regularly monitor expression of the transfected proteins. We have found that these enriched pop-
78
March et al.
ulations tend to lose expression during culture, presumable due to selective expansion of cells with lower expression. More stable, uniform expression can be obtained by deriving clones from the resistant populations, immediately following transfection or after enrichment by beads or sorting. To clone S2 cell transfectants, plate cells in medium with selection in 96-well plates at decreasing cell concentrations beginning at 10 cells per well. Threefold dilutions of the cells down to a concentration of 0.3 cell per well can be plated. Proliferating clones will usually be visible within 2 weeks. Clones should be expanded into larger volumes of medium until sufficient cells are available to screen by flow cytometry. Multiple clones, often with varying amounts of protein expression, should be selected for experimentation (see Note 9). 3.3. S2 Cells as Targets in NK Cell Assays
The usefulness of the S2 cells relies on the ability to use them in a variety of assays investigating NK cell function. We have successfully performed a variety of flow cytometry- and microscopybased assays, using the S2 cells as target cells to investigate responses of human NK cells to a variety of ligands for NK cell receptors. We have used S2 cells to monitor NK cell degranulation as measured by the surface expression of lysosome-associated membrane protein 1 (LAMP-1, also called CD107a) (31), binding of NK cells to target cells in a conjugation assay (5), clustering of activating and inhibitory receptors at NK–S2 cell synapses (34, 35), signaling induced in NK cells by contact with S2 cells (36), and the intracellular polarization of perforin-containing granules to the site of contact with target cells (31). We have also used S2 cells as target cells in a modified cytotoxicity assay. Of particular note, we have generated, through Anaspec (San Jose, CA), a rabbit polyclonal antiserum against an S2 cell membrane preparation. Addition of this serum to S2 cells provides a potent, physiological stimulus to human NK cells for ADCC through CD16 (31). Untransfected S2 cells provide negative controls for each of these assays.
3.3.1. CD107a Assay
The detection of NK cell degranulation through monitoring of the surface expression of CD107a has rapidly become the method of choice. This assay works well with S2 target cells. For a thorough description of the CD107a assay, please refer to the chapter in this issue by Bryceson et al., as well as our previous work (31). Due to a relatively high auto-fluorescence of S2 cells, it is important to obtain a bright staining of NK cells with the CD56 antibody in order obtain a stringent gate for NK cells. This may require a two-step staining protocol, using a secondary antibody against the CD56 antibody. Note that the E:T ratio used with S2 cells is 1:5 instead the 1:2 used for other target cells.
Transfected Insect Cells as Targets of NK Cells
3.3.2. Conjugation Assay
79
1. This assay has been adapted from Burshtyn et al. (37) (see Chapter 7 in this volume), which is also described for use with mammalian target cells in a chapter in this issue. If necessary, induce expression in S2 cells transfected with a metallothionein-based plasmid with 1 mM CuSO4 48 h before the conjugation assay. If the S2 cells express MHC molecules, those molecules will need to be loaded with a compatible peptide. Peptides should be added to the cells 1 day before the assay to a final concentration of 1 M. Expression of ligands on the S2 cells should always be monitored by flow cytometry on the day of the assay (see Note 10). 2. Each combination of NK cell and target cell should be assayed for conjugation at a series of time points. We routinely perform 0, 5, 10, 20, and 40 min time points. With S2 cell targets, each point in the assay will include 1 × 105 NK cells and 4 × 105 target cells, for a final E:T ratio of 1:4. In the following steps, be sure to label sufficient cells for the assay. 3. Label the S2 cells with the red PHK26 dye, according to the manufacturer’s protocol, summarized here (see Note 11). a. Pellet the required number of S2 cells by centrifugation at 300g. b. Count the cells. Use about 5 × 106 for labeling (scale up as necessary); put 5 × 106 cells into a new tube and bring them up to 10 ml total volume with serum-free medium. Pellet the cells again. c. While the cells are in the centrifuge, prepare the fluorescent dye. For labeling, you need 100 l of “2× dye” for every 106 cells; 2× dye for 5 × 106 cells is 588 ml of Diluent C (supplied with the labeling kit) + 12 l of PKH26. d. Aspirate the medium from the cells. Resuspend the target cells in 100 l of Diluent C for every 106 cells. Add the 2× dye to the cells, 100 l for each 1 × 106 cells. e. Incubate 5 min at room temperature. Add an equal volume of serum to the cells and incubate 1 min at room temperature. f. Wash the cells twice with Schneider cell medium + 10% FBS. After the second wash, resuspend the cells in 5 ml of medium + 10% FBS. Incubate the cells at 27◦ C for 2 h. 4. Label the NK cells with Celltracker Green. The cells should be incubated, in their standard medium at a concentration of 10 × 106 cells/ml, with 1 g/ml of the Celltracker Green for 30 min. The cells should be washed twice with their standard medium and then allowed to rest in 10 ml of medium in a 15 ml tube for 30 min at 37◦ C.
80
March et al.
5. Wash both the NK and the S2 cells twice with HBSS + 5% FBS. Resuspend the cells in HBSS with 5% FBS and count them. Pellet the cells and resuspend the NK cells at a concentration of 1 × 106 cells/ml and the S2 cells at a concentration of 4 × 106 cells/ml using ice cold HBSS with 5% FBS. 6. To a series of FACS tubes (one tube for each time point), add 1 × 105 NK cells and 4 × 105 of the appropriate S2 cells (100 l each), for an E:T ratio of 1:4. Vortex the cells quickly to mix. 7. Pellet the cells, at 4◦ C, for 3 min at 20g. 8. Incubate the tubes in a 37◦ C water bath for the desired lengths of time. When each time point is reached, vortex the appropriate tubes and then fix the cells by adding 1 ml of 0.5% paraformaldehyde. 9. Acquire samples on a flow cytometer, using stained NK and S2 cells alone as compensation controls. Conjugate pairs are represented by green and red double-stained events. Results are typically represented as the percentage of all NK cells that are in conjugates relative to the total number of NK cells. 3.3.3. Perforin Polarization Assay
NK cells respond to contact with sensitive target cells by polarizing their perforin-containing lytic granules to the site of contact with the target cell. This polarization can be detected through fluorescent microscopy. Certain S2 cell transfectants have been shown to induce polarization of granules in human NK cells (30, 31). 1. NK cells and S2 cells will ultimately be mixed at a 1:1 E:T ratio, with 1 × 106 of each cell type per sample. The required number of each transfected S2 cell should be labeled, in standard medium at a concentration of 10 × 106 cells/ml, with 1 g/ml of Celltracker Green for 30 min. The cells should be washed twice in standard medium and then allowed to rest in 1 ml of medium in a 15 ml tube for 30 min. Wash twice with 10 ml HBSS + 3% FBS. Resuspend at 10 × 106 cells/ml. 2. Pellet the required number of NK cells. Wash twice with 10 ml HBSS + 3% FBS. Resuspend at 10 × 106 cells/ml. 3. In a 15 ml conical tube, combine 1 × 106 NK cells and 1 × 106 target cells (100 l each). Vortex briefly to mix the cells. 4. Pellet the cells at 20g for 3 min. 5. Incubate in a 37◦ C water bath for 20 min. 6. Transfer the cells to poly-D-lysine coated culture slides. Resuspend the cells gently to preserve cell:cell contacts.
Transfected Insect Cells as Targets of NK Cells
81
Incubate the cells on the slides for 60 min at room temperature. 7. Aspirate the medium. Wash the cells gently twice with 1 ml PBS. Fix the cells by adding 1 ml 4% paraformaldehyde. Incubate for 20 min at room temperature. 8. Wash the fixed cells twice with PBS. 9. Permeablize the cells with 0.5 ml of 10% normal donkey serum (NDS) and 0.5% Triton X-100 in PBS. Incubate at room temperature for 30 min with gentle shaking. 10. Stain the cells with 3 g/ml anti-perforin antibody (clone ␦G9) in 3% NDS, 0.5% Triton X-100 in PBS. Incubate for 1 h at room temperature with gentle shaking. 11. Wash three times, for 5 min each, with 1 ml PBS. 12. Stain with a fluorescently labeled goat anti-mouse secondary antibody in 3% NDS and 0.5% Triton X-100 in PBS. We typically use an Alexa Fluor 568 conjugated secondary antibody at a concentration of 1 g/ml. Incubate for 1 h at room temperature with gentle shaking. 13. Wash three times, for 5 min each, with 1 ml PBS. 14. Aspirate the PBS and allow the slides to air dry. 15. Seal the samples on slides under a coverslip, using a drop of Prolong Gold antifade reagent as a mounting medium. 16. The cells should be imaged with a fluorescent microscope. We have acquired images on a Zeiss LSM510 confocal microscope. Z-stacks are acquired and used to create 3dimensional reconstructions of the cell contacts. Contacts between a perforin-containing NK cell and a Celltracker Green labeled target cell are identified, and the perforin is scored as polarized or not polarized by the visual appearance of the cell:cell conjugate. In most experiments, NK cells in which granules have polarized are obvious. Large numbers of cell contacts must be analyzed for rigorous analysis. In order to acquire sufficient data, acquire microscope images under relatively low magnification (e.g., multiple 40× fields). We typically analyze 150–200 contacts for each transfected S2 cell analyzed. 3.3.4. Cytotoxicity Assay by Flow Cytometry
One situation where S2 cells cannot be simply substituted for conventional target cells is cytotoxicity assays. Most cytotoxicity assays require that target cells be loaded with a radioactive or fluorescent vital label, like chromium-51, Europium, or calcein. Lysis of target cells is monitored by the release of the vital label into the medium. S2 cells label poorly with these reagents, and they have a high rate of spontaneous release. These factors combine to leave only a very small window between spontaneous
82
March et al.
and maximal release, making it very difficulty to detect specific NK cell-mediated cytotoxicity. Killing of S2 cells is therefore best measured using a flow cytometry-based assay, in which the S2 cells are labeled with a green lipophilic dye, mixed with NK cells, and then stained with propidium iodide to detect cytotoxicity. 1. If necessary, induce expression in S2 cells transfected with a metallothionein-based plasmid with 1 mM CuSO4 48 h before the cytotoxicity assay. If the S2 cells express MHC molecules, those molecules will need to be loaded with a compatible peptide. Peptides should be added to the cells the day before the assay to a final concentration of 1 M. Expression of ligands on the S2 cells should always be monitored by flow cytometry on the day of the cytotoxicity assay (see Note 10). Untransfected S2 cells must be included as a control in the assay (see Note 12). 2. Label S2 cells with the green PKH67 dye, according to the manufacturer’s protocol, as described in Step 3 of Section 3.3.2 (see Note 11). 3. During the incubation, spin down the NK cells and wash with Iscove’s medium containing 10% FBS. The number of NK cells required will depend on the effector to target ratios being used. Each point requires 20,000 targets cells and is done in duplicate. Typically, for S2 cells, the following E:T ratios are performed: 30:1, 10:1, 3:1, 1:1, and target cells alone (spontaneous release). Set up the dilutions of NK cells. Ultimately, the target cells will be resuspended at a concentration of 20,000 cells in 100 ml, and the NK cells will be set up in dilutions containing the appropriate number of NK cells in 100 ml. For example, for the 30:1 points, the NK cells will need to be at a concentration of 6 × 105 cells per 100 ml. 4. Prepare FACS tubes. The cytotoxicity assay will be conducted directly in the FACS tubes. Label 2 tubes for duplicates of every target/dilution combination. 5. Pipet 100 l of the NK cell dilutions into appropriately labeled tubes. Place these tubes in the 37◦ C incubator until the 2-h incubation of the labeled target cells is complete. 6. When the 2-h incubation of the labeled target cells is complete, bring the volume of the target cells up to 10 ml with Schneider’s medium containing 10% FBS, and spin down the cells at 215g. Wash the cells twice more with 10 ml of serum-containing medium. 7. Resuspend the target cells in 4 ml of Schneider cell medium with 10% FBS. Count the cells.
Transfected Insect Cells as Targets of NK Cells
83
8. Transfer 800,000 cells to a new tube and bring the volume up to 4 ml, resulting in a concentration of 20,000 cells in every 100 l. 9. Add 100 l (20,000 cells) to each tube with the NK cells. Vortex each tube. Then spin the tubes at 20g for 5 min. 10. Put the tubes at 37◦ C for 3 h. 11. Add propidium iodide to each tube to a final concentration of 50 g/ml and vortex gently to mix. 12. On the flow cytometer, acquisition should be set up so that the green target cells, very bright in FL1, are gated on and the PI profile for those cells is displayed. Acquire at least 2000 gated target cells. 13. The percentage of cells that are positive for both the PKH67 dye and propidium iodide is the percentage of S2 cells lysed in each sample. Values from duplicate samples are usually averaged. The percentage specific lysis is calculated according to the formula [100 × (% PI -positive cells – % Spontaneous Death)/(100 – % Spontaneous Death)] where spontaneous death is determined with a sample containing only labeled S2 cells.
4. Notes 1. In functional assays involving S2 cells adapted to serumfree conditions, medium supplemented with 0.2% BSA must be used in place of serum-containing medium. Addition of serum to adapted cells will allow the recovery of cholesterol-containing microdomains. 2. S2 cells in a healthy culture are semi-adherent. When passaged into new tissue culture plates or flasks, most of the cells will adhere to the plastic fairly firmly. The cells can be detached from the plastic by repeated washes with medium using a pipet. After several passages in the same flask, the cells will not adhere as much, although they will proliferate and remain trypan blue negative. When in suspension, healthy S2 cells will grow individually, with minimal clustering or clumping. Expression of transfected proteins can be greatly affected by the health of the cells. Cells in overgrown cultures will often express lower levels of protein, whether expression is driven from a constitutive or an inducible promoter. S2 cultures in poor health can often be rescued by seeding cells into fresh medium at 1 × 106 cells/ml and allowing the cells to grow
84
March et al.
to 2.5 × 106 cells/ml. Once the cells are proliferating at a normal rate, protein expression will often recover to previous levels. 3. We have successfully co-transfected S2 cells with six different proteins simultaneously. It is likely that an even greater number of proteins could be simultaneously transfected. 4. Any given protein is usually expressed at a similar level in independently transfected S2 cells. For instance, expression of ICAM-1 is almost always high, whereas other molecules have proven more difficult to express. In the latter case, it is preferable to isolate S2 cells expressing a decent level of the troublesome protein after a first round of transfection and to “super-transfect” plasmids for other proteins in a second round of transfection using a different drug resistance plasmid. For example, S2 cells expressing CD48 were isolated first, prior to sequential transfections for expression of additional proteins. 5. Transient expression of proteins can be achieved by transfection with either calcium phosphate or Cellfectin method. Proteins will be expressed almost immediately following the addition of the transfection mixtures, with maximal expression occurring at 48–72 h. Either protocol should be followed to Step 5 (Section 3.2.1 for calcium phosphate transfection or Section 3.2.2 for Cellfectin transfection), where the transfection mixtures are removed by washing, and the cells are cultured for 48 h. If induction is required, 1 mM CuSo4 should be added 24 h after the washes, and induction should proceed for a further 24–48 h. 6. There are a number of plasmids using different promoters that can be used to obtain expression of exogenous proteins in Drosophila cells. We have used pRmHa3 and pAc5.1 plasmids successfully, as described in Step 5 of Section 3.1.1. Our cDNA constructs for expression in S2 cells have contained the entire coding sequence of the protein of interest, including the signal sequence. Where possible, 5’and 3’-untranslated regions of the mRNA were included in the expression constructs. It has not been necessary to alter the cDNA sequences in order to get good expression of the various human and mouse proteins in S2 cells. 7. The plasmids used for expression of selectable drug resistance must have promoters for constitutive expression. Commercial plasmids exist for selection of S2 cells with blasticidin or hygromycin (Invitrogen), as well as plasmids made by individual researchers for selection with puromycin and neomycin. It is not necessary to use expres-
Transfected Insect Cells as Targets of NK Cells
85
sion vectors that carry both a selectable marker and the coding region of the protein of interest. It is much more convenient to co-transfect plasmids containing the selectable marker together with the plasmids for protein expression. S2 cells are transfected by the calcium phosphate method with 19 g of DNA, of which 18 g is the expression plasmid(s) and 1 g is the selection plasmid. In cases where expression of multiple exogenous proteins is desired, the plasmids are mixed in equal amounts to a total of 18 g of DNA (for example, 6 g each of three different plasmids). 8. The appropriate drug concentration for killing of untransfected S2 cells and selection of resistant S2 cells must be determined experimentally by serial dilutions. We have had success selecting resistant S2 cells with 1 mg/ml G418, 6 g/ml puromycin, and 300 g/ml hygromycin. Puromycin and hygromycin kill untransfected cells within 7 days. After their addition, the transfected S2 cell culture can be left alone until resistant cells grow, which usually occurs in 2 weeks. As G418 kills cells much more slowly, it is recommended to monitor live cell numbers. If the number reaches 3 × 106 cells/ml the cells should be removed from the medium by centrifugation and re-plated at 1 × 106 cells/ml in fresh medium containing G418. Protein expression may not be detectable for 2 weeks in G418 selection. 9. Selection of transfected clones is a time-consuming process, usually requiring an additional month after resistant cells have been obtained. To accelerate the process by several weeks, one can isolate expressing cells by FACS or by enrichment with antibodies coupled to magnetic beads. However, cell sorting will usually result in a broader range of expression than cell cloning and will often result in the loss or a reduction of protein over time. Therefore, it is necessary to regularly monitor expression in a sorted population and to repeat cell sorting when necessary. 10. Expression of proteins on transfected S2 cells should always be verified on the day of an assay. Expression level is dependent on the condition of the cells and can vary widely. 11. Alternatively, the S2 cells can be labeled with Celltracker dyes (Celltracker Green as a replacement for PKH67 and Celltracker Orange for PKH26). The cells should be incubated, in their standard medium at 10 × 106 cells/ml, with 4 g/ml of the Celltracker reagent for 30 min at room temperature. The cells should be washed twice with their standard medium and then allowed to rest in 10 ml of medium
86
March et al.
in a 15 ml tube at room temperature for 30 min. Celltracker dyes are more convenient to use than the lipophilic PKH dyes. Additionally, the S2 cells occasionally display reduced viability after labeling with the PKH reagents. However, S2 cells labeled with the PKH dyes often display more uniform fluorescence than cells labeled with Celltracker, simplifying the FACS analysis. The appropriate label for a given application should be determined experimentally. 12. It is common to encounter problems with high killing of untransfected S2 cells in cytotoxicity assays. To minimize such occurrences, it is essential to seed S2 cells at optimal numbers and to allow them to proliferate for at least a week prior to the assay. However, nonspecific killing of untransfected S2 cells may also be due to constitutive release of perforin and granzymes by activated NK cells. We have not found a reliable solution to this problem. Assays for NK cell degranulation and for granule polarization in NK cells are very reliable and focus on the functions of interest (i.e., NK cell responses) rather than the fate of S2 cells. Nevertheless, target cell lysis may occasionally be a useful parameter of NK cell function, as it requires the combination of granule polarization and degranulation (31).
References 1. Chiesa, S., Tomasello, E., Vivier, E., and Vely, F. (2005) Coordination of activating and inhibitory signals in natural killer cells. Mol. Immunol. 42, 477–84. 2. Lanier, L. L. (2005) NK cell recognition. Annu. Rev. Immunol. 23, 225–74. 3. Moretta, L., and Moretta, A. (2004) Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J. 23, 255–9. 4. Long, E. O. (2008) Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol. Rev. 224, 70–84. 5. Barber, D. F., and Long, E. O. (2003) Coexpression of CD58 or CD48 with intercellular adhesion molecule 1 on target cells enhances adhesion of resting NK cells. J. Immunol. 170, 294–9. 6. Bryceson, Y. T., and Long, E. O. (2008) Line of attack: NK cell specificity and integration of signals. Curr. Opin. Immunol. 20, 344–52. 7. Bryceson, Y. T., March, M. E., Ljunggren, H. G., and Long, E. O. (2006) Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 107, 159–66.
8. Lanier, L. L. (2008) Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 9, 495–502. 9. Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., and Spies, T. (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285, 727–9. 10. Pende, D., Parolini, S., Pessino, A., Sivori, S., Augugliaro, R., Morelli, L., Marcenaro, E., Accame, L., Malaspina, A., Biassoni, R., Bottino, C., Moretta, L., and Moretta, A. (1999) Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J. Exp. Med. 190, 1505–16. 11. Pessino, A., Sivori, S., Bottino, C., Malaspina, A., Morelli, L., Moretta, L., Biassoni, R., and Moretta, A. (1998) Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J. Exp. Med. 188, 953–60. 12. Shibuya, A., Campbell, D., Hannum, C., Yssel, H., Franz-Bacon, K., McClanahan, T., Kitamura, T., Nicholl, J., Sutherland,
Transfected Insect Cells as Targets of NK Cells
13.
14.
15.
16.
17.
18.
19.
20.
21.
G. R., Lanier, L. L., and Phillips, J. H. (1996) DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 4, 573–81. Moretta, A., Vitale, M., Bottino, C., Orengo, A. M., Morelli, L., Augugliaro, R., Barbaresi, M., Ciccone, E., and Moretta, L. (1993) P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J. Exp. Med. 178, 597–604. Garni-Wagner, B. A., Purohit, A., Mathew, P. A., Bennett, M., and Kumar, V. (1993) A novel function-associated molecule related to non-MHC-restricted cytotoxicity mediated by activated natural killer cells and T cells. J. Immunol. 151, 60–70. Kim, M., Carman, C. V., and Springer, T. A. (2003) Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins. Science 301, 1720–5. Shimaoka, M., Xiao, T., Liu, J. H., Yang, Y., Dong, Y., Jun, C. D., McCormack, A., Zhang, R., Joachimiak, A., Takagi, J., Wang, J. H., and Springer, T. A. (2003) Structures of the alpha L I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation. Cell 112, 99–111. Ciccone, E., Pende, D., Viale, O., Than, A., Di Donato, C., Orengo, A. M., Biassoni, R., Verdiani, S., Amoroso, A., Moretta, A., et al. (1992) Involvement of HLA class I alleles in natural killer (NK) cell-specific functions: expression of HLA-Cw3 confers selective protection from lysis by alloreactive NK clones displaying a defined specificity (specificity 2). J. Exp. Med. 176, 963–71. Vitale, M., Sivori, S., Pende, D., Moretta, L., and Moretta, A. (1995) Coexpression of two functionally independent p58 inhibitory receptors in human natural killer cell clones results in the inability to kill all normal allogeneic target cells. Proc. Natl. Acad. Sci. U S A 92, 3536–40. Tangye, S. G., Cherwinski, H., Lanier, L. L., and Phillips, J. H. (2000) 2B4-mediated activation of human natural killer cells. Mol. Immunol. 37, 493–501. Cao, W., Xi, X., Wang, Z., Dong, L., Hao, Z., Cui, L., Ma, C., and He, W. (2008) Four novel ULBP splice variants are ligands for human NKG2D. Int. Immunol. 20, 981–91. Li, C., Ge, B., Nicotra, M., Stern, J. N., Kopcow, H. D., Chen, X., and Strominger, J. L. (2008) JNK MAP kinase activation is required for MTOC and granule polar-
22.
23.
24.
25.
26.
27.
28.
29.
30.
87
ization in NKG2D-mediated NK cell cytotoxicity. Proc. Natl. Acad. Sci. U S A 105, 3017–22. Akella, R., and Hall, R. E. (1992) Expression of the adhesion molecules ICAM-1 and ICAM-2 on tumor cell lines does not correlate with their susceptibility to natural killer cell-mediated cytolysis: evidence for additional ligands for effector cell beta integrins. Eur. J. Immunol. 22, 1069–74. Johnston, S. C., Dustin, M. L., Hibbs, M. L., and Springer, T. A. (1990) On the species specificity of the interaction of LFA-1 with intercellular adhesion molecules. J. Immunol. 145, 1181–7. Sivori, S., Pende, D., Bottino, C., Marcenaro, E., Pessino, A., Biassoni, R., Moretta, L., and Moretta, A. (1999) NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur. J. Immunol. 29, 1656–66. Schneider, I. (1972) Cell lines derived from late embryonic stages of Drosophila melanogaster. J. Embryol. Exp. Morphol. 27, 353–65. Matsumura, M., Saito, Y., Jackson, M. R., Song, E. S., and Peterson, P. A. (1992) In vitro peptide binding to soluble empty class I major histocompatibility complex molecules isolated from transfected Drosophila melanogaster cells. J. Biol. Chem. 267, 23589–95. Bunch, T. A., Grinblat, Y., and Goldstein, L. S. (1988) Characterization and use of the Drosophila metallothionein promoter in cultured Drosophila melanogaster cells. Nucleic Acids Res. 16, 1043–61. Cai, Z., Brunmark, A., Jackson, M. R., Loh, D., Peterson, P. A., and Sprent, J. (1996) Transfected Drosophila cells as a probe for defining the minimal requirements for stimulating unprimed CD8+ T cells. Proc. Natl. Acad. Sci. U S A 93, 14736–41. Cai, Z., Brunmark, A. B., Luxembourg, A. T., Garcia, K. C., Degano, M., Teyton, L., Wilson, I., Peterson, P. A., Sprent, J., and Jackson, M. R. (1998) Probing the activation requirements for naive CD8+ T cells with Drosophila cell transfectants as antigen presenting cells. Immunol. Rev. 165, 249–65. Barber, D. F., Faure, M., and Long, E. O. (2004) LFA-1 contributes an early signal for NK cell cytotoxicity. J. Immunol. 173, 3653–9.
88
March et al.
31. Bryceson, Y. T., March, M. E., Barber, D. F., Ljunggren, H. G., and Long, E. O. (2005) Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J. Exp. Med. 202, 1001–12. 32. Jackson, M. R., Song, E. S., Yang, Y., and Peterson, P. A. (1992) Empty and peptidecontaining conformers of class I major histocompatibility complex molecules expressed in Drosophila melanogaster cells. Proc. Natl. Acad. Sci. U S A 89, 12117–21. 33. Eleme, K., Taner, S. B., Onfelt, B., Collinson, L. M., McCann, F. E., Chalupny, N. J., Cosman, D., Hopkins, C., Magee, A. I., and Davis, D. M. (2004) Cell surface organization of stress-inducible proteins ULBP and MICA that stimulate human NK cells and T cells via NKG2D. J. Exp. Med. 199, 1005–10.
34. Faure, M., Barber, D. F., Takahashi, S. M., Jin, T., and Long, E. O. (2003) Spontaneous clustering and tyrosine phosphorylation of NK cell inhibitory receptor induced by ligand binding. J. Immunol. 170, 6107–14. 35. Schleinitz, N., March, M. E., and Long, E. O. (2008) Recruitment of activation receptors at inhibitory NK cell immune synapses. PLoS ONE 3, e3278. 36. Riteau, B., Barber, D. F., and Long, E. O. (2003) Vav1 phosphorylation is induced by beta2 integrin engagement on natural killer cells upstream of actin cytoskeleton and lipid raft reorganization. J. Exp. Med. 198, 469–74. 37. Burshtyn, D. N., Shin, J., Stebbins, C., and Long, E. O. (2000) Adhesion to target cells is disrupted by the killer cell inhibitory receptor. Curr. Biol. 10, 777–80.
Chapter 7 Natural Killer Cell Conjugate Assay Using Two-Color Flow Cytometry Deborah N. Burshtyn and Chelsea Davidson Summary This flow cytometry-based method is a quick way to detect adhesion of NK cells to target cells. The two cell types are labeled with distinct fluorescent dyes and following co-incubation, the number of NK cells firmly adhered to target cells is quantified using two-color flow cytometry. Key words: Natural killer cells, adhesion, cell conjugates, flow cytometry.
1. Introduction Intercellular adhesion is required for NK cells to specifically lyse target cells. The formation of a stable conjugate between the NK cell and its target cell allows for signal transduction and ultimately polarized degranulation at the point of contact with the target cell. The adhesion of NK cells to target cells requires the specific interaction of adhesion molecules such as the integrin LFA-1 on NK cells and ICAM on target cells (1). Integrins such as LFA-1 can provide the initial tethering of one cell to another as well as produce stronger binding following activation of the integrin by various stimuli (chemokines, antigen receptor signaling). The latter occurs when signals provided by receptors that lead to cellular activation also modify the ability of integrins to bind to their ligands by enhancing their affinity and/or avidity for their ligands. This process of an activating receptor upregulating the binding of an integrin is known as inside-out signaling and leads to tightly bound cell:cell conjugates. The assay described here measures the formation of such tightly bound conjugates between NK cells K.S. Campbell (ed.), Natural Killer Cell Protocols, Methods in Molecular Biology 612, DOI 10.1007/978-1-60761-362-6 7, © Humana Press, a part of Springer Science+Business Media, LLC 2010
89
90
Burshtyn and Davidson
and their targets. Although we originally developed this assay as a means to optimize conditions for performing live cell imaging on NK:target cell conjugates, the assay has proved useful for studying the molecules involved in adhesion and for detecting signals involved in forming and inhibiting conjugation. We and others have performed this assay, or variations of this assay, with a variety of natural killer cells including human NK cell lines (YTS, NK92), ex vivohuman-derived IL-2-activated NK populations and clones, mouse NK cells, and rat RNK cells (2–7). The flow cytometry method described herein is versatile, avoids the tedious task of counting conjugates by microscopy required by older methods, and does not require specialized equipment beyond the flow cytometer. The cell populations under study are labeled using nonspecific fluorescent membrane dyes. Once labeled, the NK and target cells are incubated together to allow for conjugation, agitated to disperse loosely associated cells, and then fixed. Finally, the conjugates are analyzed by twocolor flow cytometry to quantitatively measure the degree of conjugation.
2. Materials 2.1. Fixative Solution
1. Add 0.5 g of paraformaldehyde to 100 ml PBS. 2. Gently warm on a heating plate while gently stirring with stir bar until completely dissolved. Do not boil. 3. Allow to cool to room temperature. 4. Store at 4◦ C for up to 1 week. Prior to experiment, chill on ice.
2.2. Cell Labeling
1. SIGMA Fluorescent cell linker kits: PKH67-GL (Green) and PKH26-GL (Red) (see Note 1). The kits contain dye in ethanol and a diluent (Diluent C) and are stored at 4◦ C protected from the light according to the manufacturer’s instructions. 2. Serum-free medium. 3. Assay medium: 5% FBS in NK cell culture medium supplemented with 1 mM L-glutamine (see Note 2). 4. FBS. 5. 15 ml conical polypropylene centrifuge tubes.
2.3. Conjugation
1. Standard 3 ml polystyrene flow cytometry tubes (Falcon 2052). 2. 0.5% paraformaldehyde/PBS. 3. Flow cytometer.
NK/Target Cell Conjugate Assay
91
3. Methods 3.1. Cell Labeling
1. Prewarm Diluent C and dye to room temperature. 2. If crystals have formed in the dye stock, warm in 37◦ C water bath until dissolved. 3. Pellet 4 × 106 NK cells and 4 × 106 target cells separately in 15 ml conical centrifuge tubes (see Note 3). 4. Resuspend in 10 ml of serum-free medium. 5. For each cell type, retain 2 × 105 unlabeled cells in a FACs tube. 6. Pellet remaining cells. 7. Resuspend cells in 0.4 ml of Diluent C (room temperature). 8. Prepare 0.4 ml of 20 M of each dye in Diluent C (8 l of stock to 392 l of Diluent C). 9. Add 0.4 ml of NK cells to the PKH67 dye and pipette up and down gently to mix. 10. Add 0.4 ml of target cells to the PKH26 dye and pipette up and down gently to mix. 11. Incubate 5 min at room temperature (22–25◦ C), resuspending the cells at 2 and 4 min by gently flicking the tube. 12. Add 2 ml FBS to stop the labeling and incubate 1 min at room temperature. 13. Wash cells twice by adding 10 ml room temperature assay medium and centrifuging 4 min at 300g. 14. Resuspend in 10 ml assay medium. 15. Incubate with the lid loose for at least 1 h at 37◦ C/5% CO2 to allow the excess dye to bleed out. 16. Perform a viable cell count. Cells should be greater than 90% viable at this stage. 17. Pellet and resuspend target cells in assay medium at 2 × 106 live cells/ml and the NK cells at 1 × 106 live cells/ml. For more information regarding the E:T, see Note 4. 18. Proceed immediately to conjugation assay.
3.2. Cell Conjugation
1. Dispense 100 l of each labeled cell type into a FACs tube to be used for setting up the flow cytometry parameters. 2. Add 300 l of ice cold 0.5% paraformaldehyde to the unlabeled and labeled control samples and store on ice. 3. For each desired time point (e.g., 0, 30 s, 1, 2, 5, and 10 min) aliquot 100 l of target cells into FACs tubes (see Note 5).
92
Burshtyn and Davidson
4. Add 100 l of NK cells. 5. Spin at 20 × g for 1 min (see Note 6). 6. Incubate at 37◦ C in a water bath for desired time points (see Notes 7 and 8). 7. At the end of each time point, vortex sample at high speed for 3 s (see Note 9). 8. Immediately fix by adding 300 l of ice-cold 0.5% paraformaldehyde. 9. Store samples at 4◦ C protected from light until analysis. 10. Analyze by flow cytometry as soon as possible (see Note 10). Use untreated NK and target cells to set up the for-
Fig. 7.1. Illustration for gating on cell:cell conjugates. YTS cells were labeled with PKH67 and 721.221 cells with PKH26. The top panels shows the forward and side scatter plots for the mixture of the two cells at the 0 and 10 min time points. The large viable gate shown was used to capture the conjugates that have shifted to the right and up for the corresponding analysis shown in the lower panels. The numbers in the upper and lower right quadrants are the event counts that are used to calculate the % YTS cells in conjugates. For this example, the background conjugation works out as 72/(4679+72)∗ 100% = 1.5% which increased at 10 min to 1271/(2594+1271) = 33%. Note that the apparent decrease in total “YTS” events is likely due to aggregates forming that are counted as a single event and leads to an underestimate of the actual % conjugation.
NK/Target Cell Conjugate Assay
93
ward and side scatter parameters and set an acquisition gate to collect at least 20,000 live cell events. Be sure to use a wide forward scatter gate to capture conjugates, which may have higher forward scatter (see Fig. 7.1). Use the untreated and labeled cells to set up the sensitivity and compensation for the FL-1 (PKH67) and FL-2 (PKH26) channels correspondingly and acquire the samples. 11. Set up the analysis leaving a generous margin for single color events when setting the quadrants. Calculate the % of conjugated NK cells = 2-color events/(2-color events + FL-1+ events) × 100%. If desired, the background value can be subtracted from each experimental point which for some cell combinations can be a significant value.
4. Notes 1 Our experience has been extensively with the PKH series of dyes from Sigma and EGFP expressing cells (2, 3, 6, 8). However, this assay is adaptable to many dye pairs (such as a variety of CellTracker dyes from Molecular Probes/Invitrogen) or live cell fluorochromes (i.e., EGFP) that are compatible with flow cytometry, provided they are stably associated with the cells (5, 7, 9, 10). It is important when using the PKH dyes not to shorten the “bleed out” incubation time as this will lead to nonspecific transfer of dye from one cell type to the other through the medium. Also, after long time points of conjugation (e.g., >1 h), we do observe some transfer of the dye from one cell type to another which may result from conjugates that have dissociated. As these are dim events, allowing a wide window for the single color events will exclude these from being scored as bona fide two-color events. 2. We find the cells perform best when they are not shocked by any changes. Therefore, we use the same medium to perform the washes and assay as used to culture the cells. Typically we culture our NK lines in Iscoves medium. If you are using RPMI or other media, it is best to supplement with HEPES to prevent the pH from rising sharply when working in small volumes on the bench. The assays were optimized in medium similar to that typically used in our laboratory for cytotoxicity assays, hence 5% serum. The rate and plateau values of conjugation may be affected by higher or lower amounts of serum but we have not investigated this ourselves.
94
Burshtyn and Davidson
3. The NK and target cells should be taken from log phase growth cultures with high viability. When certain NK cell lines become overgrown, the degree of conjugation falls off in parallel to their cytotoxicity. This is particularly obvious with NK92 and YTS cells beyond 7 × 105 cells/ml. Experiment to experiment reproducibility is best when the cells used have been cultured to a similar density each time. Primary NK cells from very dense cultures work fine as long as they are still in rapid growth. If using NK populations or NK clones, the extent of binding will vary with the donor as well as for each clone from a given donor due to the heterogenous nature of these cells. Extremely large target cells can be problematic as it is difficult to properly gate on the NK cells and NK cells in conjugates by forward and side scatter at the same time. 4. The E:T outlined in this protocol is 1:2 as we have found this to be optimal for several NK:target cell combinations. However, titration of the E:T from 2:1 to 1:5 will reveal where the binding is saturated. This should be done by altering the concentration of the targets while holding the concentration of the effectors constant and performing the assay in the same volume. Be careful to keep E:T ratios consistent between samples since small differences in ratios can greatly impact upon the results. 5. Some combinations of NK and targets will produce a considerable amount of background binding at the “zero” time point without incubation at 37◦ C. This binding is occurring before and during the centrifugation step that in reality provides considerable time for binding. This background can be reduced dramatically by incubating the cells on ice for 10 min prior to mixing the cells. However, many NK cell lines and primary NK cells temporarily lose their lytic function when exposed to low temperatures. We found that YTS cells and RNK cells were able to function well in standard chromium release assays following incubation on ice, and therefore, we do incubate these cells on ice prior to beginning the assay, while we avoid this for NK92 and primary NK cells and alternatively prepare them at room temperature. 6. The rationale for this step is to facilitate contact between the cells by concentrating them at the bottom of the tube. The spin is done very gently to avoid shocking the membranes by collision with the plastic or form a tightly packed pellet. 7. Each NK–target cell combination may exhibit a slightly different rate of binding. Generally we find that maximal conjugation has occurred by 10 min and then after 1 h
NK/Target Cell Conjugate Assay
95
begins to subside particularly when the target cells are lysed by the NK cell. When performing long time course experiments, we find it convenient to perform the assay in reverse by mixing all the samples on ice, transferring them all to the 37◦ C water bath, and then removing the samples from shortest to longest time points. Also, handling of too many samples will increase variability at the early time points. 8. The kinetics of conjugation are affected by temperature, occurring more rapidly at 37◦ C than at lower temperatures (2). For reproducibility between samples, we found round bottom tubes to be the best to maximize cell-to-cell contact and allow rapid and even heating of the sample when warmed to 37◦ C. Similarly, it is best to use a recirculating water bath to ensure even heating in order to obtain the most reproducible results particularly for early time points. 9. The vortexing step following the co-incubation prior to fixation is done to break apart loosely associated cells. Without the vortex we observe high binding for many cell:cell combinations. However, too strong or too long a vortex can cause the cells to shear resulting in patches of effector or target cell membrane attached to the other cell type that can confound the flow cytometric analysis. These can readily be visualized by fluorescence microscopy. Consistent vortexing is important to obtaining reproducible results and therefore when learning the technique it is helpful to perform duplicate samples to ensure reproducibility. 10. Typically we analyze the samples promptly. However, we have stored samples in the fixative overnight without a loss of signal or resolution.
Acknowledgments This work was supported by CIHR and AHFMR. References 1. Matsumoto, G., Nghiem, M. P., Nozaki, N., Schmits, R., and Penninger, J. M. (1998) Cooperation between CD44 and LFA1/CD11a adhesion receptors in lymphokineactivated killer cell cytotoxicity. J Immunol 160, 5781–5789. 2. Burshtyn, D. N., Shin, J., Stebbins, C., and Long, E. O. (2000) Adhesion to target cells is disrupted by the killer cell inhibitory receptor. Curr Biol 10, 777–780.
3. Standeven, L., Carlin, L. M., Borszcz, P., Davis, D. M., and Burshtyn, D. N. (2004) The actin cytoskeleton controls the efficiency of Killer cell Ig-like Receptors (KIR) accumulation at inhibitory Natural Killer cell immune synapses. J Immunol 173, 5617–5626. 4. Vyas, Y. M., Maniar, H., Lyddane, C. E., Sadelain, M., and Dupont, B. (2004) Ligand binding to inhibitory killer cell Ig-like
96
Burshtyn and Davidson
receptors induce colocalization with Src homology domain 2-containing protein tyrosine phosphatase 1 and interruption of ongoing activation signals. J Immunol 173, 1571–1578. 5. Yusa, S., and Campbell, K. S. (2003) Src homology region 2-containing protein tyrosine phosphatase-2 (SHP-2) can play a direct role in the inhibitory function of killer cell Iglike receptors in human NK cells. J Immunol 170, 4539–4547. 6. Osman, M. S., Burshtyn, D. N., and Kane, K. P. (2007) Activating Ly-49 receptors regulate LFA-1-mediated adhesion by NK cells. J Immunol 178, 1261–1267. 7. Back, J., Chalifour, A., Scarpellino, L., and Held, W. (2007) Stable masking by H-2Dd cis ligand limits Ly49A relocalization to the site of NK cell/target cell contact. Proc Natl Acad Sci U S A 104, 3978–3983.
8. Borszcz, P. D., Peterson, M., Standeven, L., Kirwan, S., Sandusky, M., Shaw, A., Long, E. O., and Burshtyn, D. N. (2003) KIR enrichment at the effector-target cell interface is more sensitive than signaling to the strength of ligand binding. Eur J Immunol 33, 1084–1093. 9. Yusa, S., Catina, T. L., and Campbell, K. S. (2004) KIR2DL5 can inhibit human NK cell activation via recruitment of Src homology region 2-containing protein tyrosine phosphatase-2 (SHP-2). J Immunol 172, 7385–7392. 10. Li, C., Ge, B., Nicotra, M., Stern, J. N., Kopcow, H. D., Chen, X., and Strominger, J. L. (2008) JNK MAP kinase activation is required for MTOC and granule polarization in NKG2D-mediated NK cell cytotoxicity. Proc Natl Acad Sci U S A 105, 3017– 3022.
Chapter 8 Studying NK Cell/Dendritic Cell Interactions Mathias Lucas, Cedric Vonarbourg, Peter Aichele, and Andreas Diefenbach Abstract Although NK cells were originally identified as “naturally” active cells believed to follow a cellautonomous activation program, it is now widely accepted that NK cells need to interact with dendritic cells for their full functional activation and for their homeostasis. In this chapter, we will provide an experimental guide to the analysis of NK cell/DC interactions in vitro and in vivo. We have put special emphasis on the recently developed mouse models allowing the inducible and specific ablation of various subsets of DCs and other myeloid cells. Key words: LCMV, Listeria monocytogenes , toll-like receptors, dendritic cells, macrophages, diphtheria toxin receptor.
1. Introduction Natural killer (NK) cells were discovered as lymphocytes that can spontaneously kill certain tumor target cells (1–3). These early findings have led to the proposal that NK cells are innate immune cells which follow a cell-autonomous activation and effector program once confronted with an appropriate target cell expressing stimulatory ligands. In contrast to T cells of the adaptive immune system, NK cells were widely believed to be independent of signals provided by other cell types for activation or priming. However, freshly isolated NK cells from mice and humans show only minimal effector functions (cytotoxicity, cytokine production) when incubated in vitro with tumor target cells or when directly trigK.S. Campbell (ed.), Natural Killer Cell Protocols, Methods in Molecular Biology 612, DOI 10.1007/978-1-60761-362-6 8, © Humana Press, a part of Springer Science+Business Media, LLC 2010
97
98
Lucas et al.
gered via their stimulatory receptors (4, 5). These data suggested that resting NK cells might depend on additional signals for their activation. Indeed, most investigators treat mice with tolllike receptor (TLR) ligands, ligands for the cytoplasmic helicase protein melanoma differentiation-associated gene 5 (MDA5) or cytokines (e.g., type I interferons, IFN-I or their synthetic inducers) or culture NK cells ex vivo in the presence of cytokines (e.g., IL-2, IL-15) to elicit detectable effector functions prior to in vitro analyses of NK cell responses (4, 6, 7). These findings have led to more detailed investigations into whether NK cells might be dependent on signals from other cells for their full functional activation. A role for myeloid cells in the induction of NK cell responses in vivo has been considered by many reports (8–16). These initial studies showed that in vitro co-cultures of stimulated or infected bone marrow (BM)-derived dendritic cells (DCs) or macrophages with NK cells resulted in NK cell activation. In other studies, BMderived DCs were injected into mice which led to enhanced NK cell activity against tumors or virally infected cells (12, 17, 18). Until recently, it was not possible to study NK cell activation in the absence of DCs or macrophages in vivo because mouse models specifically lacking DCs or macrophages were unavailable. Studies using depletion of myeloid cells from mice by injection of depleting antibodies were hard to interpret as most of the phenotypic markers used are also expressed by other hematopoietic cells. The systemic depletion of DCs can be achieved by the injection of clodronate liposomes (19). However, uptake of clodronate liposomes requires phagocytic activity of the cell resulting in the depletion of both DC and macrophage populations. In the last years, various genetically modified mouse models became available allowing for the inducible and specific ablation of myeloid cell subsets. All these models employ tissue-specific expression of the avian diphtheria toxin receptor (DTR) (20). As mouse cells are insensitive to diphtheria toxin (DT) from Corynebacterium diphtheriae, only those cells expressing the ectopic DTR are sensitive to DT. By now, various studies are available that have analyzed NK cell function in mice lacking DCs. Collectively these data demonstrate that NK cell function in response to TLR-mediated stimulation and to various pathogens strictly depends on the presence of conventional DCs (5, 21–26). On the following pages, we will provide protocols for the analysis of NK cell priming or activation by myeloid cells in vitro. Furthermore, we discuss how the available mouse models allowing for the ablation of various myeloid cell subsets can be employed to analyze NK cell function in vivo and how they can be further manipulated to reveal the molecular pathways required for the priming of NK cells by myeloid cell populations in vivo.
Studying NK Cell/Dendritic Cell Interactions
99
2. Materials 2.1. Mice
1. C57BL/6 (B6; expressing the CD45.2 antigen) 2. B6-Ly5.2/Cr (C57BL/6-Ly-5a congenic mice, expressing the CD45.1 antigen) 3. CD11c DTR transgenic mice (B6.FVB-Tg(ItgaxDTR/EGFP)57Lan/J) (27) or other mouse strains allowing for the depletion of myeloid cell subsets (Table 8.1). 4. H-2 K-BCL-2: Bcl-2 transgenic mice under the control of the H-2 K promoter (28). 5. Il15 −/− (C57BL/6NTac-IL15tm1Imx )(29) 6. All mice are maintained under specific pathogen-free conditions and used at 8–16 weeks of age.
2.2. Cell Lines
1. MC57 (H-2b ) is a C57BL/6-derived methylcholanthreneinduced fibrosarcoma cell line used to titer LCMV (Section 3.6) (30). 2. NCTC clone 929 (L-929; Connective tissue, mouse; ATCC CCL-1) 3. YAC-1 (ATCC TIB-160) is a T-cell lymphoma used for the NK cell activation assays (Section 3.8) (31). 4. RMA-S is a Tap-2-defective cell line used for the NK cell activation assays (Section 3.8) (32). 5. RMA-S-H60 cells are RMA-S cells retrovirally transduced with a ligand of the NKG2D receptor, H60 (5, 33). These cells are used as target cells in the NK cell activation assays (Section 3.8).
2.3. Solutions
1. Minimum essential medium (MEM) cell culture medium: MEM (Invitrogen) containing Earle’s Salts and nonessential amino acids (NEAA) is complemented with 5% fetal calf serum (FCS), 200 mg/l glutamine (Sigma), 50,000 U/l penicillin, and 50 mg/l streptomycin (Invitrogen), filter sterilized (0.22 m), and stored a 4◦ C. 2. 2× MEM: MEM powder (Invitrogen) is dissolved in 5 l ddH2 O (instead of 10 l) to obtain a 2× concentration. 2× MEM is complemented with 10% FCS, 400 mg/l glutamine, 100,000 U/l penicillin, and 100 mg/l streptomycin, filter sterilized (0.22 m), and stored at 4◦ C. 3. Dulbecco’s Modified Eagle Medium (DMEM) cell culture medium: DMEM (Invitrogen) containing 4.5 g/l glucose and L-glutamine is complemented with 5–10% FCS (this percentage may vary depending on the cultured
100
Lucas et al.
cells), 200 mg/l glutamine, 50,000 U/l penicillin, 50 mg/l streptomycin, 10 mg/l gentamycin sulfate (Biowhittaker), and 50 M -mercaptoethanol (Sigma), filter sterilized (0.22 m), and stored at 4◦ C. 4. Brain Heart Infusion (BHI) medium: 1 l deionized water; 37 g BHI powder (Oxoid). Heat at 100◦ C for 15–20 min in order to completely dissolve the powder. Autoclave and store at 4◦ C. 5. BHI Agar: 1 l deionized water supplemented with 16 g Bacto Agar (BD); 37 g BHI powder. Heat at 100◦ C for 15– 20 min in order to completely dissolve the powder. Autoclave and store at 4◦ C. 6. Methylcellulose solution: Mix 1 vol. of 2% methylcellulose (Sigma) in ddH2 O with 1 vol. 2× MEM. 7. BHI containing 0.05% Triton X-100 (Amresco). 8. Dulbecco’s phosphate buffered saline (DPBS; Invitrogen) containing 0.5% Triton X-100. 9. Trypsin-EDTA: 0.05% Trypsin-EDTA (Invitrogen). 10. ACK lysis buffer (red blood cell lysing buffer): 1 l deionized water supplemented with 8.025 g NH4 Cl, 1 g KHCO3 , and 200 l 0.5 M EDTA (pH 8.0); sterilize using 0.22 m filter and store at 4◦ C. 11. BD Pharm Lyse buffer (BD Biosciences). 12. FACS buffer: DPBS (Invitrogen) complemented with either 2% FCS or 0.5% BSA (Sigma), filter sterilized (0.22 m), and stored a 4◦ C. 13. MACS buffer: DPBS (Invitrogen) complemented with 0.5% BSA and 2 mM EDTA (Invitrogen), filter sterilized (0.22 m), and stored a 4◦ C. 14. PBS/EDTA: DPBS containing 5 mM EDTA (pH 8.0). 15. Monensin (GolgiStop, BD Bioscience). 16. Brefeldin A (Sigma): stock solution of 5 mg/ml in ethanol. 17. Cytofix/Cytoperm solution (BD Bioscience). 18. FACS permeabilization buffer: FACS buffer containing 0.5% saponin (Sigma). 19. FACS fixing solution: DPBS (Invitrogen) containing 4% formaldehyde (dilution of a 37% formaldehyde solution in PBS). 20. 4% Paraformaldehyde: Heat 50 ml ddH2 O to 60◦ C (glass beaker); add 4 g paraformaldehyde (Merck). Stir (stirring bar) and add few drops (2–3) of 1 N NaOH until the solution clears (if not, check 7
Studying NK Cell/Dendritic Cell Interactions
101
21. Percoll: Percoll (GE Healthcare) is not an isotonic solution. Thus, 1 vol. DPBS 10× (Invitrogen) has to be added first to 9 vol. of Percoll in order to have an isotonic Percoll solution (Percoll 90%). Dilute the 90% percoll with medium in order to obtain 40% and 60% Percoll solutions used for the separation gradient. 22. Lympholyte-M (Cedarlane). 23. Digestion buffer (for preparation of lung lymphocytes): Hank’s balanced salt solution (HBSS) containing CaCl2 and MgCl2 but no phenol red (Invitrogen) and complemented with (final concentrations) 1 mg/ml collagenase D (Roche). 24. Diphtheria toxin (DT): DT (Sigma or Calbiochem) is reconstituted in 1 ml sterile distilled water (1 mg/ml). After reconstitution, aliquot and freeze at -80◦ C. Repeated freezing and thawing is not recommended (see Note 1). 25. Cytokines: IL-12 (R&D Systems), type I IFN: IFN-␣A and IFN- (PBL Biomedical Laboratories), GM-CSF (Peprotech) M-CSF (Peprotech), IL-2 (Peprotech) and IL-15 (Peprotech). All cytokines were reconstituted and stored following the manufacturer’s protocol. 26. Peroxidase substrate: SIGMAFAST TM OPD (Sigma). 27.
2.4. Abs
51
Cr: sodium chromate [51 Cr] (Perkin Elmer), 5 mCi/ml (needs institutional approval).
1. CD3 (145-2C11) monoclonal antibody (mAb) (eBioscience). 2. CD11b (M1/70) mAb (eBioscience) reacts macrophages, neutrophils, and some NK cells.
with
3. CD11c (N418) mAb (eBioscience) reacts with different subsets of cells and mostly with DCs and NK cells. 4. CD16/CD32 (2.4G2) mAb (BD Bioscience) is used to block the Fc␥RIII/II. 5. CD19 (MB19-1) mAb (eBioscience) reacts with a coreceptor on B cells. 6. CD25 (PC61.5) mAb (eBioscience) reacts with the IL-2 receptor ␣ chain. 7. CD45R/B220 (RA3-6B2) mAb (BD Biosciences) reacts with different cell subsets but mostly with B cells. 8. CD45.1 (A20) mAb (eBioscience) is used to detect adoptively transferred cells. 9. CD45.2 (104) mAb (eBioscience) is used to detect adoptively transferred cells.
102
Lucas et al.
10. CD49b (DX5) mAb (eBioscience), which reacts with a pan-NK cell marker. 11. CD69 (H1.2F3) mAb (eBioscience) is a marker for lymphocyte activation. 12. CD122 (TM-1) mAb (eBioscience), which reacts with the IL-2/15 receptor  chain. 13. Class II MHC (M5/114.15.2) mAb (eBioscience). 14. Goat anti-rat IgG (H+L)-peroxidase Ab (Jackson Immunoresearch) used in the plaque assay experiment after LCMV infection. 15. Anti-Granzyme A rabbit serum (34). 16. Granzyme A (3G8.5) mAb (Santa Cruz) (35). 17. Anti-Granzyme B rabbit serum (34). 18. Granzyme B (GB12) mAb (Caltag) (35). 19. IFN-␥ (XMG1.2) mAb (eBioscience). 20. IL-15R␣ Ab (goat IgG; R&D Systems). 21. Ly49A (A1) mAb (eBioscience). 22. Ly49C/I (5E6) mAb (eBioscience). 23. Ly49D (4E5) mAb (eBioscience). 24. Ly49G2 (Cwy-3) mAb (eBioscience). 25. NKG2A/C/E (20d5) mAb (eBioscience). 26. NKR-P1B/C (PK136) mAb (eBioscience) reacts with a pan-NK cell marker (NK1.1) only in certain mouse strains, such as C57BL/6 (NKR-P1C) and SJL (NKR-P1B). 27. PDCA-1 (Miltenyi), which reacts with pDCs. 28. Perforin 1 (OMAK-D) mAb (eBioscience) (35). 29. Biotin-conjugated rabbit anti-goat IgG (H+L) (Zymed). 30. Rat anti-LCMV nucleoprotein (VL4) used in the plaque assay experiment after LCMV infection (30). 31. Fluorochrome-labeled goat anti-rabbit mAb (Molecular Probes) used as secondary Abs for the anti-Granzyme A and B rabbit sera. 2.5. Magnetic Beads and Columns
1. Anti-PE Microbeads (Miltenyi Biotec).
2.6. Stimulation of Myeloid Cells
1. TLR3/MDA5 agonist: poly(I:C) (Sigma) (see Note 2)
2. LS Columns (Miltenyi Biotec).
2. TLR4 agonist: ultrapure LPS from E. coli O111:B4 (Invivogen) (see Note 2) 3. TLR7 agonist: R837/imiquimod (Invivogen) (see Note 2) 4. TLR9 agonist (see Note 2)
Studying NK Cell/Dendritic Cell Interactions
103
a. CpG1668 (B class) G∗ G∗ GGGACGATCGTC∗ G∗ G∗ G∗ G∗ G∗ G b. CpG2216 (A class) T∗ C∗ G∗ T∗ C∗ G∗ T∗ T∗ T∗ T∗ G∗ T∗ C∗ G∗ T∗ T∗ T∗ T∗ G∗ T∗ C∗ G∗ T∗ T (∗ : phosphorothioate modification; both synthesized by ThermoFisher). 5. Anti-CD40 in vitro stimulant: CD40 (FGK45) mAb (36). 6. Anti-CD40 in vivo stimulant: CD40 (1C10) mAb (eBioscience). 7. Listeria monocytogenes strain EGD (needs institutional approval) (37). 8. LCMV-WE (needs institutional approval) (38). 2.7. Organ Homogenization
1. Mechanical Stirrer/grinder (Heidolph). 2. Teflon pestle and 10 ml glass tubes (e.g., Milian International). 3. Polystyrene dishes without further surface modifications (e.g., Greiner Bio-One). 4. 40 m nylon mesh or a cell strainer (BD Biosciences). 5. Frosted glass slides.
3. Methods 3.1. Generation of Bone Marrow-Derived DC or Macrophages
Bone marrow (BM) cells can be used to generate BM-DCs or macrophages required for in vitro studies of NK/DC interactions (Section 3.4) or for in vivo rescue of mice depleted of all DCs (Section 3.6). 1. Femurs and tibias are surgically dissected from mice and remaining muscle and tissue are removed with sterile gauze. It is important to isolate the entire bone that should not be damaged during the preparation procedure. 2. Bones are then placed for 3–5 min in a Petri dish containing pure ethanol (it is very important to not extend the soaking time in ethanol). 3. Sterilized bones are rinsed in DMEM medium containing 10% FCS (referred to as “medium” for the rest of this protocol) and are cut open at the epiphyses using scissors. BM cells are obtained by repeated flushing with a 27 g needle attached to a 1 ml syringe filled with medium. Alternatively, whole bones can be crushed with a sterile mortar in a Petri dish with 5 ml medium. Once bones have been entirely crushed, the cell preparation must be passed through a 40–100 m nylon mesh to remove any pieces of bone. This is very important if the cells have to be injected into mice.
104
Lucas et al.
4. BM cells are pelleted by centrifugation (300 × g for 5 min), resuspended in fresh medium and counted. 5. BM cells are seeded at 4 × 105 /ml medium in 6-well plates (2 × 106 cells per well) or in Petri dishes (12 × 106 for one 100 × 15 mm dishes). 6. For the generation of BM-derived DCs, BM cells are cultured in medium containing 10 ng/ml GM-CSF. Every other day, half of the medium is replaced with fresh GMCSF-containing medium. After 5–6 days immature DCs can be harvested and used in the experiments. It should be noted that immature DCs are not strongly adherent and can be easily detached. 7. For the generation of BM-derived macrophages, it is strongly recommended NOT to use tissue culture dishes in which macrophages become too adherent and cannot be easily detached for further use. We recommend the use of polystyrene dishes without further surface modifications like those widely used in bacteriology. BM cells are cultured in medium containing 10 ng/ml M-CSF. Every other day, half of the medium is replaced with fresh M-CSF-containing medium. After 7–10 days macrophages can be harvested with PBS containing EDTA and used in experiments. 3.2. Lymphocyte Extraction from Peripheral Organs 3.2.1. Blood
In this section, we describe methods used to prepare lymphocytes from peripheral organs such as spleen, liver, and lungs as a source of NK cells. 1. Blood samples are collected by cardiac puncture. 2. Red blood cells are lysed using the BD PharmLyse solution (BD Biosciences) according to manufacturer’s instructions.
3.2.2. Spleen
1. Spleens are surgically removed from mice. 2. Splenocyte suspensions are prepared by passing the spleen through a 40 m nylon mesh or a cell strainer using the flat side of a syringe plunger. 3. Flush out remaining cells with 5–10 ml DMEM medium complemented with 10% FCS (referred to as “medium” for the rest of this protocol). 4. Pellet cells (300 × g, 5 min). 5. For red blood cell lysis, pelleted cells are resuspended in 1 ml ACK buffer per spleen and incubated for 1–2 min. ACK is quenched with an equal volume of medium and cells are pelleted again. 6. Washed cells are resuspended in the appropriate buffer and can be processed further.
Studying NK Cell/Dendritic Cell Interactions
3.2.3. Lymph Nodes
105
1. Lymph nodes are surgically removed from mice using fine forceps. 2. Lymph nodes are crushed between the frosted ends of two glass slides in DMEM medium. 3. Cells are filtered through a nylon mesh, pelleted, and resuspended in the appropriate buffer.
3.2.4. Liver
1. Mice are euthanized and perfused through the left ventricle with 20 ml PBS. 2. Perfused livers are surgically removed. 3. Single cell suspensions are prepared by passing the liver through a 40 m nylon mesh or a cell strainer using the flat side of a syringe plunger. 4. Cells are pelleted at 400 × g for 5 min and resuspended in 10 ml 40% isotonic Percoll solution per liver. 5. 5 ml of this suspension is carefully layered on top of 5 ml 60% isotonic Percoll (i.e., two 15 ml centrifuge tubes per liver). 6. Centrifuge 20 min at 900 × g at room temperature without brake. 7. After centrifugation, red cells are located at the bottom of the tube, most of the lymphocytes are located at the interface between the two different gradients of Percoll, and hepatocytes are floating on the top of the solution forming a dense layer of cells. 8. Carefully remove the hepatocytes with a pipette. 9. Harvest the interphase and the rest of the upper phase containing the lymphocytes. Add 5 ml of fresh DMEM medium and pellet cells by centrifugation (400 × g, 5 min). 10. Washed cells are resuspended in the appropriate buffer and can be processed further.
3.2.5. Lungs
1. Mice are euthanized and perfused through the right ventricle with 20 ml PBS. 2. Lungs are surgically removed. 3. Lung tissue is cut into small pieces using a scalpel and incubated with agitation for 45 min at 37◦ C in HBSS containing collagenase D. 4. The enzymatic reaction is stopped by the addition of 0.1 vol. of 5 mM EDTA. 5. Lung pieces are passed through a nylon mesh using the flat side of a syringe plunger. 6. Cells are pelleted at 400 × g for 5 min.
106
Lucas et al.
7. The pellet is resuspended in 5 ml PBS (at room temperature) and carefully layered upon 3 ml of Lympholyte-M (also at room temperature). 8. After centrifugation (1000 × g, 20 min, room temperature, without brake), lymphocytes are recovered at the interphase using a Pasteur pipette. 9. Lymphocytes are washed in PBS, pelleted at 800 × g for 10 min, and resuspended in the appropriate buffer for further processing. 3.3. NK Cell Purification
It is very important to obtain highly purified NK cell populations for the in vitro co-culture assays. To this end, we have developed a method combining the use of magnetic beads and flow cytometry-based sorting. 1. NK cells are enriched from the various lymphocyte preparations using magnetic beads. To this end, lymphocytes (prepared as described in Section 3.2) are stained in microfuge tubes (maximally 50 × 106 cells/ml) with 2 g/ml of PEconjugated CD49b antibody (clone DX5) for 20 min on ice (staining is best performed in the dark) (see Note 3). 2. After washing two times (300 × g, 5 min, 4◦ C) with MACS buffer, cells are incubated with anti-PE microbeads and positively sorted on LS columns following the manufacturer’s instructions (Miltenyi Biotec). 3. After counting, CD49b-enriched cells are labeled with 5 g/ml of FITC-labeled CD3⑀ antibody (2C11), washed two times (300 × g, 5 min, 4◦ C), and CD49b+ CD3− NK cells are highly purified using a cell sorter. 4. Expected yield from one spleen is 1 × 106 NK cells at a purity of 95–99%.
3.4. Assays for Studying NK Cell Priming by DCs or Macrophages In Vitro
NK cell priming by myeloid cells can be analyzed in vitro by coculture of stimulated or infected myeloid cells with highly purified NK cells. Stimulation of myeloid cells is obtained by addition of TLR ligands, bacteria, viruses, cytokines, or by cross-linking of activating receptors expressed by myeloid cells (e.g., CD40). 1. BM-derived DCs or macrophages and NK cells are mixed in DMEM supplemented with 10% FCS. In our experience, various DC/macrophage: NK cell ratios can be employed. We usually use 1 × 106 BM-DC or BM-macrophages and 2 × 106 NK cells in 24 well plates. NK cells without the addition of any myeloid cells are used as a control. Several stimulation options are possible, including one or more of the following: a. If stimulation by anti-CD40 is desired, cells are added to 24-well plates previously coated at 4◦ C with 10 g/ml
Studying NK Cell/Dendritic Cell Interactions
107
anti-CD40 (clone FGK45) in PBS for 18–24 h (wash the plate three times with PBS before using it). b. Add the required stimulus (cytokine or TLR ligand) to the co-cultures. Usually, the effective concentrations of the respective stimuli need to be experimentally established. c. If desired, blocking antibodies to soluble factors or cell surface receptors involved in the activation of NK cells by myeloid cells can be added to the co-cultures. Usually, the effective concentrations of these antibodies need to be experimentally established but often are between 10–50 g/ml. d. Another way to address the molecular pathways involved in the activation or priming of NK cells by myeloid cells is through the use of myeloid cells or NK cells obtained from mice genetically deficient for gene products of interest. 2. After 18–24 h of co-culture (37◦ C in a humidified atmosphere containing 5% CO2 ), NK cell activation can be assessed as described in Section 3.8 (see Note 4). 3.5. Diphtheria Toxin-Based In Vivo Mouse Models for Depleting Myeloid Cells
The in vivo analysis of immune responses in the absence of myeloid cells has been hampered by the absence of experimental mouse models lacking myeloid cells. Recently, various mouse strains became available that allow for the inducible and specific ablation of various myeloid cell populations. These model systems are based on the tissue-specific expression of the simian diphtheria toxin receptor (DTR) under the control of a tissue-specific promoter (20). The most commonly used strategy was to express the DTR as a transgene under the control of a cell type-specific promoter or to “knock-in” the DTR cassette into the translational start of a tissue-specific gene (Table 8.1) (39). Another highly versatile strategy employed a mouse strain in which the DTR cassette is “knocked into” the ubiquitously expressed Rosa26 locus (iDTR mice) (40). In a very similar approach, the toxic subunit A of DT (DTA) was “knocked into” the Rosa26 locus (R-DTA mice) (41). Expression of DTR or DTA is prevented by a stop codon preceding the coding sequence of DTR or DTA flanked by two loxP sites. Crossing of iDTR or DTA mice with mice expressing Cre recombinase under the control of a tissue-specific or cell type-specific promoter allows for the excision of the stop sequence and expression of DTR or DTA. It should be noted that there are significant differences between the Cre/lox and the above mentioned conventional approaches. In the conventional strategy, all cells in which the promoter is active at the time of DT injection express DTR and will be depleted. In contrast, the iDTR and DTA strategies result in the expression of DTR or DTA
DTR-OVA-EGFP cassette inserted into a BAC (RPCI-24-7812) containing the full Cd11c promoter
DTR-EGFP inserted into the second exon of the Langerin gene
CD11c DTR BAC
Langerin-DTR
DTR-EGFP cassette expressed under the control of the Cd11b promoter
DTR under the control of the Rosa26 promoter (loxP) STOP (loxP)
DTA under the control of the Rosa26 promoter (loxP) STOP (loxP)
CD11b DTR
iDTR
R-DTA
Langerin-DTA
DTR-EGFP cassette expressed as a transgene under the control of the Cd11c promoter
CD11c DTR
IRES-DTR-EGFP inserted into the sixth exon (3’ UTR) of the Langerin gene Transgenic mice expressing a modified human BAC (RP11-504o1) containing the gene for Langerin (Langerin-IRES-DTA)
Constructs used
DTR model
– Depends on the Cre-expressing mouse strains used
– Depends on the Cre-expressing mouse strains used
– Macrophages
– Epidermal LC
– Lymphoid Langerin+ cells
–
4 (3–7 inj. every 24 h)
25 (2 inj. every 48 h)
–
2–16 (1 inj.)
41
40
50, 51
49
48
47
46 25
– Activated CD8 T cells
– Epidermal LC
45
– Plasma B cell blasts 8–64 (1–21 inj. every 24 h)
44
– Alveolar macrophages
27, 42 43
2–4 (1 inj.)
– CD11chigh DC
Reference
− Metallophilic and marginal zone macrophages
DT dose (ng/g body weight)
Cell-type(s) depleted
Table 8.1 Overview of genetically modified mouse strains for the depletion of myeloid cell subsets
108 Lucas et al.
Studying NK Cell/Dendritic Cell Interactions
109
by all cells that are currently able to activate the promoter and, in addition, by all cell types that had previous promoter activity during their lineage commitment. Thus, if the promoter driving Cre expression is active in a precursor subset and is subsequently silenced, the progeny of these cells will still express DTR and will be depleted following DT injection. Similarly, transient Cre expression in the DTA model will lead to DTA expression and irreversible loss of the respective population (Notes 5 and 6). 3.5.1. CD11c DTR Transgenic (tg) Mice
The best-characterized strain is the CD11c DTR tg line (27) in which DTR expression is controlled by the Cd11c promoter (52). In these mice, a single DT injection (4 ng/g body weight) results in specific ablation of conventional CD11chigh DCs (including myeloid, lymphoid, and subsets of dermal DCs) whereas pDCs and most Langerhans cells (LC) are not depleted (5, 27, 39). Although NK cells express intermediate to high levels of CD11c (53), we and others demonstrated that NK cells are not affected after DT injection (5, 22). Thus, CD11c DTR tg mice allow for the analysis of NK cell responses in the absence of DCs in vivo. Ablation is not entirely DC-specific as two distinct splenic macrophage populations (marginal zone macrophages, MZM and metallophilic macrophages, MM) (5, 43) and alveolar macrophages (44) are also depleted after injection of DT. It is important to note that after a single DT injection, DC ablation is transient and does not last more than 2–3 days. In contrast, ablation of MZM and MM lasts longer (at least 7–9 days). These different regeneration kinetics of DCs and macrophages can be exploited to distinguish between DC-mediated and macrophagemediated effects on NK cell responses. Specifically, NK cell responses should be analyzed 24–48 h after DT injection (depletion of DCs, MZM, MM) and at day 5 or 6 (DC compartment restored, ongoing depletion of MZM, MM) (5). The transient nature of DC depletion makes it impossible to analyze NK cell responses at later time points of an infection and it has been observed by various groups that a second injection of DT is lethal. Lefrancois and colleagues presented a solution to this problem by generating BM chimeric mice (lethally irradiated B6 mice are reconstituted with BM of CD11c DTR tg mice) (42). These mice can then be repeatedly injected with DT, facilitating the analysis of DC-dependent immune responses at later time points. These data also imply that the lethality observed after a second injection of DT is due to the expression of the DTR by radioresistant, likely non-hematopoietic cells (42). A concern was that repeated DT injections might lead to the generation of neutralizing antibodies. However, Waisman and colleagues showed that repeated injections of DT did not result in ineffectiveness of the DT treatment (40).
110
Lucas et al.
Very recently, another CD11c DTR tg mouse line was developed using a BAC transgenic approach that reportedly allows multiple injections of DT and might be suitable to study NK cell responses and homeostasis in more long-term experiments without the need to generate BM chimeric mice (25). Initial reports are also available regarding the suitability of the R-DTA mice for DC depletion studies. Crossing CD11cCre mice (54) with R-DTA mice led to depletion of conventional DCs but also of pDCs and thus seems to be less specific than the CD11c DTR tg mice (26). This report also confirmed previous studies by showing that relevant NK cell responses to L. monocytogenes require the presence of DCs (5). 3.5.2. Langerin DTR tg Mice
To specifically deplete LC in vivo, two groups have generated mice with a “knock-in” of the DTR into the translational start (47) or as an IRES-DTR sequence into the 3’ untranslated region of the Langerin gene (48). Depending on the dose of DT injected, both types of Langerin-DTR mice show depletion of all LCs and of Langerin-positive lymphoid organ-resident DCs (16 ng DT/g body weight: depletion of both cell populations; 2 ng DT/g body weight: selective ablation of LCs). Eradication of these DC populations lasts for up to 4 weeks after a single injection of DT. Repeated injections of DT are well tolerated by these animals. A third group generated a transgenic mouse model in which the toxic subunit A of the DT is over-expressed under the Langerin promoter (49). In these mice, LCs are constitutively absent throughout life. The role of LCs for NK cell function or homeostasis has not yet been probed.
3.5.3. CD11b DTR tg Mice
To probe the role of macrophages for NK cell responses, a CD11b DTR tg mouse line might be helpful. After injection of DT (25 ng/g body weight), CD11b+ F4/80+ macrophages and monocytes in the peripheral blood were transiently depleted (restoration after day 4), whereas neutrophil numbers did not significantly change despite their high-level expression of CD11b (50, 51). An analysis of NK cell responses and of any effects of DT injection on NK cells using CD11b DTR tg mice have yet to be performed.
3.6. Assays for Studying NK Cell Priming In Vivo
The following is a basic protocol for the analysis of NK cell responses to infections in the absence of DCs employing the CD11c DTR tg mice. This protocol can be easily modified to use other stimuli and/or other mouse strains using the DT/DTR system. 1. At day –1, CD11c DTR tg mice are injected i.p. with 2–4 ng DT/g body weight. Control mice receive PBS injections. To control for DT effects other than DC ablation, it might be
3.6.1. In Vivo Analysis of NK/DC Interactions Following TLR Ligand Stimulation
Studying NK Cell/Dendritic Cell Interactions
111
advisable to have a group of B6 mice injected with DT (see Note 7). 2. At day 0, mice are injected i.p. or s.c. (for studying NK cell responses in the local draining lymph node) with TLR ligands (TLR3: 50 or 5 g poly(I:C), TLR4: 25 or 1 g ultrapure LPS from E. coli O111:B4, TLR7: 250 or 25 g R837, TLR9: 150 or 10 g CpG1668) or with an agonistic antibody specific for CD40 (100 g 1C10; eBioscience) Control mice receive injections of PBS or 100 g isotype control antibody (rat IgG2a), respectively. 3. At day 1, (18–24 h after injection) lymphocytes are harvested from the desired organs (see Section 3.2) and activation of NK cells activity can be tested in the desired assay (see Section 3.8 and Notes 5 and 6). 3.6.2. In Vivo Analysis of NK/DC Interactions Following Listeria Infection
The following is a basic protocol for the analysis of NK cell responses to a bacterial pathogen in mice ablated of all DCs (see Note 7). It can be easily modified to study NK cell responses to other pathogens. All waste generated during this experiment must be autoclaved. All experiments are performed in a BSL2 laboratory or animal facility. 1. Preparation of Listeria monocytogenes a. The day before the infection, bacteria (inoculated from frozen stocks) are cultured overnight (O/N) in 3 ml BHI culture medium with agitation (37◦ C, shaking incubator at 200 rpm). b. Add 500 l of the O/N culture to 50 ml BHI medium and grow until they reach 0.2 OD600 (0.1 OD600 ≈ 2 × 108 bacteria/ml). c. Wash 1 ml of the culture twice in PBS (microfuge tube, 750 × g, 5 min) (see Note 8). d. Dilute bacteria at the desired concentration for injection. 2. At day −1, mice are injected i.p. with 2–4 ng DT/g body weight. Control mice are given i.p. injections of PBS. To control for DT effects other than DC ablation, it might be advisable to have a group of B6 mice injected with DT. 3. At day 0, mice are injected with 104 cfu L. monocytogenes strain EGD i.v. 4. At day 2, lymphocytes are harvested from the desired organs (see Section 3.2) and activation of NK cells can be tested in the desired assay (see Section 3.8). 5. Analysis of bacterial titers in LN and spleen: a. Organs are homogenized separately in 5 ml of BHI containing 0.05% Triton X-100 (use stainless steel wire mesh, nylon mesh, or cell strainers and 50 mm Petri dishes).
112
Lucas et al.
b. Perform three serial 1:10 dilutions of the organ homogenates in 1.5 ml microfuge tubes by adding 100 l of homogenate in 900 l BHI containing 0.05% Triton X-100, mixing well, transferring 100 l of this first dilution into 900 l BHI containing 0.05% Triton X-100, mixing well again, and repeating the previous step one more time for the last dilution. c. Serial dilutions of the homogenates are plated on BHI agar plates. d. Colonies are counted after incubation at 37◦ C in a humidified atmosphere containing 5% CO2 for 24 h. 3.6.3. In Vivo Analysis of NK/DC Interactions Following LCMV Infection
The following is a basic protocol for the analysis of NK cell responses to a viral pathogen in mice ablated of all DCs (see Note 7). It can be easily modified to study NK cell responses to other pathogens. All waste generated during this experiment must be autoclaved. All experiments are performed in a BSL2 laboratory or animal facility. 1. Preparation of LCMV a. 1 × 107 mouse fibroblast cells L929 are seeded about 14 h before infection (O/N) in a 150 cm2 tissue culture flask (in DMEM culture medium containing 5% FCS). b. The next day, medium is removed and cells are infected with LCMV-WE at an MOI (multiplicity of infection) of 0.01 (in 5 ml DMEM containing 2% FCS). This should allow the infection of 1 × 105 cells. c. Incubate for 1.5 h at 37◦ C in a humidified atmosphere containing 5% CO2 . d. Remove the medium (dispose as autoclave waste). e. Add 30 ml of DMEM culture medium containing 5% FCS. f. Harvest the supernatant 48 h later (harvest I), centrifuge at 650 × g for 20 min at room temperature in a table-top centrifuge and freeze harvest I at −80◦ C (see Notes 9 and 10). g. Add 30 ml of DMEM culture medium containing 5% FCS to the infected cells. h. Harvest the supernatant 24 h later (harvest II, 72 h after infection), centrifuge at 650 × g for 20 min at room temperature in a table-top centrifuge and freeze harvest II at −80◦ C. i. Before any further use, experimentally determine virus titers of harvest I and II using a modified version of the focus formation assay described in Step 6 below (30).
Studying NK Cell/Dendritic Cell Interactions
113
Replace the serial dilutions of the organ homogenates by serial dilutions of harvest I and II (start at 1:1000). j. Freeze aliquots containing the desired viral titer for mouse injection. 2. At day −1, mice are injected i.p. with 2–4 ng DT/g body weight. Control mice are given i.p. injections of PBS. To control for DT effects other than DC ablation, it might be advisable to have a group of B6 mice injected with DT. 3. At day 0, mice are injected with 200 pfu of LCMV i.v. 4. At day 2, lymphocytes are harvested from the desired organs (see Section 3.2) and activation of NK cells can be tested in the desired assay (see Section 3.8). 5. Analysis of viral titers in spleen and organs: a. Spleens from infected mice are homogenized in 10 ml glass tubes with a Teflon pestle coupled to a grinder/mechanical stirrer (2 ml MEM + 2% FCS; 2000 rpm for approximately 30 s per organ; see Notes 11 and 12). b. Organ homogenates are centrifuged (650 × g; 20 min) to remove cell debris. Supernatants are used to determine viral titers (see Note 11). c. Six serial 1:10 dilutions of the organ homogenates are performed in culture medium containing only 2% FCS (1 ml final). d. Add 200 l of cell culture medium containing 5% FCS and 8 × 105 cells/ml MC57 cells to each well of a 24well plate. e. Add 200 l of the organ homogenate dilutions. f. Incubate 4–5 h at 37◦ C in a humidified atmosphere containing 5% CO2 . g. Prepare a 2% methylcellulose solution in 2 × MEM (prepare more than 12 ml per 24-well plate). h. Add 400 l of pre-warmed (37◦ C) 1% methylcellulose to each well of a 24-well plate. Incubate 48 h at 37◦ C in a humidified atmosphere containing 5% CO2 . i. Remove medium and fix cells by addition of 200 l of 4% formaldehyde in PBS (the formaldehyde must be gently pipetted down the side of the well). Incubate 20 min at room temperature and then discard the supernatant (dispose as autoclave waste). j. Lyse the cells in 200 l of 0.5% Triton X-100 in PBS (5 ml/plate). Incubate 30 min at room temperature. k. Discard the supernatant and wash wells with PBS (you can soak the entire plate in a receptacle containing PBS).
114
Lucas et al.
l. Block with 200 l PBS containing 10% FCS per well. Incubate 1–1.5 h at room temperature. m. Flick the plate (do not wash it) and add 200 l of the PBS diluted anti-LCMV nucleoprotein Ab (VL4) per well (the dilution factor of the VL4 supernatant has to be first established; prepare about 5 ml/plate). Incubate 1 h at room temperature. n. Wash wells with PBS. o. Add 200 l of a 1:400 dilution (in PBS 1% FCS) of the goat anti-rat IgG-peroxidase secondary Ab. Incubate 30– 60 min at room temperature. p. Wash wells three times with PBS. q. Prepare and add the Peroxidase substrate (SIGMAFASTTM OPD) following the manufacturer’s protocol. r. Once colored spots appear, stop the reaction by replacing the substrate solution (discard it in the toxic waste) with tap water. s. Flick and dry the plate on paper towels. t. Count the plaques. 3.7. Studies of the Molecular Program of NK Cell/DC Interactions
In order to analyze the cytokines, receptors, or signaling molecules involved in the priming of NK cells by DCs a tissuespecific gene targeting strategy can be employed. A limitation of this approach is that the availability of floxed cytokine or cytokine receptor loci is rather limited. To this end, we and others have developed a mixed bone marrow chimera system in which lethally irradiated mice are reconstituted with a 1:1 mixture of BM cells from a mouse strain genetically deficient of cytokine, cytokine receptor, or a signaling molecules and from CD11c DTR tg mice (carrying a different congenic marker) or any other DTR strain (5, 24). After injection of DT, DCs (or other DTR+ cells) are removed as the source of the molecule of interest and NK cell responses can be tested. This strategy is required for the analysis of molecules such as IL-15 and IL-15R␣ that are permissive for NK cell development (29, 55). Another approach in this scenario is the adoptive transfer of wild-type NK cells into genetically deficient mice. As IL-15 and IL-15R␣ are required for the survival of NK cells, either shortterm experiments need to be performed (< 12 h after NK cell transfer) or Bcl-2 tg NK cells should be employed, which survive independent of IL-15 or IL-15R␣ (56). In the first scenario, the survival and functional competence of the transferred NK cells should be controlled for.
Studying NK Cell/Dendritic Cell Interactions
3.7.1. Bone Marrow Chimeras (see Note 12)
115
1. Mice are lethally irradiated (e.g., for C57BL/6 background: 12 Gy are applied in two sessions of 6 Gy each separated by 4 h in order to avoid collateral organ damage). 2. A carefully filtered (40 m) 1:1 mixture of 1–2 × 106 BM cells derived (see Section 3.1, steps 1–4) from the desired mouse strains (CD11c DTR tg mice and mice genetically deficient of gene of interest) are injected i.v. (the two bone marrow grafts should have different congenic markers (e.g., CD45.1 vs. CD45.2) in order to distinguish cells of different origin later). 3. BM chimeric mice are analyzed 8–12 weeks after transplantation in order to evaluate the chimerism (FACS analysis of blood leukocytes for the congenic markers). 4. Mice are then depleted of DCs and stimulated as described above (Sections 3.6.2 and 3.6.1). It is important to control these experiments with groups of chimeric mice that do not receive DT. 5. NK cell function can then be assessed as described in Section 3.8.
3.7.2. Adoptive Transfer of NK Cells into Mice Genetically Lacking Genes Implicated in NK Cell Priming
1. Purify splenic NK cells from C57BL/6 mice as described in Section 3.3. It is important to ensure that the transferred NK cell population is free of contaminating DCs. 2. 2–5 × 106 purified NK cells are injected i.v. into the host mice. 3. Four hours post-transfer, mice are stimulated as discussed above (Sections 3.6.1 and 3.6.2). Stimulation can be performed 18–24 h following NK cell injection if NK cells can survive in the new environment (see Note 13). 4. NK cell function can be assessed after 4–6 h post stimulation (18–24 h if the injected NK cells can survive in the host environment; see Note 14).
3.8. NK Cell Activation Assays
3.8.1. Analysis of NK Cell Activation Markers (CD69, CD25)
All the experiments described so far require the analysis of NK cell function as a final readout. We are providing four protocols to assess NK cell activation (up-regulation of “activation markers,” cytokine production, cytotoxic effector molecule expression, and cell-mediated cytotoxicity). 1. Cells from the desired organs or cells from in vitro co-culture experiments are prepared as a single cell suspension in icecold FACS buffer. 2. Immunofluorescent labeling of cell suspensions can be performed in U- or V-bottom 96-well plates containing 0.1–2 × 106 cells per well in 25–100 l of FACS buffer containing Abs on ice (see Notes 3 and 15).
116
Lucas et al.
3. Spin plates at 400–500 × g for 5 min at 4◦ C. Remove supernatant by flicking plates. 4. Resuspend cells in 50 l FACS buffer containing 5–10 g/ml 2.4G2 Ab to block non-specific binding to Fc receptors. 5. Wash the cells (by filling the wells with 150 l FACS buffer followed by centrifugation at 400–500 × g, 3–5 min, 4◦ C). Remove the supernatant by simply flicking the plate above the sink and briefly dry any liquid outside of the wells by blotting the inverted plate on a paper towel. 6. Activation of NK cells is measured by staining of cells with 50 l of FACS buffer containing fluorescently conjugated antibodies specific for CD25 and CD69. In order to detect CD25 and CD69 expressed by NK cells, cells are co-stained with a combination of anti-NKp46 (or anti-NK1.1 or antiDX5) and anti-CD3⑀ Abs. Additional antibodies visualizing various NK cell subsets can be added (e.g., Ly49C/I for “armed” NK cells of B6 mice, CD11b or KLRG1 for “mature” NK cells). Usually, 1–5 g/ml of fluorescently conjugated antibodies are used for cell surface staining. It is a good idea to experimentally establish the amount of antibody required for a decent stain. 7. Staining is performed for > 15 min on ice protected from light. 8. Cells are washed 3× in ice-cold FACS buffer. 9. Cells can either be directly analyzed on a flow cytometer or fixed in FACS buffer containing 1% formaldehyde and can be stored protected from light (aluminum foil) for < 3–4 days at 4◦ C. 3.8.2. Intracellular Cytokine Stain
1. In order to assess cytokine production by NK cells, NK cells are re-stimulated for 4–6 h in vitro in the presence of 2 M monensin (GolgiStop diluted at 1:1500) or 10 g/ml brefeldin A in order to block protein export and facilitating cytokine accumulation inside cells. 2. In vitro restimulation of NK cells can be performed by either of these methods: a. Adding cells to flat-bottom 96-well plates coated with antibodies specific for activating NK cell receptors (e.g., NKG2D, NKp46, NKR-P1B/C, Ly49D, Ly49H). Plates should be pre-coated overnight at 4◦ C with the desired concentration of the antibody in PBS. Before use, coated wells are washed three times with PBS (see Note 16). Cell suspensions can then be directly added to the wells. The optimal concentration of antibody for NK cell stimulation should be experimentally determined. In our experience, 10 g/ml of most
Studying NK Cell/Dendritic Cell Interactions
117
commercially available antibodies work quite well. After stimulation, lymphocytes are transferred to a U- or Vbottom 96-well plate for intracellular cytokine staining. b. Co-culturing of NK cell-containing cell suspensions with target cells (e.g., YAC-1, RMA-S or RMA-S-H60 cells) is generally performed at a 1:1 ratio (e.g., 1 × 106 splenocytes for 1 × 106 target cells) in cell culture medium and U-bottom 96-well plates (200 l final volume). 3. At the end of the incubation period, cells are spun down and resuspended in 50 l FACS buffer containing 5– 10 g/ml 2.4G2 Ab to block non-specific binding to Fc receptors. 4. Wash the cells by filling the wells with 150 l FACS buffer, followed by centrifugation at 400–500 × g, 3–5 min, 4◦ C. Remove the supernatant by simply flicking the plate above the sink and briefly dry any liquid outside of the wells by blotting the inverted plate on a paper towel. 5. Resuspend the cells in 50 l FACS buffer containing 5– 10 g/ml of Ab to markers defining the NK cells or NK cell subsets (see Section 3.8.1, Step 6; see Notes 3 and 15). 6. After the extracellular staining step, cells are permeabilized and fixed using 100 l Cytofix/Cytoperm) for 20 min and protected from light on ice. 7. Cells are washed twice in FACS buffer containing 0.5% saponin. 8. The intracellular staining is performed in 50 l FACS buffer containing 0.5% saponin and the desired antibodies (usually anti-IFN-␥ at 1–2 g/ml) for 20–30 min (on ice, protected from light). In addition to the intracellular staining antibody, a separate sample should be stained with an isotype control antibody conjugated with the same fluorescent dye. 9. Cells are washed two times with FACS buffer containing 0.5% saponin and two times with regular FACS buffer (no saponin). 10. Cells can either be directly analyzed on a flow cytometer or fixed in FACS buffer containing 1% formaldehyde and can be stored protected from light (aluminum foil) for <3– 4 days at 4◦ C. 3.8.3. Intracellular Stain for Effector Molecules (Granzymes and Perforin)
Detection of cytotoxic effector molecules (granzymes, perforin) in NK cells and CD8 T cells from mice has been problematic as specificity of some of the commercially available antibodies has been questioned. We used antibodies specific for granzymes A
118
Lucas et al.
and B generated by the group of Dr. M. Simon (Max-PlanckInstitute of Immunobiology, Freiburg, Germany) that have been carefully tested for their specificity with the help of mouse models genetically deficient for those molecules (34). Recent reports have successfully employed commercially available antibodies specific for perforin and granzymes A and B (35). All those antibodies have been listed in Section 2.4. 1. Cells from the desired organs or cells from in vitro coculture experiments are prepared as a single cell suspension in ice-cold FACS buffer. 2. Immunofluorescent labeling of cell suspensions can be performed in U- or V-bottom 96-well plates containing 0.1–2 × 106 cells per well in 25–100 l of FACS buffer containing Abs on ice. 3. Spin plates at 400–500 × g for 5 min at 4◦ C. Remove supernatant by flicking plates. 4. Resuspend cells in 50 l FACS buffer containing 5– 10 g/ml 2.4G2 Ab to block non-specific binding to Fc receptors. 5. Wash the cells (by filling the wells with 150 l FACS buffer followed by centrifugation at 400–500 × g, 5 min, 4◦ C). Remove the supernatant by simply flicking the plate above the sink and briefly dry any liquid outside of the wells by blotting the inverted plate on a paper towel. 6. Cells are extracellularly stained with Abs to markers defining the NK cells or NK cell subsets (see Section 3.8.1, Step 6, and Notes 3 and 15). 7. After the extracellular staining step, cells are permeabilized and fixed using 100 l Cytofix/Cytoperm for 20 min and protected from light on ice. 8. Cells are washed twice in FACS buffer containing 0.5% saponin. 9. The intracellular staining is performed in 50 l FACS buffer containing 0.5% saponin and the desired antibodies for 20–30 min (on ice, protected from light). If not specified by the manufacturer, the antibody dilution is usually 1–5 g/ml for a monoclonal Ab. Concerning sera, the concentration has to be established by the user (e.g., we used the rabbit sera against granzymes A and B at a 1:700–1:800 dilution). In addition to the intracellular staining antibody, a separate sample should be stained with an isotype control antibody conjugated with the same fluorescent dye. 10. Cells are washed two times with FACS buffer containing 0.5% saponin. 11. Optional: If a secondary Ab is used, incubate cells in 50l FACS buffer containing 0.5% saponin and the desired
Studying NK Cell/Dendritic Cell Interactions
119
secondary antibody for 20–30 min (on ice, protected from light). Repeat step 10. 12. Cells are washed two times more in regular FACS buffer (no saponin). 13. Cells can now be analyzed on the flow cytometer. 3.8.4. Cytotoxicity Assay
3.8.4.1. Target Cell Labeling
Cytotoxicity of NK cells against target cells (e.g., YAC-1, RMAS, or RMA-S-H60 cells) is determined in a modified standard 4 h 51 chromium release assay (5). We and others have observed that following priming of NK cells by DCs, the fraction of NK cells of all splenocytes is decreased (5). Thus, it is very important to normalize the assay based on the total number of NK cells present in each organ suspension. To this end, the percentage of NKp46+ CD3− cells in the lymphocyte populations should be determined prior to the cytotoxicity assays and lymphocyte numbers should be adjusted to contain the same absolute number of NK cells. The starting NK cell:target ratio should be 6:1 (roughly equivalent to a 100–200:1 splenocyte:target ratio). Threefold serial dilutions of the effector cells should be performed. Usually four E:T ratios (6:1, 3:1, 0.8:1, 0.2:1) are sufficient. It should be considered that 10,000 target cells per well or 1 × 106 target cells per 96-well U-bottom plate are needed for the assay. Maximally eight different experimental groups or conditions can be assayed per plate with four different E:T ratios and triplicate determinations. Since some cells will be lost during the labeling procedure, it is necessary to start with double the amount of cells needed for the assay (i.e., if one 96-well plate will be used, 1 × 106 target cells are necessary and labeling should be started with 2 × 106 cells). 1. Split target cell(s) the day before the experiment (1:3) into fresh medium. This procedure will result in a lower spontaneous release by the target cells. 2. Harvest target cells, count cells, pellet cells, and resuspend them at 1–5 × 106 per 470 l of tissue culture medium. 3. From this step onward, target cell handling needs to performed behind leaded shielding in a designated area for radioactive work. Add 30 l (ca. 150 Ci) 51 Cr (see Note 17). 4. Incubate cells on a rotating platform for 90 min at 37◦ C in a humidified atmosphere containing 5% CO2 .
3.8.4.2. Effector Cell Preparation
1. Prepare/count Section 3.2.
cells
from
organs
as
described
in
2. Stain an aliquot of cells from each organ (or each condition if an in vitro assay has been performed) with Abs and
120
Lucas et al.
analyze by FACS to determine the fraction of NK cells (see Section 3.8.1). 3. Prepare U-bottom 96-well plates. Add 100 l of culture medium to each well, except those of row A and row E. 4. Add 150 l of effector cells in triplicates to each well in row A and/or row E. Usually, we start with a 6:1 NK:T ratio, which means that 60,000 NK cells per well will be needed. To facilitate the threefold dilutions, we add to the first well 150 l tissue culture medium containing 90,000 NK cells (6 × 105 NK cells/ml). Serial dilutions are performed using a multichannel pipette by taking 50 l from the initial cell suspension and transferring them to the next well containing 100 l medium. This procedure is repeated until the desired lowest E:T ratio is reached. The remaining 50 l at the end will be discarded. 3.8.4.3. Target Cell Preparation
1. Wash labeled target cells three times with 10 ml of 5% FCS DMEM culture medium (300 × g, 5 min, room temperature) 2. After the